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Designing Allosteric Inhibitors of Thrombin 
 
By Preetpal Singh Sidhu 
 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy 
at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2011 
 
Director: Dr. Umesh R. Desai 
Professor, Department of Medicinal Chemistry 
 
Thrombin is a key enzyme of the coagulation cascade exhibiting important roles in both pro-
coagulation and anti-coagulation processes. Most clinically used anticoagulant drugs, including polymeric 
heparin, warfarin, hirudin, argatroban and the recently approved dabigatran, aim to reduce thrombin 
activity. There are several binding domains on thrombin including the active site, anion-binding exosites I 
and II, and the sodium binding site. We hypothesized that thrombin may be better regulated through an 
allosteric process mediated by small molecules binding to either exosite I or II. An appropriately designed 
allosteric regulator that reduces the procoagulant signal in a finely tuned manner may maintain a delicate 
balance between procoagulant and anticoagulant signals in blood resulting reduced bleeding 
complications.  
xvii 
 
 
In this work, we synthesized and studied a library of potent, small, aromatic molecules as allosteric 
inhibitors of thrombin. Of the 28 potential inhibitors, 11 molecules inhibited thrombin with reasonable 
potency. Structure activity relationship studies showed that sulfation at the 5-position of the benzofuran 
scaffold was essential for targeting thrombin. Michaelis-Menten kinetic studies indicated a non-
competitive, allosteric mechanism of inhibition. Site-directed mutagenesis, competitive binding and 
molecular modeling studies led to the identification of the most plausible binding pose for a potent 
sulfated dimer. To further improve the potency, a small library of sulfated benzofuran trimers was 
synthesized and studied for thrombin inhibition. Further, to find new scaffold to inhibit thrombin 
allosterically, docking-based virtual screening approach was used. All these molecules were found to be 
moderately potent thrombin inhibitors and can serve as lead to develop allosteric inhibitor.  
Overall, this work presents the first small, synthetic, sulfated aromatic molecules as potent 
allosteric modulators of thrombin. Finally, this work also highlights the opportunity of exploring 
allosteric modulators of other coagulation enzymes, e.g., factors Xa, IXa and XIa, based on the sulfated 
benzofuran scaffold.  
 
 1 
 
Chapter 1 Introduction 
 
 
1.1 Background 
Cardiovascular diseases have been responsible for the highest number of deaths 
worldwide counting up to 17.1 million people. It is estimated that the mortality may reach 23.6 
million by the end of 2030.1-3 Venous thrombocytopenia (including deep vein thrombosis and 
pulmonary embolism) is a serious and fatal condition. It causes significant mortality and 
morbidity in modern society that imposes a major burden on healthcare.1, 4 Approximately one in 
every 1000 individuals are diagnosed with this condition annually. These numbers may actually 
be much higher due to unreported cases because of the asymptomatic nature of the ailment.5 
Other examples of clotting disorders include acute myocardial infarction, unstable angina, 
disseminated intravascular coagulation, cerebrovascular thrombosis and atrial fibrillation. 
Complications resulting from mechanical heart values and surgery are also related. The risk of 
developing thrombotic disorder is higher in cancer patients.6 Besides the enormous interest and 
research in advancing treatment of thrombotic disorders, safety still remains a major concern. 
The primary reason for excessive bleeding associated with thrombotic therapy lies in the 
complexity of hemostatic system and the high sequence homology in proteases involved in the 
coagulation target.1, 7 The primary targets for thrombotic treatment are thrombin and factor 
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Xa.8  Modern therapy has significantly reduced the side effects of traditional therapy, but is still 
associated with side effects like compromised immune responses, liver toxicity and requires 
regular blood monitoring. Consequently, there is significant medicinal potential for the design 
and synthesis of novel anticoagulant agents that are potent and selective with minimal side 
effects.2, 4 
1.2 Blood Coagulation Cascade 
Hemostasis is a spontaneous process that arrests the blood flow to prevent the blood loss 
in the event of damage to the vascular wall.9 Blood coagulation can be defined as the body’s 
defense mechanism against blood loss and microbial infiltration upon injury.10 It is a complex 
interplay involving various plasma proteins, the cell membrane, tissue factors, platelets and 
inorganic ions such as calcium and sodium.11 The hemostatic system is comprised of three 
mechanisms: the platelet-dependent mechanism, coagulation and fibrinolysis, which are also 
termed as primary, secondary and tertiary hemostasis, respectively. The mechanism of 
coagulation is highly conserved throughout the animal kingdom.12, 13 
Coagulation begins instantly after an injury to the vascular wall that exposes the 
transmembrane tissue factor. This is a vascular trigger required to initiate coagulation of blood 
flow. Exposure of the blood to this tissue factor and endothelial cells initiates the changes in the 
platelet and other proteases required for the generation of a clot. Platelets are thus immediately 
activated upon exposure to tissue factor and begin to form a plug at the site of the vascular 
injury.14 Simultaneously, the secondary hemostasis mechanism is activated leading to a cascade 
of events for the formation of fibrin, the primary component of a blood clot.15 
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1.2.1 Primary Hemostasis Mechanism 
The primary hemostasis mechanism (platelet activation) leads to the exposure of 
collagens on the surface of endothelial cells.16 Platelets adhere to the exposed collagen through 
the von Willebrand Factor (vWF), which acts as a bridge between a glycoprotein complex on the 
surface of platelets and collagen fibrils.17 The vWF also binds to factor VIII and is required for 
its survival while circulating in the blood. Upon binding to collagen, platelets release the 
contents of their granules, which in turn attract more platelets for aggregation.18 The activation of 
platelets is also mediated by thrombin binding to specific receptors on the surface of the 
platelets. Thrombin is important for initiating the signal transduction cascade. Activation of 
platelets finally leads to formation of a platelet plug.19 
 
1.2.2 Secondary Hemostasis Mechanism 
The secondary hemostasis mechanism is divided into two pathways: intrinsic and 
extrinsic (Figure 1).20 The intrinsic pathway (also known as the contact activation pathway) is 
thought to be less significant for blood coagulation than the extrinsic pathway under normal 
physiological conditions.15 However, in disease states, such as hyperlipidemic conditions or 
bacterial infection, the intrinsic clotting cascade initiates the clot formation. In the state of 
vascular injury, the extrinsic pathway is mainly responsible for the clot formation. Both 
pathways merge at the point of conversion of inactive factor X to its active form factor Xa into a 
common pathway leading to generation of thrombin.10 
The intrinsic pathway is comprised of the clotting factors (VIII, IX, X, XI, and XII), 
proteins including prekallikrein (PK) and high-molecular-weight kininogen (HK), along with 
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calcium ions and phospholipids.21 The intrinsic pathway begins when PK, HK, factor XI and 
factor XII are exposed to a negatively charged surface such as that of phospholipids, lipoproteins 
or a bacterial outer membrane. This is known as the “contact phase”.22 The accumulation of 
contact phase components results in conversion of PK to kallikrein, which in turn leads to 
activation of factor XII to factor XIIa. Upon activation, factor XIIa activates another inactive 
zymogen factor XI to form factor XIa. Factor XIIa further converts PK to kallikrein through a 
positive feedback mechanism. In the presence of Ca2+, factor XIa activates factor IX to form 
factor IXa. Active factor IXa cleaves factor X at an internal Arg-Ile bond, leading to its 
activation and forming factor Xa. The assembly of factors VIIIa, IXa and X (inactive form of 
factor Xa) and Ca2+ create the intrinsic tenase complex on the surface of activated platelets. This 
tenase complex is required for activation of factor Xa.13, 15, 23 Factor VIIIa acts as receptor for 
factors IXa and X.21 Thrombin regulates the formation of the tenase complex by playing a dual 
role via regulating the activation (at low concentration) and inhibition (at high concentration) of 
factor VIIIa.24 The extrinsic pathway (also known as the tissue factor pathway) is initiated at the 
site of injury in response to exposure of tissue factor to the blood. Tissue factor is a cofactor in 
the factor VIIa-catalyzed activation of factor X. The exposed tissue factor binds to activated 
factors VIIa and X to form the extrinsic tenase.14 The activation of factor VII is regulated by 
action of thrombin and factor Xa. The activation of factor VII by factor Xa generates the 
connection between the intrinsic and extrinsic pathways (Figure 1).25, 12, 17 
The common point in both pathways is the activation of factor X to factor Xa. In the 
common pathway, factor Xa activates prothrombin (factor II) to thrombin (factor IIa). This 
occurs on the surface of activated platelets and requires formation of a prothrombinase 
complex. It is comprised of platelets, phospholipids, Ca2+, factors Va and Xa, and prothrombin.26 
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Factor V plays the role of cofactor in the formation of the prothrombinase complex, similar to 
the role of factor VIII in intrinsic tenase complex. Similar to the intrinsic pathway, activation of 
factor Va is regulated by thrombin in a concentration-dependent manner.27 Thus, thrombin 
regulates its own production by regulating the activation of factor VIIIa and Va. Once thrombin 
is activated, it converts the inactive fibrinogen into an active form by release of two 
polypeptides. This thrombin-mediated release of the fibrinopeptides then generates fibrin 
monomers, which spontaneously aggregate in a regular array to form a weak fibrin clot. The 
weak clot is strengthened by the formation of cross-linked covalent bonds between the fibrin 
monomers by factor XIIIa,28 which is activated by the action of thrombin.29 
1.2.3 Tertiary Hemostasis Mechanism 
The tertiary hemostasis mechanism, also known as fibrinolysis, is the degradation of a 
blood clot.28 Plasmin is a serine protease that circulates in the blood in its inactive form, 
plasminogen. Plasmin degrades the cross-linked fibrin resulting in dissolution of the clot. The 
inactive plasminogen binds to both fibrinogen and fibrin, thereby being incorporated into a 
clot.30 Tissue plasminogen activator (tPA) and urokinase are serine proteases that convert 
plasminogen to plasmin. Plasmin digests the fibrin to a soluble degradation product to which 
neither plasmin nor plasminogen can bind. Once the plasminogen and plasmin are released from 
clot, the free circulating plasmin in the blood is rapidly inactivated by α2-antiplasmin.31 
 
  
Figure 1. Blood coagulation cascade. The intrinsic and extrinsic pathway merges into a common 
pathway leading to the formation of 
coagulation by thrombin at various levels.
 
1.3 Regulation of Coagulation 
Several endogenous proteins regulate the coagulation mechanism to prevent the condition 
of hyper-coagulation by inhibiting various proteases involve
also limit the size of the clot formed
Tissue factor pathway inhibitor (TPFI)
complex. It mediates the feedback inhibition of the tissue factor
decreased activation of both factor
6 
a fibrin clot. The red arrows represent the regulation of 
 
d in the coagulation process. They
 at the site of injury.  
: TPFI modulates the formation of the extrinsic tenase 
-factor VIIa complex, resulting
s IX and X.12 A small amount of factor Xa
 
 
 in 
 is required for 
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TFPI to achieve inhibition of factor VIIa-tissue factor complex. Heparin increases activity of 
TFPI by 2-4 folds by bringing TFPI and the TF-FVIIa complex closer and hence increasing their 
interaction. Heparin is also known to increase the release of endothelial stores of TFPI.10, 13, 32 
Protein C: Protein C is a vitamin-K dependent inhibitor of the procoagulant system involved in 
inactivating factors Va and VIIIa. The binding to the thrombin-thrombomodulin complex 
activates protein C. By inactivating factors Va and VIIa, protein C significantly decreases the 
thrombin generation, thereby dampening the cascade.33, 34 
Antithrombin III: Antithrombin III (AT) directly binds and inactivates thrombin and several 
serine proteases such as factors IXa, Xa, and XIa.35 The reaction between the serine proteases 
and AT is relatively slow, but is catalyzed in the presence of heparin. In the presence of heparin 
or similar sulfated glycosaminoglycans, the reaction between AT and serine proteases is virtually 
instantaneous, resulting in the immediate arrest of fibrin formation.36 
 
1.4 Anticoagulants Therapy and Targets 
Over last five decades, anticoagulant therapy relied mainly on the use of traditional 
anticoagulants such as heparin and warfarin. The available drugs can be broadly categorized into 
anticoagulant and antithrombotic, depending on their effects to prolong plasma-based assays. 
Anticoagulant drugs exert their effect solely by inhibiting the coagulation cascade and hence 
prolonging the clotting time as indicated in prothrombin (PT) and activated partial 
thromboplastin time (APTT) assays. In contrast,  antithrombotic drugs exert anticoagulation by 
other mechanisms, apart from any direct effect on the coagulation cascade.37 Recent advances in 
the development of direct inhibitors of thrombin and factor Xa have resulted in more specific 
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agents with better pharmacokinetic and pharmacodynamic profiles. Currently, there are three 
major classes of anticoagulants available in the United States. These are the vitamin-K 
antagonists, indirect and direct thrombin and factor Xa inhibitors.38 
Vitamin-K antagonists: Warfarin was the only oral anticoagulant used over the last 50 years until 
the discovery of direct inhibitors of thrombin and factor Xa (Figure 2). Warfarin exerts its 
anticoagulant effects by inhibiting the hepatic synthesis of vitamin-K dependent coagulation 
factors II, VII, IX and X and anticoagulant proteins C and S. Warfarin not only decreases the 
synthesis of these coagulation factors, but also reduces their biological activity by inhibiting their 
activation.39 Warfarin has no effect on circulating coagulation factors, therefore attainment of 
full antithrombotic effects is delayed depending on the half-lives of the coagulation factors. 
Warfarin displays an initial transient phase of procoagulation due to the shorter half-life and fast 
clearance of its anticoagulant protein C.40 It has a slow onset of action and needs frequent 
monitoring of its anticoagulant effects, resulting in increased cost and discomfort to patients. 
Beside these side effects, warfarin has a narrow therapeutic window due to undesired drug-drug 
and drug-food interactions. This is even more complicated by significant patient-to-patient 
variations.41 
Heparins: Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are used in 
the clinics as primary anticoagulant therapy. Despite their numerous side effects, they are still 
considered as first line anticoagulants.38 Heparin is a heterogeneous mixture of polysaccharides 
chains of molecular weight ranging from 5,000-30,000 Daltons (Figure 3). LMWHs are 
synthesized by chemical or enzymatic cleavage of UFH to reduce the average molecular weight 
to 5000 Daltons.42 Heparin exerts its biological effect by forming a ternary complex with 
thrombin and antithrombin. 
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Figure 2. Structure of warfarin, a vitamin-K antagonist. 
Heparin binds to antithrombin through a specific pentasaccharide unit causing a major 
conformational change in antithrombin that accelerates its activity to inhibit factor Xa, thrombin 
and factor XIa.43 The heparin molecule with the pentasaccharide unit (Figure 3) and an 
additional 13 saccharide units are able to inhibit thrombin by the bridging mechanism.38 LMWHs 
having shorter chain lengths are not able to inhibit thrombin as well, but are able to induce a 
major conformational chain in antithrombin that is required to inhibit factor Xa.44 The 
advantages of LMWHs that helped it to replace the clinical usage of UFH is that of longer half-
life, allowing the once-daily dosing regimen and its more predictable ADME properties, 
eliminating the need of regular laboratory monitoring. It also has a lesser risk of 
thrombocytopenia due to reduced binding to platelet factor 4 (PF4).45, 46 The synthetic compound 
fondaparinux has advantage over LMWHs because it is homogeneous in nature. It is thus safer 
and carries lower risk of thrombocytopenia than LMWHs and UFH.47 Although enormous 
progress has being made in heparin-based drugs, this class of anticoagulant still has much room 
for improvement. Heparin and LMWHs are not available orally and require parenteral 
administration. Heparin also induces thrombocytopenia by binding to PF4. The immune system 
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produces antibodies for the heparin-PF4 complex, which leads to reduced platelet count.48 
Fondaparinux is an indirect inhibitor of factor Xa. It is unable to inhibit thrombin due to its 
shorter chain length. The major drawback of fondaparinux is unavailability of an antidote to 
neutralize excessive bleeding.49-51 
 
 
Figure 3. Structure of heparin with various labeled sugar units. 
Direct Thrombin Inhibitor (DTI): Hirudin is a peptide-based natural inhibitor of thrombin 
obtained from the medicinal leech, hiruda medicinalis. It is a 65 amino acid long peptide 
(molecular weight 7000 Daltons), stabilized in three different structural forms by disulfide 
bridges.52 Unlike the heparins, it is a direct inhibitor of thrombin.52 It irreversibly inhibits 
thrombin by binding at two of its sites, thus it is classified as a bivalent DTI.53 Hirudin has other 
advantages over the heparins by inhibiting both free and clot-bound thrombin.54 Hirudin shows 
no interaction with plasma proteins and has predictable dose response.55 Bivalirudin is 
dodecapeptide from the carboxy-terminal region of hirudin and bridged with an active site-
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specific tetrapeptide (D-Phe-Pro-Arg-Pro) by four glycine residues (Figure 4). Like hirudin, it is 
also a divalent DTI, but only produces transient inhibition of thrombin due to its shorter half-life 
(Figure 4).56 Currently, it is used as alternative to heparin for angioplasty and unstable angina.57 
On the other hand, hirudin and hirudin-based anticoagulants suffer from serious drawbacks 
leading to discontinuation of hirudin from clinical use. Hirudin has a strong dependence of the 
pharmacokinetics of renal function, resulting in difficulties in dosing for elderly patients. 
Increased risk of bleeding and lack of an antidote worsen the safety profile. In addition, its non-
human source and polypeptide nature can lead to serious immune reactions. However, 
immunogenicity is reduced in bivalirudin and argatroban (a direct active site inhibitor of 
thrombin).52 
 
Figure 4. The mechanism of action of DTIs lepirudin, bivalirudin and argatroban. This figure is 
adapted from Greincher et al.52 
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Active site inhibitors of thrombin: The design and development of active site inhibitors of 
thrombin is driven by three major factors: 1) the increasing incidence of immune response 
against heparin and its analogs, 2) their inhibition of only free thrombin and 3) the non-specific 
interaction of heparin with other plasma proteins.58 Argatroban was the first univalent active site 
DTI (Figure 4). It is small synthetic molecule derived from L-Arginine and is a competitive and 
reversible inhibitor.57 Melagatran and ximelagatran (prodrug of melagatran) are peptide-based 
active site DTIs, which significantly eliminated the need of regular laboratory monitoring of 
anticoagulation level. The clinical success of these inhibitors led the trail for discovery of various 
other active site DTIs, which are currently under clinical investigation.59, 60 
Aptamers: Aptamers are single stranded nucleotides that bind to molecular targets and inhibit 
their  function by physically blocking their interaction with ligands and substrates. The aptamers 
specific for exosite II (a positively charged patch on the thrombin surface) were successfully 
designed and tested in vitro for competition with exosite II ligands.61 Toggle-25 is a selective 
exosite II aptamer that specifically competes with glycosaminogylcan (GAGs) for binding with 
thrombin. It helps the thrombin to escape inactivation by antithrombin, thus leading to a higher 
concentration of active thrombin in circulation. It is also known to interfere with binding to the 
platelets.62 HD22 is another aptamer for thrombin that specifically inhibits the activation of 
platelets by thrombin.63 It is also possible to design aptamers that specifically inhibit the 
activation of factors VIII and V by thrombin, which could lead to blockage of the positive 
feedback loop.64 Exosite II aptamers could also serve as potential antidotes for exosite II based 
allosteric inhibitors, such as UFH and LMWHs, to reduce the effect of drug overdose.  
Selective indirect factor Xa inhibitors: Fondaparinux is the first known selective anticoagulant 
designed to inhibit a single protease. It is synthetically derived with a highly specific 
 13 
 
pentasaccharide unit of heparin, as required for antithrombin activation. The anticoagulant effect 
is achieved by high-affinity binding and activation of antithrombin, which further selectively 
inhibits factor Xa. Fondaparinux accelerates by 300-fold inactivation of factor Xa by 
antithrombin.65 It has a predictable ADME profile and better safety profile than its parent UFH. 
Owing to its synthetic source and homogeneous nature, there has been reduced incidence of 
immunogenicity and thrombocytopenia. Idraparinux is a hypermethylated pentasaccharide unit 
with a very long half-life for once-weekly dosage. It has a 30-fold higher binding affinity for 
antithrombin and similar clinical properties as fondaparinux.66, 67 
Direct factor Xa inhibitors: The successful design of argatroban opened new pathways for design 
of active site inhibitors of factor Xa. Razaxaban was developed by Bristol-Myers-Squibb as the 
first direct active site inhibitor of factor Xa to reach higher-stage clinical studies (Figure 5). 
Razaxaban studies were, however, discontinued due to the development of its congener 
Apixaban. Apixaban has a more favorable safety profile than Razaxaban and a better ADME 
profile. Rivaroxaban is another small molecule inhibitor targeting the active site of factor Xa 
developed by Bayer Health Care (Figure 5). It is currently used for prevention and treatment of 
thrombosis, marketed under the name of “Xarelto” in the United States. In addition, there are 
many more active site inhibitors of factor Xa currently under clinical trials.20, 68 
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Figure 5. Structures of direct factor Xa inhibitors. A) razaxaban, B) apixaban and C) 
rivaroxaban. 
 
Factors XIa and IXa active site inhibitors: The development of active site inhibitors targeting 
factors IXa and XIa is in the early stages. Initial results show promising advantages in terms of 
the role this class of inhibitors may play.69 
TF/Factor VIIa inhibitors: The TF/Factor VIIa complex plays an integral part in initiating the 
extrinsic pathway for blood coagulation. By activating factor XIa, it also initiates the intrinsic 
pathway.70 The function of TF/FVIIa can be blocked by many different approaches: 1) designing 
antibodies to prevent the complex formation; 2) designing active site inhibitors of factor VIIa; 3) 
designing exosite inhibitors that prevent binding of TF with factor VIIa; and 4) synthesizing the 
recombinant protein of naturally occurring inhibitors of the TF/Factor VIIa complex.69, 71 The 
naturally occurring nematode anticoagulant proteins (NAPs) are known to inhibit formation of 
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the TF/Factor VIIa complex.72 The recombinant TFPI also inhibits the activation of factor Xa by 
the TF/factor VIIa complex.73 
 
1.5 Limitations of Current Therapy 
Both heparin and warfarin have been used successfully in the clinics as primary 
anticoagulant therapy for more than 50 years. Being highly effective, they are associated with 
numerous side effects and safety issues that make regular blood monitoring obligatory. The 
interaction of heparin and warfarin with numerous targets leads to side effects, and hence new 
strategies are required to develop anticoagulants with high degrees of specificity for single 
targets.74 Recently developed anticoagulants like direct thrombin and factor Xa inhibitors are 
relatively safe as compared to heparin and warfarin. The most important advantage of direct 
inhibitors is that they can inhibit both free and clot bound thrombin. Thrombin gets entrapped in 
the growing clot and is responsible for clot maturation. Inhibition of clot-bound proteases is an 
advantage of direct inhibitors over traditional anticoagulants. Clot-bound thrombin is 
inaccessible to heparin or other AT-dependent drugs.39 However, the direct inhibitors suffer from 
side effects such as liver toxicity and lack of available antidotes. Other available anticoagulants 
such as hirudin, thrombin antibodies and natural products are not orally available and thus have 
short durations of action. Thus, they require frequent dosing and are associated with higher 
cost.75 
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1.6 Thrombin: Its Structure and Role 
Thrombin is derived from its inactive zymogen prothrombin which is a 70,000 Daltons 
glycoprotein synthesized in the liver. The inactive prothrombin is converted to its active 
thrombin form by the prothrombinase complex, consisting of factors Xa and Va, anionic 
phospholipids and Ca2+.24, 76 Factor Xa cleaves prothrombin at Arg320 to generate the 
meizothrombin and subsequently cleaves meizothrombin to generate active thrombin. The 
activated thrombin has a very short half-life of few minutes due to its inactivation by 
antithrombin present in plasma. Thrombin is activated upon cleavage of the Arg15-Ile16 bond, 
generating a new N-terminus end. This new N-terminus end, containing Ile16-Val17 residues, 
inserts into the main body and forms a salt bridge with carboxylate group of residue Asp194. 
This inward rotation of the side chain causes the outward rotation of the preceding loop causing 
the opening of the specificity pocket knows as “S1”.77-79 
Thrombin consists of two polypeptide chains: a 36 amino acid light chain and a 259 
residue heavy chain linked by a disulfide bridge. The heavy chain consists of all the functional 
epitopes of thrombin.80, 81 Thrombin molecules have a typical serine protease fold, containing 
two six-stranded β-barrels packed asymmetrically forming the catalytic triad of His57, Asp102 
and Ser195. The 60-loop structures form the upper lid of the active site, restricting the access of 
solvent to His57 and Ser195. Asp102 anchors His57 in the correct orientation for proton transfer 
from Ser195. The orientation of the catalytic triad polarizes the side chain of Ser195 for 
nucleophilic attack on the carbonyl carbon in the scissile bond of the substrate molecules.23, 82 In 
the transition state, the carbon atom attains tetrahedral geometry, which is stabilized by hydrogen 
bonding between the charged oxygen atom of the scissile bond and the amide hydrogen of 
Gly193 and Ser195, forming the “oxyanion” hole. The substrate is acylated by the Oγ atom of 
  
Ser195 by transferring the proton to His57 and 
molecule catalyses the deacetylation process by releasing the carboxylic acid and
end of the substrate. A particularly striking feature of 
distribution of charge over its surface
 
 
Figure 6. Thrombin plays a central role in blood coagulation regulating its own production by 
positive and negative feedback loops. Broken red arrows represent the inhibition of thrombin 
activity, red arrows represent the negative feedback regulation of thrombin to
production and green arrows represent the positive feedback regulation of thrombin to increase 
its production. 
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by losing its C-terminal end (Figure 7). The water 
the thrombin molecule is its uneven 
 causing patches of both positive and negative charges.
 
 the N-terminal 
83-86
 
 
regulate its own 
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1.6.1 Active Site 
The active site residues are located inside the narrow cleft formed between the two barrels. The 
active site is divided into various sub-pockets. To the left of the active site resides the S1 
specificity site, a narrow deep pocket containing the acidic Asp189 at the bottom.87 This pocket 
is guarded by uncompensated charge of Glu192 residue at the entrance, which plays a significant 
role in the specificity of thrombin in selecting substrates andinhibitors.88 The apolar binding 
region on the top of the S1 pocket is further divided into two sub-pockets: S2 and S4. These are 
hydrophobic pockets and also contribute to the specificity of thrombin. The access of substrate 
and inhibitors to these pockets is limited by the “60-loop”. The S1’ pocket lies on the right side 
of the catalytic triad. It is limited in size and can only accommodate small polar residues. The 
natural substrate of thrombin holds the following criteria: medium to bulky hydrophobic P4 
residue, proline at the P2 site, positively charged (especially Arg) at the S1 site, serine at P1’, a 
hydrophobic residue at P2’ and a basic residue at P3’.89-91 There are exceptions for this scheme, 
but suboptimal substrates utilize additional binding sites on thrombin to compensate for the lost 
binding energy.88 
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Figure 7. Chemical mechanism of catalysis for serine proteases. 
 
1.6.2 Exosite I 
Exosite I is a highly anionic notched surface depression located to the right side of the 
active site formed by the 70-80 loops. This region is similar to the calcium binding site of trypsin 
where the required Ca2+ is replaced by the insertion of the side chain of Lys70. In the center of 
the highly positive electrostatic potential formed by Arg63, Arg73, Arg75 and Arg77 lies the 
hydrophobic region formed by the side chains of Tyr76 and Ile82. Structural and functional data 
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suggest that exosite I is involved in the binding of thrombin with fibrinogen.92, 93 The α- and β-
chain fragments of fibrinogen bind at exosite I to provide the additional binding energy required 
to overcome the suboptimal substrate residues at the cleavage site.94, 95 Thrombomodulin binds at 
exosite I and allosterically induces changes in the active site to reverse the role of thrombin from 
a procoagulant to potent anticoagulant.96 The natural inhibitors, such as hirugen, rhodniin, 
ornithodorin and triabin, also induce allosteric changes in the catalytic triad.97 The nature of 
interactions for these inhibitors with exosite I varies from ionic to hydrophobic in nature. 
Thrombin also utilizes exosite I residues to interact with the protease-activated receptor-1 
(PAR1).98 PAR1 is a thrombin receptor found on the surface of platelets that mediates the action 
of thrombin in activation of platelets. The specific thrombin inhibitors such as heparin cofactor-II 
and antithrombin-III utilize the exosite I to interact with thrombin in the blood. It is known that 
the binding on exosite I communicates changes to the catalytic site and is thus involved in 
allosteric modulation of thrombin.99, 100 The importance of exosite I is demonstrated by the fact 
that the β- and γ- forms of thrombin, which lack the region of exosite I fail to cleave fibrinogen 
but retain the catalytic activity at the active site.99, 101 
 
1.6.3 Exosite II 
The extreme cluster of positive charge located to the left of the active site is called the 
anionic exosite II (also known as the heparin-binding site). This is formed primarily by Arg89, 
Arg98, Arg245, Lys248 and Lys252. Basic arginine residues surround the small hydrophobic 
Leu234 residue.92, 102, 103 Exosite II is known for its interaction with polyanionic ligands like 
heparin and other GAGs that are required for forming the ternary complex for inhibition of 
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thrombin by antithrombin. The binding at exosite II allosterically modulates the catalytic site of 
thrombin by disturbing the position of the Asp102 residue. In addition to its role in GAGs 
binding, exosite II is also involved in activation of factors V and VIII. The thrombin inhibitor 
haemadin derived from leech utilizes exosite II for binding with thrombin.94, 95 
 
1.6.4 Role of the Light Chain 
The boomerang-like thrombin light-chain is formed in a multiple turn conformation. The 
light- and heavy-chains are linked mainly by salt bridges (Figure 8). However, the light-chain is 
devoid of any known epitope for substrate recognition.104 Due to lack of any catalytic or 
regulatory function, the light-chain of thrombin has received very little attention and almost can 
be considered as an “appendage” of thrombin. Various studies have concluded that the bovine 
thrombin with an omitted light-chain retains most of its catalytic functions. On the contrary, 
phenotypes with mutations in residues of the light-chain are associated with moderate to severe 
bleeding. The best explanation for this discrepancy may be the involvement of the light-chain in 
the activation of prothrombin. The importance of the side light-chain is shown by the single 
mutation of Lys9, which not only affects the activation of thrombin, but also impairs the catalytic 
activity of thrombin for the chromogenic substrate, fibrinogen, PAR1 and protein C.105 It is rich 
in acidic residues engaged in intra- and intercellular interactions. The major function of the light-
chain is in its stabilization of the heavy-chain through various ionic interactions that neutralize 
the basic residues on the heavy-chain.106, 107 
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Figure 8. Graphical model of thrombin created by Sybyl8.1 showing the interaction of chain-A 
(shown in space filled model) with chain-B (shown as molcad surface). 
 
  
 
Figure 9. Graphical model of human thrombin generated by Sybyl8.1 shows the location of 
active site, sodium binding site, exosite I and II. The model is generated from crystal structure 
co-ordinates obtained PDB (ID: 3EQ0).
 
1.6.5 Sodium Binding Site 
The sodium binding site is located in the center of the 220
catalytic triad and 5 Å away from Asp189 in 
and communicates with the catalytic triad through a network of eleven water molecules. It is 
located in a cylindrical cavity formed by three antiparallel 
residue controlling sodium binding in thrombin
three ion pairs formed by Arg221a
ion pair with Arg187 render stability to this site
coordinated by two backbone O atoms from Arg221a and Lys224 and four burie
molecules anchored by the side chains of Asp189 and Asp221 and the backbones of Gly223 and 
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-loop, 15-20 Å away from the 
the S1 pocket.108 This site is highly solvent exposed 
β-strands. Tyr225 is 
 and is conserved in other serine proteases.
-Glu146, Lys224-Glu217 and Asp221 and Asp222 bidentate 
. The bound sodium ion is octahedrally 
 
the most crucial 
 The 
d water 
 24 
 
Tyr184a. Asp189 anchors the orientation of one of the four water molecules ligating sodium ion 
and thus provides an important link between the sodium site and the P1 residue of the substrate 
(Figure 10).109, 110 
 
 
Figure 10. Model of the molecular environment of the Na+ binding site of thrombin showing the 
residues of the allosteric core (purple). The bound Na+ is shown in blue with its coordinating 
water molecules (purple balls). H-bonds are depicted as broken lines. The residues affecting the 
Na+ affinity >3-fold (green) or <3-fold (cyan).111 
 
Thrombin displays a striking feature in its ability to get activated by interaction with 
sodium in a specific and allosteric manner.112 Sodium binding converts thrombin from the low 
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activity slow state to the high activity fast state.24 This also has a significant effect on thrombin’s 
interaction with procoagulant (fibrinogen), prothrombotic (PAR) and anticoagulant (protein C) 
substrates.85, 113 The Kd of sodium binding is 110 mM at 37 °C and the physiological 
concentration of sodium is 140 mM.109 The procoagulant and anticoagulant activities of 
thrombin correspond to the slow and fast forms, respectively. Hence, any factor that disturbs the 
sodium binding increases the anticoagulant effect of thrombin leading to prolonged clotting time 
and reduced platelet activation.76 
The structures of E (slow form) and E:Na (fast form) are very similar with limited 
structural changes being required to explain the complexity of the full range of allosteric 
transitions. The few major structural differences between from slow and fast forms are the 
favorable orientation of Asp189 in the specificity pocket, which explains the improvement in kM 
and the position of Ser195, which explains the improvement in catalytic efficiency (Kcat). The 
most significant structural change is the long-range communication between the sodium binding 
site and the active site. In the fast form, the network of H-bonds in eleven water molecules 
allosterically communicate information from the sodium binding site, whereas in the slow form 
only seven water molecules form this network, thus significantly altering the connectivity.114 
The perturbation of the primary specificity pocket is evident in the slow to fast transition 
of thrombin. In the fast form, orientation of Asp189 is optimal for interaction with the basic P1 
residue of the substrate. In the slow form, the carboxylate group of Asp189 rotates 30° from its 
optimal position and this disturbs the interaction with the basic P1 residue of the substrate. The 
conformation of Glu192 changes in this transition from fast to slow form. In the slow form, the 
side chain of Glu192 moves away from active site region and thus minimizes the clash between 
the acidic residues of P3 and P3’ of protein C. The orientation of Glu192 compensates the 
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deleterious changes in Asp189 and Ser195. This results in a conformation that retains the activity 
toward protein C, and explains the anticoagulant nature of the slow form of thrombin. The 
rotation of the hydrophilic side chain of catalytic Ser195 by 35° breaks the critical H-bond with 
the catalytic His57, which is crucial for catalysis (Figure 11).24, 76 
 
 
Figure 11. Model of the structural changes induced by the slow → fast transition of thrombin 
depicted by the structures of F (free fast form, gold) and S (free slow form, red).111 
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The physiological importance of sodium binding is demonstrated by bleeding phenotypes 
such as prothrombin Frankfurt,115 Salakta116 and Greenville.117 Mutations in these phenotypes 
significantly compromise sodium binding to thrombin. Conditions such as hypernatremia (high 
sodium conc.) and hyponatremia (low sodium conc.) are associated with thrombosis and 
bleeding, respectively.  
 
1.6.7 Platelet Activation and Role of Thrombin 
Human platelets circulate in the blood in dormant state and their premature activation is 
prevented by the presence of the endothelial monolayer, prostaglandin and nitric oxide, which 
limits the local accumulation of platelet agonists.118 Platelets start activating once these barriers 
are overcome in response to local trauma or rupture of the atherosclerotic plaque.83 Thrombin 
plays an essential role in activating platelets to form the platelet plug, similar to the formation of 
the fibrin clot. When thrombin is added to human platelets in vitro, it causes the platelets to 
change shape, stick to each other, and secrete their content of stored granules.119, 120 
Thrombin displays many structurally distinct features that help it to interact specifically 
with different ligands, proteins, receptors and substrates to modulate the various procoagulant 
and anticoagulant functions responsible for maintaining the fine regulation of hemostasis.121 The 
procoagulant role of thrombin is mediated by cleavage of seven transmembrane thrombin 
receptors that, in turn, activate the platelets. Humans have two prototypes of protease-activated 
receptors (PAR): PAR1and PAR4, of which PAR1 is thought to be more important.120 
PAR1 is characterized as a seven transmembrane domain G-protein-coupled receptor 
activated by specific cleavage of its N-terminal domain by thrombin. Thrombin cleaves at 
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Arg41-Ser42 exposing a new N-terminus that acts as a tethered ligand by binding to the 
intramolecular body of the receptor and leading to activation of platelets.98 PAR1 has “tow” 
domains that interact with thrombin. Mutant studies showed that the receptors cleavage 
recognition site and hirudin-like acidic domain are critical for interaction of the receptor with 
thrombin. The hirudin-like acidic domain interacts with the anionic exosite I and is responsible 
for overcoming the unfavorable interaction at the cleavage recognition site.122 The hirudin-like 
domain of PAR1 has a similar proportion of acidic and hydrophobic residues to other exosite I 
ligands of thrombin such as fibrinogen, hirudin and thrombomodulin. Mutant studies showed that 
these residues are important for receptor activation and, thus, electrostatic and hydrophobic 
interactions play an important role in PAR1 activation by thrombin.123, 124 Synthetic ligands that 
mimic the newly exposed tethered ligand of PAR1 and PAR4 act as agonists for the receptor and 
hence can be used as pharmacological tools to study the role of these receptors in various 
cells.125, 126 
 
1.7 Therapeutic Uses of Thrombin 
Since 1930, there has been extensive work on the use of thrombin as a topical agent for 
the treatment of surface bleeding.127 While there is sparsely published literature on the use of 
thrombin as topical hemostatic agent, it is used extensively in surgery. Thrombin is frequently 
used as adjuvant therapy to stop the residual bleeding in cardiothoracic and cardiovascular 
surgery. Thrombin was also used for treatment of burns but now it has been replaced by 
epinephrine.128 
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The extensive use of thrombin is supported by the minimal risk to system damage due to 
higher thrombin levels. The reason for such a low risk may be due to the low level of thrombin 
and its application to confined space. It is also known that thrombin is well contained within 
fibrin clots and that leaked thrombin is rapidly inactivated by antithrombin and other serpins in 
systemic circulation. This is further supported by the fact that most of the global parameters such 
as pro-thrombin time, thrombin time and partial thromboplastin time remain unchanged after 
topical use of thrombin.34 Bovine thrombin had been extensively used as topical hemostatic 
agent for a number of years without any reported incidences of adverse effects.129 In the last few 
years, some serious immunological adverse effects were reported, such as the development of 
antibodies to bovine thrombin or factor V.129 Bovine thrombin is available as topical preparation 
is the most common source of thrombin for therapeutic use. Human thrombin is obtained by use 
of recombinant DNA technology for therapeutic use. It is available as a lyophilized powder, 
spray kit and as a syringe spray kit.  
Production of native human thrombin is done in a multi-step process involving the 
separation of crude prothrombin from plasma using the alcohol fractionation process of Cohn.129 
Prothrombin is absorbed on an insoluble barium salt and subsequently eluted with sodium citrate. 
In an alternative method, prothrombin is absorbed on the anion-exchanger DEAE-agarose and 
subsequently eluted. The crude prothrombin is obtained as a mixture of factors VII, IX and X. 
Prothrombin is activated by adding crude tissue factor, which initiates the activation cascade 
leading to generation of thrombin. Activated thrombin is purified using a cation-exchange 
chromatography method.129 
 
 30 
 
1.8 Other Components of Coagulation System 
1.8.1 Factors VII/VIIa 
Factor VIIa along with the tissue factor (TF) initiates the extrinsic pathway upon injury to 
the vascular wall. The TF/Factor VIIa complex activates factor X to initiate the clotting 
process.130 In addition, this complex also activates factor IX and initiates the intrinsic pathway.131 
The majority of factor VII is present in inactive zymogen, along with traces of the activated 
form.132 Factor VIIa consists of two chains: the heavy chain and the light chain covalently linked 
by disulfide bridges. The light chain of factor VIIa contains the 10 γ-carboxyglutamic acids 
residues and two growth factor homology domains, whereas the heavy chain contains the 
catalytic region.133 The activation of factor VII is also catalyzed by factors XIIa,134 IXa, Xa135 
and thrombin136 suggesting the importance of its production in physiology.  
Factor VII is activated upon the cleavage of the peptide bond between Arg15 and Ile16, 
thus generating new N-terminal residue Ile16.137 After cleavage, Ile16 buries its side chain in a 
hydrophobic region and forms a salt bridge between its α-amino nitrogen atom and Asp194. The 
formation of this salt bridge orients the neighboring Ser195 residue of the catalytic triad 
optimally for proteolytic cleavage. Along with Ser195, three adjacent loops undergo 
conformational changes to construct the substrate-binding region. Beside cleavage by proteases, 
activation of factor VII also requires the binding of the TF. The function of TF is partly to 
protect the chemical modification of the α-amino nitrogen atom of Ile16.138 Thus, factor VII 
exists in equilibrium between its partially and fully active forms. TF binds specifically to the 
active form of factor VIIa.138 TF is expressed in the vascular smooth muscle cells, pericytes and 
fibroblasts in vessel walls. The binding of factor VII to TF is mediated by calcium ion at the Gla-
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containing region. Factor VIIa has three allosteric sites: the TF binding region, the active site 
binding region and the macromolecular binding exosite.139 The binding of TF allosterically 
enhances both proteolytic and amidolytic activities of factor VIIa.140 
 
1.8.2 Factors IX/IXa 
Factor IX, with a molecular weight of 54,000 Daltons, is a vitamin-K dependent single 
chain glycoprotein of 415 amino acid residues. Factor IX consists of a Gla-containing region and 
two epidermal growth factor-like regions. The Gla-region consists of 12 γ-carboxy glutamyl 
residues and functions as a calcium binding region. It also serves as a site for interaction with 
phospholipid monolayers.141 Gla is formed by the post-transitional modification of a glutamic 
residue by enzyme γ-glutamyl carboxylase.142 The two epidermal growth factor-like domains 
serve as binding sites with various cell receptors.143 Factor IX is activated by factor XIa in the 
presence of calcium ion that, upon activation, binds to the surface of endothelial cells.144 This is 
the first calcium dependent reaction in the intrinsic pathway. Activation of factor IX does not 
require the presence of phospholipids. Factor IX can also be activated by the factor VIIa-TF 
complex.131 This reaction bridges the intrinsic and extrinsic pathways. Factor IX is activated 
upon cleavage at two sites: Arg145-Ala146 and Arg180-Val181. There is no cofactor required 
for activation of factor IX.145 The cleavage at these sites generates two polypeptide chains: the 
light and heavy chains, which are linked covalently by a disulfide bridge. The carboxy-terminal 
heavy chain contains the catalytic triad formed by Ser365, His221 and Asp269. The structures of 
both metal-bound and metal-free factor IX have been solved by NMR spectroscopy. The 
structure of the metal-free form is slightly disordered, whereas the calcium ion bound form is 
well ordered, containing all the domains.  
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The vascular surface provides the site for achieving high local concentration of factor IXa 
to activate the factor X. Factor IXa along with calcium and modified factor VIII activate factor 
X.146 Patients deficient in factor IX suffer from the bleeding disorder hemophilia B. 
Recombinant factor IX is widely used worldwide for treatment of hemophilia A and B.146 
 
1.8.3 Factors XI/XIa   
Factor XI is 160,000 Daltons dimeric protein of two identical 607 amino acid chains 
containing subunits linked by a disulfide bond.147 It consists of four apple-like domains and a C-
terminal trypsin-like catalytic domain.148 It circulates in blood complexed of with high molecular 
weight kininogen.149 Blood also contains a monomeric homolog of factor XI, prekallikrein.  
Factor XI zymogen is activated in the blood to form factor XIa and the process is mediated by 
activators such as thrombin, factor XIIa and XIa (auto activation), by cleaving the Arg369-Ile370 
bond.150 Thrombin activates factor XI in the presence of charged surfaces such as dextran sulfate 
or heparin.151 The exosite I of thrombin interact with the A1 domain of factor XI, with residues 
like Glu66, Lys83, and Gln84. These residues are located in close proximity to the activation 
loop that contains the Arg369-Ile370 cleavage site.152 
It was postulated earlier that factor XI was involved in fibrin generation, 152 but later it 
was observed that the patients with factor XII deficiency do not have an excessive bleeding 
tendency. Thus, there are alternative pathways that can activate factor XI. Recently, factor XIa 
has been considered as a part of the positive feedback loop to sustain the process of thrombin 
generation.152 Activated factor XIa is regulated in blood by plasma serpins such as antithrombin, 
the C1-inhibitor, protease nexin 1, and protein Z-dependent protease inhibitors.148 Heparin 
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enhances the serpin-mediated inactivation by binding on the A3 domain and the catalytic domain 
through a template mechanism.153 
The four apple-like domains (A1-A4) of factor XIa are similar to those of other vitamin-
K dependent proteases. Each apple domain is comprised of 7 β-strands that fold into curved 
antiparallel sheets that frame into an α-helix.154 Two disulfide bonds lock the helix onto the 
central β4 and β5 strands, and the third one connects the N- and C-terminals. The two loops, β4-
β5 and β5-β6 generate a small pocket on the other side of the α-helix.155 The dimeric units are 
attached to each other through the A4 domain, with an interface area of 886 Å.154 The β-sheets of 
the two units pack against each other, and Cys321 forms an interchain disulfide bond.156 
 
1.8.4 Factors XII/XIIa 
Factor XII is a glycoprotein with a single polypeptide chain composed of 596 amino acid 
residues, with a molecular weight ranging from 76,000 to 80,000 Daltons.157 It is also called the 
“Hageman” factor. Inactive zymogen factor XII is activated in the presence of negatively 
charged surfaces by kallikrein, factor XIa and plasmin. Factor XII auto-activates in presence of 
negatively charged surfaces such as glass, kaolin, ellagic acid, sulfatide micelle, polyethylene, 
silicon rubber, cartilage, skin, fatty acids, endotoxins, heparins, phospholipids and many more.158 
The fact that factor XII can be auto-activated in the presence of negatively charged surfaces 
makes it medically important for clinical plasma assays (activated partial thromboplastin time) to 
well predict the bleeding risk.159 Activation, either by auto-activation or plasma kallikrein, 
results in formation of a heavy chain (MW 52,000) and a light chain (MW 28,000) that are 
covalently linked by a disulfide bridge. The light chain contains the catalytic triad formed by 
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Ser544, His393 and Asp442, which are responsible for the proteolytic function of the enzyme. 
After the initial cleavage, a second slower cleavage occurs at the heavy chain thus retaining the 
activity of the enzyme and resulting in two forms of activated factor XII enzymes in the blood 
circulation.160 
Once activated, factor XIIa activates factor XI, which is associated with the high 
molecular weight kininogen and prekallikrein. Beside this, factor XIIa is also involved in the 
activation of C1 of the complement system, activation of factor VII and down regulation of 
monocyte receptors of IgG.161 The activity of factor XIIa is inhibited in the blood by a plasma 
protease inhibitor and the C1 inhibitor. The presence of activating surfaces such as kaolin, 
dextran sulfate and sulfatides can protect the deactivation of factor XIIa.162 It has been shown 
that the presence of factor XII influences the size of thrombus growth and thus makes it an 
important pharmacological target.163 Besides its involvement in blood coagulation, factor XII is 
also known to play a role as a growth factor. It is important for tissue repair after thrombosis or 
inflammation.164 
 
1.8.5 Thrombomodulin and Protein-C 
Thrombomodulin (TM) is a glycosylated type-I transmembrane protein of 75 Daltons 
with no intrinsic enzymatic activity.165 TM is present in endothelial cells and in capillary rich 
endothelial cell surfaces.166 The presence of multiple disulfide bonds ensures TM stability under 
extreme pH conditions. The mature TM contains six epidermal growth factor (EGF) like-
domains.167 Domains 4, 5 and 6 are involved in thrombin binding and protein C activation 
(Figure 12).168 In addition, these domains are also responsible for signaling posttranslational 
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Figure 12. Structure of thrombomodulin showing the domains involved in thrombin binding and 
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1000-fold in the presence of calcium ion.78 The presence of endothelial protein C receptor 
(EPCR) further enhances the reaction by another 10-fold.174 Protein C can also be activated by 
factor Xa and plasmin.175 Activated protein C (APC) circulates in the blood as a light and heavy 
chain molecule covalently linked by a single disulfide bond.176 The N-terminal light chain of 
APC contains the non-catalytic Gla domain and two epidermal growth factor domains. The Gla 
domain mediates calcium dependent interaction with protein S on its negatively charged 
surface.177 Protein S is a vitamin K-dependent plasma cofactor of protein C that amplifies the 
anticoagulant function of protein C. The C-terminal heavy chain contains the catalytic site. APC 
is inactivated in the blood circulation by α1-antitrypsin, α2-antiplasmin and α2-macroglodulin.178 
The APC anticoagulant pathway is also regulated by protein S activity and inhibition of the 
thrombin-TM complex by antithrombin.172,177 
Upon binding to TM, thrombin switches its function from procoagulant to anticoagulant 
by increasing its specificity to cleave protein C to form APC (Figure 13). The binding of TM 
induces allosteric changes in the active site of thrombin to alleviate the activating function 
towards the procoagulant proteases, fibrinogen, PAR-1, and cofactors V and VIII.173 Besides 
activating protein C, TM-thrombin complex also activates the thrombin activatable fibrinolysis 
inhibitor (TAFI).179 Hirudin competes with TM for binding with thrombin and thus inhibits the 
activation of protein C. Thrombin bound to TM is inhibited more rapidly by antithrombin and 
protein C inhibitor, with a half-life of approximately 2 seconds.180 
 
  
 
Figure 13. Graphical model of interaction of thrombin
of protein C. 
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initial rapid cleavage at Arg506 followed by slower cleavage at Arg306. The inactivation of 
factor Va is accelerated by the presence of protein S.184 In the case of factor VIIIa, APC cleaves 
the cofactor at Arg336 and Arg562. Cleavage at either of these sites leads to complete 
inactivation of factors VIIIa, Va and VIIIa, in complex with factors Xa and IXa, are resistant to 
inactivation by APC, but the presence of protein S inactivates the bound form of factor Va and 
VIIIa.185,186 APC can also inactivate the native forms of factors V and VIII and prevent their 
participation in the coagulation reaction. APC has a long half-life of 10 minutes in the blood 
circulation, favoring the enzyme remaining in circulation for localization and degradation of 
cofactors.187 
The regulation of the TM level is clinically significant, as high levels lead to bleeding, 
whereas low levels lead to thrombosis. The qualitative and quantitative deficiencies of protein C 
and protein S and defective APC lead to significant risk of venous thromboembolism and 
myocardial infarction.187 APC also exhibits cytoprotective, anti-inflammatory and profibrinolytic 
properties.188, 189 
 
1.9 Thrombin Engineering 
Thrombin has two important but functionally opposite roles in the blood coagulation 
system. The procoagulant role is initiated by conversion of fibrinogen into an insoluble fibrin 
clot, followed by activation of platelets to platelet plugs and initiate wound repair.190 This action 
is amplified by the activation of factor XIII that stabilizes the fibrin clot, activation of TAFI to 
inhibit fibrinolysis and activation of factors V, VIII and XI in a positive feedback loop to 
increase its own production. In its anticoagulant role, thrombin activates protein C upon binding 
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with TM. This action is amplified in the presence of endothelial cell receptors.76 Binding with 
TM initiates allosteric changes in the active site of thrombin leading to an enhanced specificity 
for protein C over fibrinogen and PAR1. Activated protein C inactivates the factors Va and VIIIa 
in a negative feedback loop to decrease the thrombin generation (Figure 14). The role of 
thrombin is further complicated by the allosteric effect of occupancy of sodium ions at the 
sodium binding site. Sodium binding converts thrombin from the slow anticoagulant form to its 
fast procoagulant form. Sodium binding is required for cleavage of fibrinogen, activation of 
factors V, VIII and XI, and activation of PAR1.191 Sodium binding is the major force driving the 
procoagulant role of thrombin. A sodium-free state converts thrombin into a slow form to 
produce an anticoagulant role, by activation of protein C and reduction of the platelet activation. 
Under physiological conditions, the balance between the procoagulant and anticoagulant roles of 
thrombin is optimal. Any effect that destabilizes the sodium-binding site converts thrombin into 
a potent anticoagulant. Several naturally occurring mutants of thrombin and physiological 
conditions that disturb the sodium binding equilibrium are associated with severe bleeding. 
There are some examples where multifunctional roles of thrombin were dissociated into 
procoagulant and anticoagulant activities.106 
 
  
 
Figure 14. Schematic model of regulation of thrombin function by binding of sodium ion. “F” 
represents the fast form of sodium with procoagulant function and “S” represents the slow form 
of thrombin with anticoagulant function. 
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spread over the region of the exosite I, the 60-loop, the sodium binding site, and the active site. 
In the case of protein C, the surface recognition is limited to the primary specificity pocket and 
portions of the 60-loop. Thus, it is easy to identify the residues that are significant for fibrinogen 
binding and to construct mutants with enhanced anticoagulant activity. A thrombin mutant with 
lower proteolytic cleavage activity for fibrinogen but retaining activity for protein C can act as 
an anticoagulant by generating APC in blood circulation. In one of the studies by Cera et al.,192 
the double mutant W215A/E217A (WE) was found to be a safe and potent anticoagulant in a 
baboon model. At the dose of 0.011 mg/kg, it reduced the platelet thrombus accumulation by 
80%. Subjects treated with WE showed no signs of hemorrhage or organ failure. There was no 
procoagulant activity observed in plasma until the end of one week. At high doses, it exhausted 
the cofactors for protein C activation before consuming the substrate reserve and the effect of 
overdose is thus down regulated rapidly. Protein C activation by WE appeared to be safe when 
compared with other methods of anticoagulation.192 In another study by Cera et al., the double 
mutant R221aA/K224A completely abolished the sodium affinity by retaining the discrimination 
among monovalent cations. The disturbance of two ions pairs formed by these residues elicited 
drastic changes in structure such that fibrinogen specificity is completely lost but the specificity 
for protein C is retained, making the thrombin act as an anticoagulant.113 
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Chapter 2 Hypothesis 
 
 
2.1 The Era of Small Molecule Inhibitors of Thrombin 
Thrombin is an attractive target for designing anticoagulants owing to its most central 
role in the coagulation cascade. “Direct” and “indirect” are the two most important approaches 
used to target the inhibition of thrombin.69 Heparin, an indirect inhibitor of thrombin, mediates 
its action through activation of antithrombin. Direct inhibitors mediate their action by binding 
directly to the active site of thrombin.193 Hirudin was the first direct inhibitor of thrombin 
reported in literature. Hirudin is the most potent inhibitor of thrombin, making it an essentially 
irreversible inhibitor.52 Based on the hirudin structure, ximelagatron was the first orally available 
direct thrombin inhibitor (DTI).75 Later, hundreds of small molecules were identified as active 
site inhibitors of thrombin and factor Xa. Recently, a number of selective inhibitors of thrombin 
and factor Xa have been identified by exploring the specificity site in the active site region.194 
DTIs have certain advantages over indirect inhibitors.  They have the potential to inhibit the 
fibrin-bound thrombin whereas heparin fails to inhibit it. Secondly, small molecule inhibitors do 
not elicit thrombocytopenia.195 Also, the direct inhibitors demonstrate a predictable dose 
response, which translates into a reduced requirement for regular laboratory monitoring. They 
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also demonstrate both  larger therapeutic windows and rapid onset of action, yet they suffer from 
certain disadvantages such as higher cost, patient compliance, hepatotoxicity and the need for 
regular dosage adjustment.44 
 
2.2 Inhibition of Thrombin Through Exosites 
 
Thrombin can be also be targeted by the action of inhibitors at its two exosites.196 These 
exosites can be used for designing allosteric inhibitors of thrombin. Besides acting as functional 
epitopes for defining high specificity binding, the exosites can also allosterically modulate the 
proteolytic activity of thrombin. It is known that thrombin has excellent communication between 
its exosites and active site.76 The long range communication of the sodium binding site with the 
active site through a network of eleven water molecules is the best known example of thrombin’s 
allosteric modulation.109 The binding of thrombomodulin to exosite I of thrombin distorts the 
active site in such a way that it changes the specificity from a procoagulant role to an 
anticoagulant role. This proves that a communication pathway between exosite I and the catalytic 
site.168 Sucrose octasulfate (SOS), which is considered to be a surrogate for heparin, binds at 
exosite II. It is found that SOS weakly inhibits thrombin activity by an allosteric mechanism 
mediated by binding to exosite II. Low molecular weight lignins (LMWLs) previously 
synthesized in our group were found to be potent allosteric inhibitors of thrombin. This set of 
examples encourages a new pathway for designing the inhibitors that mediate the allosteric 
inhibition of thrombin by binding to one of the exosites. 
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2.3 Advantages of Allosteric Over Direct Inhibitors 
The major disadvantage of DTIs is that they can completely inhibit the catalytic activity 
of thrombin. Besides inhibiting its procoagulant role, these inhibitors will also block the 
anticoagulant function of thrombin by inhibiting activation of protein C. This can lead to 
rebound hyper-coagulability.96 The active site DTIs are also known to have an antiplatelet effect 
through reduced platelets activation. Furthermore, the clinical data on the longer use of DTIs 
suggests a higher risk of fatal hepatotoxicity and other side effects. However, these effects are 
asymptomatic and reversible on discontinuation of therapy. Severe hepatotoxicity led to 
disapproval of ximelagatran by FDA followed by its withdrawal from the European market.197 
Moreover, a suitable monitoring method for anticoagulant therapy using DTIs has not been well 
established. The activated partial-thromboplastin time (APTT) assay suffers from poor linearity 
and reproducibility. Recombinant hirudin and its analogs can be monitored with activated 
partial-thromboplastin.44 Finally, the lack of an available antidote for reversing the effect of 
overdosed active site directed DTIs further increases the risk associated with this therapy. The 
requirement for an antidote is of extreme necessity in high bleeding risk patients.198 
Beside these limitations, DTIs are also not optimal therapy for most of the thrombotic 
disorders. None of the DTIs have shown better efficacy and safety profile than LMWHs for long-
term treatment of acute coronary syndrome. DTIs are also less effective than LMWHs for 
treatment of thromboprophylaxis after orthopedic surgery. Altogether, lower efficiency, poor 
safety profile, hepatotoxicity and the lack of an antidote drives research toward the path of 
allosterically inhibiting the thrombin for anticoagulant therapy.199 
It is easy to attain selectivity for a single protease in allosteric design of inhibitors. The 
active sites are mostly conserved in proteases in the coagulation cascade, thus making it difficult 
 45 
 
for selective inhibition. Selectivity for a single protease will be translated into lesser side effects 
and lower risk of excessive bleeding. The partial inhibition of thrombin to maintain the balance 
between anticoagulation and coagulation can be easily achieved by allosteric inhibitors. One of 
the major advantages of allosteric inhibitors is the relatively easy design of antidotes for reversal 
of the effects of accidental over-dosing.   
 
2.4 Rationale for Design of Benzofuran scaffold 
To design functional mimics of heparin that are orally available and safe, our laboratory 
previously designed sulfated LMWLs, which are synthetic versions of naturally occurring 
lignins. 200, 201 The synthesis involved enzymatic oxidative coupling of commercially available 4-
hydroxycinnamic acids, caffeic acid, sinapic acid and ferulic acid using horseradish peroxidase. 
The oligomeric intermediates were sulfated to give three sulfated LMWLs, named CDSO3, 
SDSO3 and FDSO3, having interesting anticoagulant profiles and modes of action.202 
Sulfated LMWLs are oligomeric and polyanionic in nature. Similar to heparin, they are 
polydisperse and heterogeneous in nature. Beside these similarities with heparin, the mechanism 
of inhibition of thrombin is significantly different from heparin.202 This is owing to the nature of 
scaffold being less anionic and more hydrophobic as compared to heparin. The saccharide 
scaffold chain in heparin is replaced by an aromatic scaffold chain in sulfated LMWLs. 
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Figure 15. Structure and scheme of synthesis of LMWLs displaying the various linkage 
formations leading to pool of different structures 
 
Sulfated LMWLs are a heterogeneous mixture arising from multiple inter-monomeric 
unit linkages (β-5, β-β, β-O-4, and 5-5).200, 202, 203 This mixture is further complicated by variable 
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chain lengths and patterns of sulfation. The presence of multiple chiral centers further adds to the 
heterogeneity of the mixture. A simple calculation gives 262,144 distinct structures in the 
decamer-length unit.200, 203 The average molecular weight of CDSO3 (the most interesting 
LMWL) was found to be 3320, with a range of chain lengths between 5 and 13 monomeric units. 
CDSO3 contains an average of 0.4 sulfate groups/unit as compare to 0.7 sulfate groups/unit on 
heparin.200 The substrate hydrolysis assay of CDSO3 for thrombin in the presence and absence of 
antithrombin suggested that CDSO3 inhibits thrombin by the direct mechanism.202 Unlike 
heparin, CDSO3 does not require the presence of antithrombin to inhibit the activity of 
thrombin.202 Based on these studies, it was found that CDSO3 is a potent direct inhibitor of 
thrombin. In a Michaelis-Menten kinetics analysis, it was found that the KM of substrate 
hydrolysis by thrombin was not affected by the presence of CDSO3. At the same time, VMax was 
significantly reduced. This result suggested that CDSO3 does not compete with the substrate for 
binding.201 Competitive binding studies with known ligands for exosite I and II indicated strong 
competition with UFH and H8. Based on these biochemical studies, it was concluded that 
CDSO3 is a non-competitive, direct thrombin inhibitor. Interestingly, human plasma and blood 
studies indicated that CDSO3 possessed anticoagulant potency similar to clinically approved 
LMWHs.201, 202 
The major concerns with LMWLs are their poly-dispersity and heterogeneity in structure. 
This can result in batch-to-batch variation in structural population, thus affecting the potency of 
the mixture. The presence of structures with different binding features can also bind at various 
non-target sites leading to severe side effects. The lack of structural information of such a 
heterogeneous mixture presents a hurdle for rational design of newer molecules to improve 
potency and ADME profiles. 
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To design homogeneous structures with potent anticoagulant activity based on the 
sulfated LMWL scaffold, we envisioned sulfated LMWLs as aromatic units formed by various 
random linkages of 4-hydroxy-cinnamic monomers. Literature suggests an abundance of β-5 
linkages in natural lignins.204, 205 We initiated the design of new classes of anticoagulants based 
on the β-5 linkage of sulfated LMWLs (Figure 16). The β-5 linked monomers of CDSO3 form a 
dihydrobenzofuran moiety having carboxylate and sulfate groups at 3- and 7- positions, 
respectively. It also has two stereo-centers at the 2- and 3- positions. Simplification of the above 
structure, gave the benzofuran unit. After incorporating synthetic feasibility, we proposed 5, 6-
dihydroxy-benzofuran-3-carboxylate ester as the first designed, small molecule scaffold for 
allosteric modulation of thrombin’s activity.  
 
 
Figure 16. The development of design of benzofuran scaffold from the DHPs, showing various 
inter-monomeric linkages present in sulfated lignin. The β-5 linkage forms the Dehydro-
benzofuran ring, which is modified to benzofuran to remove the complexity of two chiral centers 
and for ease of synthesis. 
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Based on this hypothesis, a small library of sulfated benzofuran monomers were 
synthesized and evaluated for thrombin inhibition. It was found that the selected sulfated 
monomer inhibited thrombin with low potency but that Michaelis-Menten kinetic analysis 
revealed that these molecules do not compete with spectrozyme-TH.205 Thus, based on these 
findings, it can be concluded that, although inhibition potency of sulfated monomers is low, the 
design of allosteric inhibition of thrombin is proven. This led us to further ask whether:  
1) Can we design dimeric or higher oligomeric sulfated benzofurans to improve the 
inhibition potency? 
2) Can we still retain the allosteric mode of inhibition for higher oligomeric sulfated 
benzofurans and explore the binding region? 
3) Can in vitro potency of these inhibitors translated in higher systems? 
4) Is it possible to propose newer scaffolds based as potential leads for allosteric inhibition 
of thrombin? 
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Chapter 3 Synthesis of Library of Sulfated Benzofuran Monomers and Dimers 
 
 
3.1 Introduction 
Thrombin is a key enzyme of the coagulation cascade, exhibiting important roles in both 
pro-coagulation and anti-coagulation processes. Most clinically used anticoagulant drugs, 
including polymeric heparin, warfarin, hirudin, argatroban and the recently approved dabigatran, 
aim to reduce thrombin activity.197 Although these drugs have been successful in treating many 
thrombotic disorders, anticoagulation therapy continues to suffer from bleeding risk, narrow 
therapeutic index and other drug-specific adverse effects, which highlight the critical need to 
develop agents with better therapeutic profiles. 
Structurally, thrombin is a complex serine protease of the trypsin family that displays 
multiple ligand-binding domains that modulate its activity and interactions with other molecules. 
These domains include the active site, the anion-binding exosites I and II, and the sodium 
binding site. The design of thrombin inhibitors has focused almost exclusively on blocking the 
substrate’s access to the active site through a competitive process.197 This paradigm has resulted 
in the design of thousands of molecules distributed across a large number of scaffolds.20, 80, 197, 206 
Of these, a select group of scaffolds, including the pyrazoles, napthylamidines, indoles, 
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biphenyls, and benzimidazoles, are preferred because of their high thrombin selectivity. 
Fundamentally, these designed inhibitors attempt to mimic the D-Phe-Pro-Arg recognition 
sequence through the incorporation of a guanidine or amidine moiety. Recently, however, newer 
molecules have been designed with a P-1 halophenyl substituent so as to interact with Tyr228 in 
the S1 pocket, which improves the poor oral bioavailability of most P-1 guanidine-based 
inhibitors.197, 207, 208 
An exciting alternative to competitive inhibition of thrombin is allosteric inhibition 
through either exosite I or II. It is well established that binding of ligands in these exosites can 
induce conformational changes in the active site of thrombin.79, 86, 209, 210 An example of this is 
thrombomodulin, which interacts with exosite I so as to change the substrate specificity of 
thrombin from fibrinogen to protein C.210 Likewise, hirugen binding in exosite I increases or 
decreases the catalytic efficiency of thrombin, depending on the nature of the chromogenic 
substrate.86, 209 Similarly, exosite I – active site allosteric coupling is also the reason why 
peptides such as bothrojaracin inhibit thrombin.101, 102 Nevertheless, no small organic molecule 
has been designed to date that utilizes exosite I to effect physiological thrombin inhibition. 
Exosite II ligands include heparin, chondroitin sulfate, haemadin, and fibrinogen γ’. 
These can be broadly classified as either highly anionic polysaccharides or traditional peptides. 
Interaction of heparin with exosite II is known to induce greater reactivity with antithrombin and 
recent work shows that formation of the antithrombin – thrombin complex disrupts exosite II.211 
Also, exosite II – active site coupling is suggested by the change in fluorescence properties of 
para-amino benzamidine, a non-covalent active site probe, upon heparin binding to exosite II.212 
However, no exclusive II ligand has been found to date that reduces the catalytic efficiency of 
thrombin. 
 52 
 
Allosteric regulation is a promising strategy for thrombin inhibition. Nature tends to 
utilize allosterism to confer specificity of recognition and also to effect regulation. For thrombin, 
the possibility of regulation, or controlled inhibition, is of considerable importance because 
nearly all current anticoagulants are associated with risk of bleeding. An appropriately designed 
allosteric regulator that does not fully nullify the procoagulant signal may maintain a finely tuned 
balance between procoagulant and anticoagulant signal resulting in reduced bleeding 
complications. In pursuit of such allosteric regulators, we had earlier designed sulfated low 
molecular weight lignins (LMWLs) as functional mimetics of heparin targeted to exosite II-like 
regions of coagulation enzymes, including thrombin.213, 214 Sulfated LMWLs, chemo-enzymatic 
variants of the naturally available lignin (Fig. 1), were found to potently inhibit thrombin with an 
IC50 of 18–34 nM under physiological conditions.213 More importantly, sulfated LMWLs also 
inhibited blood clotting under ex vivo conditions with potency comparable to the LMW 
heparins.215 
Despite their excellent in vitro and ex vivo anticoagulant properties, sulfated LMWLs are 
challenging because of their polydispersity and microheterogeneity, which parallel that observed 
with the heparins. Sulfated LMWLs represent a large library of structures arising from multiple 
inter-monomeric linkages, variable sulfation and chain length, and the presence of many chiral 
centers.216 These variables introduce considerable structural diversity to these molecules, which 
nevertheless bind to exosite II of thrombin and allosterically induce thrombin inhibition.213 
Sulfated LMWLs represent the first examples of an exclusive exosite II-mediated inhibition of 
the key coagulation protease. 
In this and the next chapter, we present a study of 28 monomeric and dimeric sulfated 
benzofurans, molecules derived from the sulfated LMWL structure, as inhibitors of thrombin. 
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Enzyme inhibition studies show that the library of molecules displays a range of inhibition 
potential, while Michaelis-Menten kinetic studies show the inhibition to arise from an allosteric 
process. Collectively, this work establishes the potential of allosteric inhibition of thrombin 
through the interesting and unusual features of sulfated benzofurans that direct the interaction 
with thrombin. 
 
3.2 Synthesis 
3.2.1 Simple Synthesis Procedure of Highly Functionalized Benzofuran Unit 
Our initial synthesis of ethyl 5,6-dihydroxy-2-methylbenzofuran-3-carboxylate on a 5-
gram scale using the method reported by Pei et al 217 produced the desired product only in yields 
below 20% and required several rounds of chromatographic purification. In order to obtain 
enough hydroxylated benzofuran as a building block for the thrombin inhibitors, various solvent 
systems, base and reaction times as well as a simplified purification procedure were investigated. 
It was found that solvent composition played a crucial role in defining the reactivity of 
components. Detailed studies indicated that the amount of water played a crucial role in the 
reaction (Table 1).  Whereas 1:1 water – ethanol mixture was completely ineffective, a 3:1 was 
found to be optimal in yielding the desired highly functionalized benzofuran. Likewise, neither 
water alone nor ethanol alone yielded any product. The reason for this significant stringency 
appears to be the insolubility of catechol and ethyl acetoacetate. Yet, other solvents such as 
acetonitrile or DMF, in which both reactants are fully soluble, also failed to give any product. 
Attempting to improve solubility by heating to 50 °C also failed as it resulted in tar, possibly due 
to polymerization. Preventing this tar formation by removing atmospheric oxygen (flushing with 
nitrogen) gave back the starting materials in nearly quantitative yields. The reaction requires 
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atmospheric oxygen to promote oxidative addition and cyclization, although no experiments 
were performed to assess the minimal level of atmospheric oxygen necessary to sustain the 
reaction. 
Table 1. The effect of different solvent composition on reaction yield. The following reaction 
condition was used: catechol (20 mmol), ethyl acetoacetate (10 mmol), base (40 mmol), NaIO3 
(10 mmol) at room temperature for 14 hours. 
 
OHO
HO
O
OEt
HO
HO
OEt
O O
Base, NaOI3
 
Solvent Yield 
Water 0 
Water: Ethanol (96:4) 0 
Water: Ethanol (90:10) 7% 
Water: Ethanol (85:15) 10.5% 
Water: Ethanol (80:20) 18% 
Water: Ethanol (75:25) 25% 
Ethanol 0 
Acetonitrile 0 
Acetonitrile: Ethanol (80:20) 0 
*
Water: Ethanol (75:25) 0 (Heating at 50 °C) 
*
Water: Ethanol (75:25) 0 (under nitrogen) 
 
To further improve the yield of the reaction, various bases with increasing pKa were 
screened (Table 2). Bases such as triethylamine and DIPEA improved the yield to 40-50%, most 
probably arising from better deprotonation of acidic hydrogen from ethyl actetoacetate. Yet, 
stronger bases such as K-t-butoxide (pKa = 19) resulted in no products.  Reaction time of 10-12 
hours was also found to be critical (Table 2). Extending the reaction time beyond 12 hours led to 
a significant decrease in yield probably because of oxidative degradation of the product. 
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Finally, purification of the desired product could be achieved through direct precipitation 
in ethyl acetate as the yield had increased to a sufficiently high level. Thus, an effective 
procedure for the synthesis of highly funcationalized benzofuran was developed. In this process, 
catechol (4.4 g), ethyl acetoacetate (5.6 g) and DIPEA (10.14 g) were added and stirred for 5 
minutes to make a slurry. Ethanol (50 mL) and then water (150 mL) were added to the slurry, 
stirred for 10 minutes followed by addition of sodium iodate (4 g). The reaction was allowed to 
proceed unattended at room temperature for 10 hours, then quenched with ethyl acetate (400 mL) 
and extracted with acidified brine followed by vacuum concentration. The desired product was 
obtained with > 95% purity by direct precipitation from ethyl acetate. 
 
Table 2. The effect of various bases and reaction time on percentage yield of 1a. The following 
reaction condition were used: 1catechol (20 mmol), ethyl acetoacetate (20 mmol), NaIO3 (10 
mmol), water: ethanol (3:1) at room temperature for 14 hours; 2DIPEA (40 mmol) was used as 
the base. 
 
Impact of different bases1 Impact of reaction time2 
Base %Yield Time (Hours) % Yield 
Pyridine (2 equiv.) 25 8 15 
Pyridine (1 equiv) 10 10 60 
Triethylamine 40 12 50 
DIPEA 50 14 40 
K
+-
O-tBu 0 24 20 
 
To evaluate the feasibility of this synthetic procedure to other reactants, various 
commercially available alkyl acetoacetates including methyl, ethyl, t-butyl, methoxy ethyl and 
allyl ester were investigated at a 10 g scale. It was observed that yield improved with polarity of 
the esters such as methoxyethyl ester and decreased with hydrophobic t-butyl ester (Table 3).  On 
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the other hand, the simple purification method of direct precipitation in ethyl acetate is 
applicable to all of these esters. Thus, overall a significant advance could be achieved in the 
application of this useful reaction to synthesis of a library of highly functionalized benzofurans. 
 
Table 3. The effect of substitutions on the dicarbonyl compound. The following reaction 
condition were used: catechol (20 mmol), ethyl acetoacetate (20 mmol), DIPEA (40 mmol),  
NaIO3 (10 mmol), water: ethanol (3:1) at room temperature for 10 hour. 
 
 
 
Compound -R % Yield 
1a -CH3 60 % 
1b -CH2CH3 60 % 
1c -C(CH3)3 40 % 
1d -CH2CH2OCH3 70 % 
1e -CH2CH=CH2 60 % 
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Figure 17. Synthesis of a library of sulfated benzofurans as potential allosteric regulators of 
thrombin. The library consists of 15 monomers (5a – 5j, 6, 7, 9a, 9b, and 10) and 13 dimers (12a 
– 12f, 13 – 19). Reactions: a) Cs2CO3, alkyl or acyl halide , an. DMF; b) TBDMSCl, Imidazole, 
i, f)
16
h, e, f)
17
14 
c, l, e, f)
9a,9b
e, f)
8a, 8b
5a – 5j
6
7
10
13
j, e, f)
j, e, 
k, e, f)
b, c, d, e, f)
18
f)
i, f)
i, f)
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g)
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DMF; c) NBS, CCl4; d) Cs2CO3, 2; DMF; e) KF, CH3COOH, DMF; f) Et3N:SO3, CH3CN:DMF 
(4:1), MW; g) Me3Al, R-H, toluene; h) Cs2CO3, 1a, DMF; i) LAH, an. THF; j) Cs2CO3, 
morpholine, DMF; k) Cs2CO3, 4a, DMF; l) Cs2CO3, DMF, desilylated 8a; m) alc. LiOH. 
 
3.2.2 Synthesis of Benzofuran Monomer and Dimer Precursors  
The detailed protocol for the synthesis of each benzofuran precursor is provided in the 
Experimental Section (3.4). The overview of the highly branched synthesis scheme is described 
in Figure 17. This highly branched synthesis scheme was required for the synthesis of a diverse 
library in term of number and position of sulfate and variable substitutions at the 2-, 3- and 6-
positions. 
 
3.2.3 Hydrolysis of Ethyl Ester  
Initially, several attempts failed to hydrolyze the ethyl ester present at 3- and 3’- positions 
of the sulfated benzofuran dimer. In addition to the abundance of literature on mild hydrolysis of 
ester groups, the reaction required effort to optimize the conditions to hydrolysis ester in the 
presence of labile sulfate groups (Table 4). The following conditions were tried: 
To the solution of 12a in anhydrous DMSO was added K-t-butoxide (2 equiv) and a 
catalytic amount of water. The reaction was stirred at room temperature for 12 hours. No product 
was observed. The use of a different solvent system such as DMF also failed to give the desired 
product. At low temperature, no product was observed and mostly starting material was retained. 
At room temperature, the conditions were too harsh for the sulfate group. An enzymatic method 
was used as an alternative approach for ester hydrolysis. Pig liver esterase was used in various 
buffer systems. However, no product was observed even after prolonged reaction time. t-Butyl 
ammonium hydroxide was also used to facilitate the hydrolysis of ester group. It also failed to 
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give desired the product at room temperature. Under microwave radiations for 20 minutes at 80 
°C, degradation of starting material was observed. High temperature conditions were not suitable 
for the stability of the product. Other bases such as cesium carbonate and NaOH were used. The 
solvent systems such as methanol, ethanol and water: methanol (1:1) failed to give desired 
product.  
There were several reports on the use of LiOH for hydrolysis of ethyl ester. Initially, it 
failed to give the desired product in the acetonitrile:DMF (4:1) and THF:water (4:1) solvent 
systems. The saturated solution of LiOH in methanol led to degradation of starting material. 
Finally, 3 equivalents of LiOH in methanol at room temperature in 5 hours gave the desired 
product in good yield.  
Table 4. The reaction condition tried for hydrolysis of ethyl ester group of 12a 
Base Solvent Condition Result 
K-t-butoxide DMSO Water (cat.) Sulfate removal 
K-t-butoxide DMF Water (cat.) Sulfate removal 
Pig Liver Esterase Phosphate buffer RT No product 
Bu4NOH THF RT and MW (80°C) No product 
Cesium Carbonate Water/methanol RT No product 
NaOH Ethanol RT Sulfate removed 
LiOH ACN: DMF RT No Product 
LiOH THF: water RT Degradation 
Sat. LiOH Methanol RT Degradation 
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Reason: The major concern in this step was the stability of the sulfate group. It is known that 
sulfate groups are not stable under strong basic conditions as well as under moderate acidic 
conditions, limiting the use to stronger bases and higher temperatures. Secondly, both ester 
groups were sterically hindered, which limits the access of bulkier bases. The steric issue was 
further exacerbated by Π-stacking of aromatic rings. The planar nature of these molecules 
increases the probability of Π-stacking and aggregation. 
3.2.4 Reduction Benzofuran Dimer to Diversify the Number and Position of Sulfate Group 
 In order to observe the effect of sulfate group at the 3- position, we tried to convert ethyl 
ester to hydroxyl and methyl hydroxyl group at this position. For the introduction of 3-hydroxy 
and 3-methylhydroxy groups, the Baeyer-Villiger reaction and reduction of ester were tried. 
Procedure for Baeyer-Villiger Reaction: To a solution of 3a (1 mmol) in dry methylene chloride 
was added meta-chloroperoxy benzoic acid (mCBPA, 2 mmol) and a catalytic amount of p-
toluene sulfonic acid. The reaction mixture was stirred for 12 hours at room temperature. The 
product formation was monitored using thin layer chromatography and 1H-NMR on the crude as 
well as after initial work up using brine and methylene chloride. The reaction failed to give the 
desired product. To optimize the reaction conditions, the reaction was performed at 50 °C to 
overcome the energy barrier, but still no product was observed. The reaction conditions were 
further modified using different equivalents of mCBPA and by varying the amount of p-toluene 
sulfonic acid. All the above reaction conditions failed to give the desired product. 
Procedure for Reduction Using Lithium Aluminum Hydride: To a solution of 2a, 3a and 11a-
reduced (1 mmol) in dry THF was added lithium aluminum hydride (2 mmol). The reaction 
mixture was stirred at room temperature for 3 hours and then quenched by adding a small 
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amount of water. The reaction product was extracted between brine and methylene chloride 
layers. The organic layer was concentrated and purified by flash chromatography using a silica 
gel column. The product formation was monitored using thin layer chromatography and H-NMR 
of crude as well as the purified product. No product was observed. In order to check the 
efficiency of the reducing agent, lithium borohydride was used, but still no product was 
observed. It was concluded that the reducing agent was either not of sufficient activity or had 
been deactivated by moisture. Further, an excess of LAH was used and thus was transferred 
under nitrogen atmosphere to prevent the deactivation by air moisture. When a large excess of 
LAH (5-8 equiv) was used, product was observed in 70% yield. Reaction was purified using 
silica gel flash chromatography using ethyl acetate in hexanes (10-50%) as solvent.  
The product obtained was sulfated using a microwave-based protocol. The triethyl amine 
salts of sulfated 6, 7 and 16 were purified by flash chromatography using a silica gel column. 
Ethyl acetate in hexanes (30%-80%) was used as solvent. It was observed that the product started 
degrading after purification. Initially, it was believed that the acidic nature of silica might be 
responsible for degradation as it is known that the sulfate group is unstable in acidic condition. 
To overcome this, a neutral alumina column was used for purification, but still degradation was a 
major issue. To check the stability of the product, a small 1H-NMR study was performed to 
check the stability of the product in various solvents. The 1H-NMR for 7 was recorded in various 
solvents over times of 10 minutes to few days. It was observed that the product was stable in 
CH3CN even after 10 days. In methanol, extra peaks corresponding to degradation product 
started appearing in the proton spectra over the period of 2 hours and complete degradation of 
product was observed in 2 days. In methanol-water (1:1), prominent peaks of degraded product 
were observed after both 10 minutes and 2 hours. In the case of water as solvent, degradation of 
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product started immediately and significant excess peaks started appearing in proton spectra in 
just 10 minutes. Furthermore, no peaks corresponding to 6 were observed after separation on a 
cation-exchange column, which is consistent with instability of the product in water. Based on 
these studies, it can be concluded that 6 is stable in polar aprotic solvents, but starts degrading in 
protic solvents. The nature of protic solvents to stabilize ions and promote protonation, might be 
the factor responsible for degradation. The position of the sulfate group and resonance effects 
may lead to the removal of the 3- position sulfate group.  
Reason: The reason for the instability of these molecules in aqueous solvents is not fully 
understood. But based on 1H-NMR data, it can be postulated that the electronic effects of the 
sulfate group as well as of the aromatic ring play a major role. The sulfate group is highly 
electron withdrawing in nature causing electron “pull” from the aromatic unit, which is further 
supported by the electron donating nature of the oxygen atom. This movement of electrons can 
lead to removal of the sulfate group as well as the resonance of aromatic unit to hydroquinone.  
 
3.3 Results and Discussion 
3.3.1 Design of the Sulfated Benzofuran Scaffold  
 Sulfated LMWLs, which recognize exosite II of thrombin, are based on an aromatic 
scaffold, a scaffold dramatically different from the highly anionic polysaccharide scaffold of 
heparin.216 Nevertheless, sulfated LMWLs retain one characteristic of heparin – structural 
complexity arising from the presence of multiple inter-monomeric linkages, such as β-5, β-β, β-
O4, and 5-5 (Figure 16). A simple calculation suggests that LMWL molecules as small as a 
tetramer can exhibit nearly 1400 distinct structures even if sulfation and inter-residue linkage are 
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the only variables considered. To uncover distinct structures that may be the seat of 
anticoagulant activity, we visualized lignin structure as concatenated, aromatic units, instead of 
repetitions of 4-hydroxy-cinnamic acid monomers joined together through different inter-residue 
linkages. In this alternative analysis, oligomeric lignin can be considered as a combinatorial 
library of dihydro-benzofuran, phenoxy-propanoic acid, biphenyl and fused furan monomers 
(Figure 16). We reasoned that one or more of these aromatic units with appropriate sulfate 
groups could be the seat of thrombin recognition and inhibition. 
To begin assessing the contribution of these individual aromatic units, we focused on the 
benzofuran unit, which is a common scaffold used in many synthetic studies. In a preliminary 
investigation, we had prepared a library of sulfated and carboxylated benzofuran monomers, of 
which a small group of molecules were found to inhibit thrombin, albeit with IC50 in the 
millimolar range. Interestingly, mechanistic studies had suggested allosteric inhibition by these 
molecules.218 This promise led us to explore a more diverse set of sulfated benzofuran monomers 
and dimers as potential inhibitors of thrombin (Figure 17). 
 
3.3.2 Overall Description of the Sulfated Benzofuran Library  
The benzofuran unit of sulfated LMWLs contains substitutions at the 2, 3, 5- positions 
(Fig. 17). Of these, the 2- and 5- positions are utilized for inter-monomeric linkage and the 3- 
position may bear a carboxylate or an alkylsulfate group. Considering these variations, charged, 
polar and hydrophobic substitutions were engineered on this scaffold to obtain a structurally 
diverse library. Figure 17 describes the multi-modal approach developed to synthesize 15 
sulfated monomers and 13 sulfated dimers. This library reflects significant variations in: 1) the 
number of negatively charged groups (1 to 3 anions); 2) the position of anionic and polar 
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substitutions from the terminal to the center of the scaffold; 3) the size and nature of hydrophobic 
groups; and 4) inter-residue linkage geometry. A characteristic feature is that each member of the 
library is nearly fully water soluble because of the presence of one or more sulfate groups, 
despite the primarily hydrophobic benzofuran backbone. This combination of water solubility 
and hydrophobicity has been known to introduce novel physicochemical characteristics in the 
sulfated lignin-based scaffold, e.g., higher than expected partition coefficient,219 and greater 
proportion of non-ionic forces in binding to proteins.220 
 
3.3.3 Synthesis of Sulfated Benzofuran Monomers  
The first step in the synthesis of the library was the generation of base structures, 5,6-
dihydroxy-benzofuran-3-carboxylic acid esters 1a – 1e (Figure 17), from catechol in one step 
using oxidative Michael addition conditions following the report of Pei et al.217 The reaction was 
strongly susceptible to substituent effects, which required extensive optimization of reaction 
conditions, especially the organic base, reaction time and solvent. Eventually, products 1a – 1e 
were obtained in reasonably good yields (50–65%). Monoalkylation or acylation of 
dihydroxybenzofurans proceeded smoothly to selective 6-substituted derivatives 2a – 2j. That 
the substitution occurred at the 6-position of the benzofuran ring was confirmed through two 
dimensional nuclear Overhauser spectroscopy experiments (ROESY), which showed a 
correlation between the protons of the 3-alkyl ester and 6-alkoxy groups (not shown). The 
monomeric benzofurans 2a – 2j so synthesized in two steps formed one major group of 
precursors for library construction. Another set of monomer precursors 3a – 3g and 4a – 4g were 
synthesized from 2a – 2j through silyl protection and bromination, respectively (Figure 17). 
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Mono-sulfated benzofurans 5a – 5j were prepared by direct sulfation of precursors 2a – 
2j. Phenolic molecules are typically more challenging to sulfate than alcoholic molecules.221 We 
had previously developed a microwave-based sulfation protocol for introducing multiple sulfate 
groups in a crowded environment using the triethylamine-sulfur trioxide complex at 100 °C.218, 
222
 This method gave good yields of mono-sulfated benzofurans 5a – 5j in their ammonium salt 
forms, which were exchanged for sodium using a Sephadex C-25 exchange column. To test 
whether the number and location of sulfate groups on the benzofuran scaffold play a significant 
role in recognizing thrombin, we also introduced a sulfate group at the 3- position. Thus, 
benzofurans 2a and 3a were reduced with LAH and sulfated to yield 6 and 7, respectively. 
However, both 6 and 7 were found to degrade within a couple of hours after dissolution in water 
at room temperature. The reason for the reduced aqueous stability of these 3-methylene sulfated 
benzofurans is not clear, although the dual combination of electron pull by sulfate groups and 
electron push by ring oxygen may be cause of more rapid desulfation. 
To assess the importance of the nature of the carbonyl group at the 3-position, silyl-
protected benzofuran ester 3 was directly converted to morpholinyl and 4-methylpiperidinyl 
amides 8a and 8b, respectively. Desilylation and sulfation gave mono-sulfated benzofuran 
amides 9a and 9b in excellent yields. Finally, 2-morpholino monomer 10 was prepared from 4a 
to study the effect of varying the 2-substituent. 
 
 
 
 
 
 66 
 
3.3.4 Synthesis of Sulfated Benzofuran Dimers  
The construction of the library of dimers relied on the nucleophilic displacement of the 
allylic bromide at the 2- position by free phenolic group at the 5-position. The apparent 
simplicity of this reaction and the availability of ten nucleophilic monomers 2a – 2j and seven 
allylic bromides 4a – 4g enticed us to construct a combinatorial library (Figure 17). However, 
the coupling was challenging on both synthesis and purification fronts. Steric crowding around 
both the nucleophile and the electrophile resulted in less than optimal yields (<50%) of 11a – 
11f. In addition, the synthesized dimers typically co-eluted with monomers in a wide range of 
multi-solvent systems, thus creating significant purification issues. We suspected that co-elution 
may be occurring because of Π-stacking at high concentrations. Thus, a higher yielding 
dimerization reaction was desirable, which was made possible through implementation of 
microwave coupling. Using this strategy silylated dimers 11a – 11f were synthesized in excellent 
yields (>90%). These were then de-protected and sulfated to yield mono-sulfated benzofuran 
dimers 12a – 12f. Likewise, mono-sulfated benzofuran dimers 13 and 14, which contain a 
morpholine ring at 2- and 3- positions, respectively, were synthesized starting from monomers 
4a and 8a, respectively, through a series of silyl protection, allylic bromination, deprotection, 
nucleophilic coupling and sulfation steps (Figure 17). 
To evaluate the role of multiple anionic groups on the small hydrophobic scaffold, 12a 
was hydrolyzed in alcoholic LiOH223 to yield 15, a mono-sulfated, dicarboxylated dimer. 
Likewise, 11a was reduced with LAH and sulfated to yield 16, which is a di-sulfated dimer, but 
as with monomers 6, 7 and 16 was found to degrade rapidly in water. Finally, coupling of 4a 
with 1a followed by desilylation and sulfation gave 17, which is also a di-sulfated dimer, but 
with a structure completely different from 16. Likewise, another variant of di-sulfated dimer, i.e., 
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18, was synthesized by coupling 1a and 2a in five steps (Figure. 17). In combination, dimers 15 
– 18 display anionic groups around three key positions (3, 5, and 6) of the benzofuran scaffold. 
These contain either two or three negative charges, which approximate the number of charges 
typically found on a heparin disaccharide. 
 
3.4 Experimental Section 
3.4.1 Chemicals, Reagents and Analytical Chemistry  
Microwave-based sulfation reactions were performed using a CEM-Discover synthesizer 
(Matthews, NC) in sealed reaction vessels (7 mL) at 50 W. The temperature of the reaction was 
maintained at the desired setting using cooled nitrogen (45 psi) flow. Reagents and chemicals 
used in reactions were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher 
(Pittsburgh, PA) and used as supplied. Analytical thin layer chromatography (TLC) was 
performed using UNIPLATETM silica gel GHLF 250 µm pre-coated plates (ANALTECH, 
Newark, DE) that were analyzed by fluorescence (254 nm). 
Column chromatography was performed using a Teledyne ISCO (Lincoln, NE) Combi 
flash RF system and disposable normal silica cartridges of 30 – 50 µm particle size, 230 – 400 
mesh size and 60 Å pore size. Sodium exchange chromatography was performed using SP 
Sephadex C-25 sodium cation exchange columns from GE Healthcare Life Sciences 
(Piscataway, NJ). An approximately 100 mg sulfated sample was loaded onto 10 g of the cation 
exchanger in a 10 × 460 mm column and eluted with either water or 20% EtOH/H2O at 0.5 
mL/min. Anhydrous reactions were carried out under nitrogen atmosphere in glassware dried at 
high temperature. Reagent solutions and solvents were handled under nitrogen atmosphere using 
syringe techniques. The HPLC purification of sulfated benzofurans was carried out on a Jasco 
chromatography system (Easton, MD) using a 250×10 mm Varian Dynamax Microsorb C4 
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column. An acetonitrile – water gradient (5 to 100% acetonitrile in 20 min) at 3 mL/min was 
used to purify the compounds on milligram scale. The eluents were detected at 300 nm.  
1H and 13C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or 
Bruker UltrashieldTM Plus) in appropriate deuterated solvents including CDCl3, DMSO-d6, 
CD3OD, acetone-d6, or D2O. All signals are reported in ppm with the internal chloroform, 
DMSO, acetone, and D2O signals at 7.26, 2.50, 3.31, 2.05, and 4.79, respectively, as standards. 
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, t = triplet, m 
= multiplet), coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all 
synthesized molecules using a Micromass ZMD 4000 single quadrupole mass spectrometer with 
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples, 
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source 
block temperature and the probe temperature were typically held at 100 and 120 OC, 
respectively, while corona and cone voltages were selected through manual optimization. The 
desolvation nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from 
110 to 1000 Daltons at 400 amu/sec. 
 
3.4.2 Detailed Description of Syntheses 
Syntheses of (1a ̶ e) 
 
To a solution of catechol (20 mmol) in 75 mL of ethanol were added the ester of acetoacetate (20 
mmol) and N, N-Diisopropylethylamine (40 mmol). The reaction mixture was stirred for 5 min. 
To this mixture was added sodium iodate (20 mmol) and stirred vigorously for 5 min and then 25 
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mL of water was added. The reaction mixture was stirred for 10 hours at room temperature and 
quenched with 400 mL of ethyl acetate and extracted with 150 mL of brine and 30 mL of 0.5 N 
HCl. The organic layer was dried over magnesium sulfate and concentrated. The product was 
purified by passing through plug of silica (1 inch in height) using 2% methanol in methylene 
chloride. The product was concentrated and dried under vacuum to provide yield of 40% (see 
Appendix, Page 239-241 for NMR spectra). 
1a: 1H NMR (Acetone-d6, 300 MHz) δ 1.36 (t, J=3 Hz, 3H), 2.63 (s, 3H), 4.31 (q, J=6 Hz, 2H), 
6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83, 
117.56, 144.09, 144.92, 147.79, 161.79, 164.48.  
1b: 1H NMR (CDCl3, 300 MHz) δ 2.65 (s, 3H), 3.97 (s, 3H), 6.99 (s, 1H), 7.43 (s, 1H). 
1c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 6.96 (s, 1H), 7.39 (s, 1H). 
1d: 1H NMR (CDCl3, 300 MHz) 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 4.46 (t, J=12 
Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
1e: 1H NMR (CDCl3, 300 MHz) 2.71 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d, 2H), 6.00 (m, 
1H), 6.91 (s, 1H), 7.46 (s, 1H). 
 
Synthesis of (2a ̶ 2j) 
 
To a solution of 1a ̶ 1e (1.44 mmol) in DMF (12 mL) were added cesium carbonate (0.72 mmol) 
and acyl or alkyl halide (1.44 mmol) and stirred for 15 hours under an N2 atmosphere. The 
reaction was quenched by adding 0.5 N HCl and extracted with ethyl acetate. The organic extract 
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was dried over magnesium sulfate, concentrated and  purified on silica gel (0-25% ethyl acetate 
in hexanes) to give product in 53% yield (see Appendix, Page 242-247 for NMR spectra). 
2a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6 
Hz, 2H), 5.58 (s, 1H), 6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3, 300 MHz) δ 14.60, 14.66, 
56.54, 60.43, 94.33, 106.04, 109.23, 119.19, 143.37, 145.18, 147.86, 162.87, 164.88. 
2b: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 6.95 (s, 1H), 7.44 (s, 
1H). 
2c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 3.92 (s, 3H), 6.92 (s, 1H), 7.39 (s, 
1H). 
2d: 1H NMR (CDCl3, 300 MHz) δ 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 3.82 (s, 3H), 
4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
2e: 1H NMR (CDCl3, 400 MHz) δ 1.45 (s, 6H), 2.70 (s, 3H), 4.13 (d, 2H), 4.36 (d, 2H), 6.93 (s, 
1H), 7.43 (s, 1H). 13C NMR (CDCl3) δ 14.34, 14.43, 14.76, 31.42, 36.45, 60.15, 65.02, 76.69, 
77.00, 77.32, 94.97, 105.73, 109.04, 118.95, 143.34, 144.13, 147.63, 162.50, 162.58, 164.63. 
2f: 1H NMR (CDCl3, 300 MHz) δ 1.40 (d, J=1.5 Hz, 6H), 1.43 (t, J=1.8 Hz, 3H), 2.71 (s, 3H), 
4.38 (t, J=1.8 Hz, 2H), 4.58 (m, 1H), 6.96 (s, 1H), 7.44 (s, 1H). 
2g: 1H NMR (CDCl3, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.71 (s, 3H), 3.76 (s, 3H), 4.36 (q, J= 
18 Hz, 2H), 5.53 (s, 2H), 7.05 (s, 1H), 7.54 (s, 1H). 
2h: 1H NMR (CDCl3, 400 MHz) δ 1.40 (t, J=18 Hz, 3H), 2.71 (s, 3H), 3.74 (m, 8H), 4.38 (q, 
J=18 Hz, 2H), 6.95 (s, 1H), 7.58 (s, 1H). 
2i: 1H NMR (CDCl3, 400 MHz) δ 2.71 (s, 3H), 3.83 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d, 
2H), 6.00 (m, 1H), 6.91 (s. 1H), 7.46 (s, 1H). 
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2j: 1H NMR (CDCl3, 400 MHz) δ 1.38 (t, J=18 Hz, 3H), 2.67 (s, 3H), 3.78 (s, 3H), 4.33 (q, J=18 
Hz, 2H), 5.02 (s, 2H), 6.89 (d, J=21 Hz, 2H), 6.98 (s, 1H), 7.32 (d, J=21 Hz, 2H), 7.41 (s, 1H). 
 
Synthesis of (3a ̶ 3f) 
 
To a solution of 2a ̶ 2f (3.63 mmol) in DMF (30 mL) was added imidazole (18.15 mmol) and 
TBDMSCl (21.83 mmol) and the mixture was stirred. After 16 hours the reaction mixture was 
quenched with water and extracted with diethyl ether. The organic layer was dried over 
magnesium sulfate, concentrated and purified by flash chromatography on silica gel (0-15% 
EtOAc in hexanes) to obtain product in 85-90 % (see Appendix, Page 250-254 for NMR 
spectra). 
3a: 1HNMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 2.69 (s, 3H), 
3.87 (s, 3H), 4.39 (q, J=6 Hz, 2H), 7.05 (s, 1H) 7.41 (s, 1H). 13C NMR (CDCl3, 300 MHz) δ 4.5, 
14.47, 18.73, 22.25, 25.96, 55.99, 61.00, 95.23, 111.31, 112.77, 118.07, 143.56, 149.97, 151.43, 
157.60, 163.69. 
3b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.70 (s, 3H), 3.83 (s, 3H), 3.91 (s, 
3H), 6.93 (s, 1H), 7.37 (s, 1H). 
3c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.03 (s, 9H), 1.62 (s, 9H), 2.69 (s, 3H), 3.83 (s, 
3H), 6.92 (s, 1H), 7.36 (s, 1H). 
3d: 1H NMR (CDCl3, 300 MHz) 0.13 (s, 6H), 1.01 (s, 9H), 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, 
J=12 Hz, 2H), 3.82 (s, 3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
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3e: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 2.71 (s, 3H), 4.03 (d, 
2H), 4.35 (d, 2H), 6.93 (s, 1H), 7.40 (s, 1H). 
3f: 1H NMR (CDCl3, 400 MHz) δ 0.19 (s, 6H), 1.04 (s, 9H), 1.37 (d, 6H), 1.42 (t, 3H), 2.71 (s, 
3H), 4.40 (d, 2H), 6.94 (s, 1H), 7.40 (s, 1H). 
 
Synthesis of (4a ̶ 4f) 
 
To the solution of 3a ̶ 3f (1 mmol) in THF (20 mL) was added NBS (1 mmol) and refluxed at 65 
oC under a halogen lamp for 1 hour. The reaction mixture was cooled and quenched with water 
and extracted with hexanes. The organic layer was concentrated and product was obtained in 90-
95 % yield (see Appendix, Page 258-260 for NMR spectra). 
4a: 1HNMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H), 
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.05 (s, 1H) 7.41 (s, 1H). 
4b: 1H NMR (CDCl3, 300 MHz) δ 1.17 (s, 6H), 1.02 (s, 9H), 3.83 (s, 3H), 3.91 (s, 3H), 4.91 (s, 
2H), 6.93 (s, 1H), 7.37 (s, 1H). 
4c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.65 (s, 9H), 3.85 (s, 3H), 4.93 (s, 
2H), 6.96 (s, 1H), 7.40 (s, 1H). 
4d: 1H NMR (CDCl3, 300 MHz) 0.17 (s, 6H), 1.02 (s, 9H), 3.45 (s, 3H), 3.76 (t, J=12 Hz, 2H), 
3.86 (s, 3H), 4.50 (t, J=12 Hz, 2H), 4.96 (s, 2H), 6.98 (s, 1H), 7.45 (s, 1H). 
4e: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 4.03 (d, 2H), 4.35(d, 
2H), 4.96 (s, 2H), 6.93 (s, 1H), 7.40 (s, 1H). 
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4f: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.38 (d, 6H), 1.43 (t, 3H), 4.48 (d, 
2H), 4.57 (s, 2H), 6.97 (s, 1H), 7.41 (s, 1H). 
 
 
Synthesis of (11a ̶ 11f) 
 
To the solution of 2a ̶ 2f (0.3 mmol) and 4a ̶ 4f (0.4 mmol) in ethyl acetate (4 mL) were added 
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred 
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene 
chloride and extracted with brine. The organic layer was dried over magnesium sulfate and 
concentrated. Purification was done by using flash chromatography on silica gel using (0-20) % 
ethyl acetate in hexanes. The product was obtained in 60-65 % yield (see Appendix, Page 261-
265 for NMR spectra). 
11a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H),  1.46 (m, 6H), 2.71 (s, 3H),  3.87 
(s, 3H), 3.91 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 
1H). 13C NMR (CDCl3, 300 MHz) δ 4.55, 14.41, 14.73, 14.68, 18.92, 25.57, 55.77, 56.62, 60.62, 
61.93, 64.47, 95.27, 98.31, 103.47, 109.31, 112.55, 112.73, 117.90, 119.98, 143.29, 146.34, 
147.95, 148.08, 151.20, 150.69, 157.66, 162.67, 164.17, 164.83. 
11b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.71 (s, 3H), 3.84 (s, 3H), 3.87 (s, 
3H), 3.91 (s, 3H), 3.92 (s, 3H), 5.60 (s, 2H), 6.98 (s, 1H), 7.01 (s, 1H), 7.44 (s, 1H), 7.59 (s, 1H) 
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11c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.59 (s, 9H), 1.60 (s, 9H), 2.68 (s, 
3H),  3.82 (s, 3H), 3.87 (s, 3H), 5.57 (s, 2H), 6.92 (s, 1H), 6.98 (s, 1H), 7.41 (s, 1H), 7.54 (s, 1H). 
11d: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 2.71 (s, 3H), 3.43 (s, 3H), 3.71 
(m, 4H), 3.83 (s, 3H), 3.86 (s, 3H), 4.45 (m, 2H), 5.59 (s, 2H), 6.97 (s, 1H), 7.00 (s, 1H), 7.47 (s, 
1H), 7.64 (s, 1H). 
11e: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.03 (s, 9H), 1.37 (s, 12H), 2.70 (s, 3H), 4.08 
(d, 4H), 4.33 (d, 4H), 5.57 (s, 2H), 6.98 (d, 2H), 7.44 (s, 1H), 7.58 (s, 1H). 13C NMR (CDCl3) δ 
4.71, 14.19, 14.36, 14.38, 14.68, 14.74, 18.46, 25.75, 60.10, 60.16, 60.46, 64.31, 64.62, 65.01, 
76.68, 77.00, 77.20, 77.32, 94.96, 96.01, 96.82, 109.13, 109.26, 111.63, 112.57, 117.85, 118.55, 
143.03, 146.17, 148.42, 149.33, 149.90, 149.98, 158.17, 162.49, 163.71, 164.46. 
11f: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.34 (d, 12H), 1.43 (m, 6H), 2.70 
(s, 3H), 4.35 (t, 4H), 4.48 (m, 2H), 5.54 (s, 2H), 6.98 (d, 2H), 7.44 (s, 1H), 7.58 (s, 1H). 13C 
NMR (CDCl3, 400 MHz) δ 4.59, 14.19, 14.38, 18.43, 21.01, 21.92, 21.98, 22.05, 25.78, 60.09, 
60.36, 60.43, 64.75, 70.94, 72.65, 76.68, 77.00, 77.32, 98.11, 100.29, 109.13, 109.78, 111.54, 
112.74, 118.05, 119.37, 143.96, 147.23, 147.51, 148.54, 149.29, 149.82, 158.39, 162.78, 163.69, 
164.43. 
 
Deprotected form of 11a ̶ 11f 
 
To a solution of 11a ̶ 11f (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and glacial acetic 
acid (10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by 
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methylene chloride and extracted with brine solution. The aqueous layer was again extracted 
with a fresh batch of methylene chloride. The organic layer was combined and dried over 
magnesium sulfate and concentrated in vacuum. The solid was precipitated using methanol to 
obtain product in 90% yield (see Appendix, Page 270-274 for NMR spectra). 
11a deprotected form: 1H NMR (CDCl3, 300 MHz) δ 1.46 (m, 6H), 2.71 (s, 3H), 3.80 (s, 3H), 
3.85 (s, 3H), 4.39 (m, 4H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H). 
11b deprotected form: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H), 
3.85 (s, 3H), 3.87 (s, 3H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H). 
11c deprotected form: 1H NMR (CDCl3, 300 MHz) δ 1.57 (s, 9H), 1.59 (s, 9H), 2.68 (s, 3H), 
3.84 (s, 3H), 3.93 (s, 3H), 5.57 (s, 2H), 6.95 (s, 1H), 7.05 (s, 1H), 7.46 (s, 1H), 7.58 (s, 1H). 
11d deprotected form: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.43 (s, 3H), 3.71 (m, 4H), 
3.83 (s, 3H), 3.86 (s, 3H), 4.45 (m, 2H), 5.59 (s, 2H), 6.97 (s, 1H), 7.01 (s, 1H), 7.50 (s, 1H), 
7.63 (s, 1H). 
11e deprotected form: 1H NMR (CDCl3, 400 MHz) δ 1.45 (m, 12H), 2.69 (s, 3H), 4.10 (m, 4H), 
4.35 (m, 4H), 5.58 (s, 2H), 6.97 (s, 1H), 6.99 (s, 1H), 7.49 (s, 1H), 7.56 (s, 1H). 
11f deprotected form: 1H NMR (CDCl3, 400 MHz) δ 1.38 (d, 12H), 1.47 (m, 6H), 2.70 (s, 3H), 
4.37 (t, 4H), 4.39 (t, 4H), 5.57 (s, 2H), 7.02 (d, 2H), 7.50 (s, 1H), 7.57 (s, 1H). 13C NMR (CDCl3, 
400 MHz) δ 14.31, 14.37, 14.38, 21.99, 22.05, 60.11, 60.53, 64.64, 72.40, 72.71, 76.69, 77.01, 
77.21, 77.32, 96.70, 100.36, 106.03, 109.12, 109.60, 111.67, 118.50, 119.39, 143.83, 144.45, 
147.15, 147.46, 148.66, 149.25, 158.69, 162.79, 163.67, 164.43. 
 
Sulfation of Appropriate Precursors to Yield Sulfated Benzofuran Monomers and Dimers 
The synthesis of sulfated benzofurans was developed following our earlier report on the 
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synthesis of sulfated flavonoids.222 Briefly, to a solution of unsulfated benzofuran monomer or 
dimer (typically 50 mg) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were added 
triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The reaction 
mixture was exposed to microwaves (50 W) for 40 min at 100 ºC followed by vacuum 
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C-
25 cation exchange resin and eluted with water. Fractions containing the sulfated product were 
lyophilized to obtain a solid residue, which was further purified on reverse-phase gradient HPLC 
to remove residual unsulfated contaminants (see Appendix, Page 282-305 for NMR spectra and 
Page 307-318 for Mass Spectra). 
5a: 1H NMR (D2O, 400 MHz) δ 1.45 (t, J=6 Hz, 3H), 2.51 (s, 3H), 3.76 (s, 3H), 4.36 (q, J=6 Hz, 
2H), 5.38 (s, 1H), 7.15 (s, 1H), 7.57 (s, 1H).  
5b: 1H NMR (D2O, 400 MHz) δ 2.48 (s, 3H), 3.89 (s, 3H), 4.21 (s, 3H), 6.98 (s, 1H), 6.61 (s, 
1H). ESI MS (-ve) m/z calcd. for C12H11O8SNa [(M-Na)-)] 315.02, found 315.01 (M-Na)-. 
5c: 1H NMR (D2O, 400 MHz) δ 1.62 (s, 9H), 2.49 (s, 3H), 3.89 (s, 3H), 6.98 (s, 1H), 6.61 (s, 
1H). 13C NMR (D2O, 400 MHz) δ 13.40, 21.22, 61.33, 73.87, 99.93, 107.79, 114.00, 118.54, 
139.23, 147.28, 150.45, 164.37, 165.49.  ESI MS (-ve) m/z calcd for C13H17O8SNa [(M-Na)-)] 
357.05, found 357.08 (M-Na)-. 
5d: 1H NMR (D2O, 400 MHz) δ 2.48 (s, 3H), 3.21 (s, 3H), 3.62 (t, J=12 Hz, 2H), 3.72 (s, 3H), 
4.26 (t, J=12 Hz, 2H), 6.91 (s, 1H), 7.59 (s, 1H). ESI MS (-ve) m/z calcd. for C13H13O9SNa [(M-
Na)-)] 345.02, found 345.01 (M-Na)-.  
5e: 1H NMR (D2O, 400 MHz) δ 1.70 (m, 6H), 2.99 (s, 3H), 4.41 (q, J=17 Hz, 2H), 4.66 (q, J= 17 
Hz, 2H), 7.55 (s, 1H), 8.21 (s, 1H). 13C NMR (D2O, 400 MHz) δ 16.36, 16.39, 16.76, 63.15, 
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67.53, 99.69, 110.66, 116.09, 119.96, 141.73, 146.05, 151.33, 152.58, 165.90, 167.00. ESI 
HRMS (-ve) m/z calcd. for C14H16O8SNa [(M-Na)-)] 343.0512, found 343.0357 (M-Na)-.  
5f: 1H NMR (D2O, 400 MHz) δ 1.37 (m, 9H), 2.36 (s, 3H), 4.23 (q, J=18 Hz, 2H), 4.54 (m, 1H), 
6.96 (s, 1H), 7.60 (s, 1H). 13C NMR (D2O) δ 13.40, 13.48, 21.22, 61.33, 73.87, 99.93, 107.79, 
114.00, 118.54, 139.23, 147.28, 150.45, 164.37, 165.49. ESI HRMS (-ve) m/z calcd. for 
C14H15O8SNa [(M-Na)-)] 357.0532, found 357.0600 (M-Na)-.  
5g: 1H NMR (D2O, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.50 (s, 3H), 3.64 (s, 3H), 4.31 (q, J=18 
Hz, 2H), 5.33 (s, 2H), 7.15 (s, 1H), 7.64 (s, 1H). ESI HRMS (-ve) m/z calcd. for C14H15O9SNa 
[(M-Na)-)] 359.0420, found 359.0395 (M-Na)-. 
5h: 1H NMR (D2O, 400 MHz) δ 1.39 (t, J=18 Hz, 3H), 2.57 (s, 3H), 3.87 (m, 8H), 4.29 (q, J=18 
Hz, 2H), 7.45 (s, 1H), 7.57 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.48, 13.72, 44.11, 44.94, 
61.53, 61.58, 66.25, 105.77, 106.60, 108.11, 114.53, 123.18, 139.99, 140.26, 149.66, 154.36, 
165.33, 166.19. ESI HRMS (-ve) m/z calcd for C17H18O10SNa [(M-Na)-)] 428.0332, found 
428.0889 (M-Na)-. 
5i: 1H NMR (D2O, 400 MHz) δ 2.51 (s, 3H), 3.63 (s, 3H), 4.65 (d, 2H), 5.02 (d, 1H), 5.16 (d, 
2H), 5.91 (m, 1H), 6.81 (s. 1H), 7.56 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.40, 55.05, 61.19, 
70.68, 97.79, 107.91, 113.75, 114.30, 118.36, 128.61, 128.99, 138.55, 148.09, 150.16, 158.52, 
163.59, 165.06. ESI HRMS (+ve) m/z calcd. for C20H19O9SNa [(M+Na)+)] 481.0632, found 
481.1400 (M+Na)+. 
5j: 1H NMR (D2O, 400 MHz) δ 1.28 (t, J=18 Hz, 3H), 2.09 (s, 3H), 3.54 (s, 3H), 4.12 (q, J=18 
Hz, 2H), 4.78 (s, 2H), 6.57 (s, 1H), 6.68 (d, J=21 Hz, 2H), 7.17 (d, J=21 Hz, 2H), 7.67 (s, 1H). 
13C NMR (D2O, 400 MHz) δ 13.40, 55.05, 61.19, 70.68, 97.79, 107.91, 113.75, 114.30, 118.36, 
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128.61, 128.99, 138.55, 148.09, 150.16, 158.23, 163.59, 165.06. ESI MS (-ve) m/z calcd. for 
C14H13O8SNa [(M-Na)-)] 325.03, found 325.04 (M-Na)-. 
6: 1H NMR (CD3OD, 300 MHz) δ 2.61 (s, 3H), 3.86 (s, 3H), 6.88 (s, 2H), 7.15 (s, 1H), 7.86 (s, 
1H). 13C NMR (CD3OD, 300 MHz) δ 10.85, 55.78, 59.93, 95.76, 110.69, 112.67, 120.71, 
138.55, 150.48, 151.65, 154.22.  
7: 1H NMR (CD3OD, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H), 6.68 (s, 
2H), 6.98 (s, 1H), 7.36 (s, 1H). 13C NMR (CD3OD) δ 4.48, 12.29, 18.70, 26.02, 55.88, 56.04, 
95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81. 
9a: 1H NMR (D2O, 400 MHz) δ 2.47 (s, 3H), 3.55-3.90 (m, 8H), 3.91 (s, 3H), 7.25 (s, 1H), 7.41 
(s, 1H). 13C NMR (D2O, 400 MHz) δ 12.48, 42.76, 47.82, 56.43, 66.41, 66.79, 96.68, 110.52, 
112.70, 118.31, 137.35, 149.74, 151.36, 156.79, 166.23. ESI HRMS (-ve) m/z calcd. for 
C15H16NO8SNa [(M-Na)-)] 370.0544, found 370.0652 (M-Na)-. 
9b: 1H NMR (D2O, 400 MHz) δ 0.89 (d, J=17 Hz, 3H), 1.01 (m, 1H), 1.61-1.81 (m , 4H), 2.39 
(s, 3H), 2.92 (m, 1H), 3.08 (m, 1H), 3.56 (m, 1H), 3.92 (s, 3H), 4.45 (m, 1H), 7.27 (s, 1H), 7.64 
(s, 1H). 13C NMR (D2O, 400 MHz) δ 12.47, 12.55, 14.88, 20.89, 30.17, 55.67, 56.59, 96.67, 
111.46, 112.63, 118.67, 137.67, 149.82, 151.26, 155.45, 165.32. ESI HRMS (-ve) m/z calcd. for 
C17H20NO7SNa [(M-Na)-)] 482.1022, found 382.0847 (M-Na)-.  
10: 1H NMR (D2O, 400 MHz) δ 1.47 (t, J=18 Hz, 3H), 2.71 (m, 4H), 3.81 (m, 4H), 3.95 (s, 3H), 
4.02 (s, 2H), 4.39 (q, J=18 Hz, 2H), 7.25 (s, 1H), 7.74 (s, 1H). 13C NMR (D2O, 400 MHz) δ 
13.45, 52.47, 52.64, 56.34, 61.82, 66.07, 96.24, 111.83, 114.82, 117.14, 137.95, 150.45, 151.64, 
159.30, 164.77. ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 414.0933, found 
414.0847 (M-Na)-. 
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12a: 1H NMR (CD3OD, 300 MHz) δ 1.32 (t,  J=6 Hz, 3H), 2.65 (s, 3H), 3.82 (s, 3H), 3.86 (s, 
3H), 4.29 (q, J=6 Hz, 2H), 5.52 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.43 (s, 1H), 8.04 ( s, 1H). 13C 
NMR (CD3OD) δ 13.12, 13.53, 13.54, 55.65, 60.20, 60.67, 63.93, 95.54, 95.63, 109.19, 112.32, 
115.57, 117.40, 118.31, 139.89, 145.50, 149.74, 152.08, 152.20, 158.70, 162.67, 163.51, 164.48. 
ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found 577.1146 (M-Na)-. 
12b: 1H NMR (CD3OD, 300 MHz) δ 2.67 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 3.86 
(s, 3H), 5.55 (s, 2H), 7.13 (s, 1H), 7.24 (s, 1H), 7.47 (s, 1H), 8.03 (s, 1H). ESI HRMS (-ve) m/z 
calcd. for C24H21O13SNa [(M-Na)-)] 549.0723, found 549.0795 (M-Na)-. 
12c: 1H NMR (CD3OD, 300 MHz) δ 1.49 (s, 9H), 1.51 (s, 9H), 2.65 (s, 3H), 3.83 (s, 3H), 3.88 
(s, 3H), 5.47 (s, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.37 (s, 1H), 8.09 (s, 1H). 13C NMR (CD3OD, 
300 MHz) δ 13.09, 27.30, 27.45, 55.59, 55.66, 64.26, 81.00, 81.62, 95.44, 95.56, 109.89, 110.21, 
113.55, 115.59, 117.70, 118.42, 139.79, 145.31, 149.83, 151.87, 152.05, 158.16, 162.26, 162.63, 
163.80. ESI MS (-ve) m/z calcd. for C30H33O13SNa [(M-Na)-)] 633.16, found 633.19 (M-Na)-. 
12d: 1H NMR (D2O, 400 MHz) δ 2.30 (s, 3H), 3.26 (s, 3H), 3.32 (s, 3H),  3.57 (m, 2H), 3.63 (m, 
5H), 3.77 (s, 3H), 4.18 (m, 2H), 4.27 (m, 2H), 5.17 (s, 2H), 6.49 (s, 1H), 6.89 (s, 1H), 6.93 (s, 
1H), 7.67 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.49, 55.40, 56.07, 58.13, 58.24, 62.74, 62.96, 
63.79, 69.76, 69.89, 93.22, 95.76, 105.85, 107.40, 111.06, 114.98, 116.73, 117.17, 138.28, 
144.55, 147.64, 148.10, 150.78, 151.62, 158.55, 162.96, 163.49, 164.40. ESI HRMS (-ve) m/z 
calcd. for C28H29O115SNa [(M-Na)-)] 637.1223, found 637.1161 (M-Na)-. 
12e: 1H NMR (D2O, 400 MHz) δ 1.14 (m, 12H), 2.32 (s, 3H), 3.72 (m, 4H), 4.06 (m, 4H), 5.15 
(s, 2H), 6.51 9s, 1H), 6.71 9s, 1H), 6.98 (s, 1H), 7.56 (s, 1H). ESI HRMS (-ve) m/z calcd. for 
C28H29O13SNa [(M-Na)-)] 605.1312, found 605.0708 (M-Na)-. 
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12f: 1H NMR (D2O, 400 MHz) δ 1.07 (m, 18H), 2.27 (s, 3H), 3.99 (m, 4H), 4.20 (m, 2H), 5.05 
(s, 2H), 6.64 (s, 1H), 6.67 (s, 1H), 6.99 (s, 1H), 7.81 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.29, 
13.50, 13.69, 13.78, 20.94, 21.19, 21.40, 60.34, 61.09, 63.81, 71.86, 72.97, 98.90, 108.13, 
111.04, 114.71, 117.74, 118.33, 139.92, 146.62, 146.72, 148.33, 148.60, 151.24, 158.69, 162.57, 
163.34, 164.08. ESI HRMS (-ve) m/z calcd. for C30H33O13SNa [(M-Na)-)] 633.1236, found 
633.1494 (M-Na)-. 
13: 1H NMR (CD3OD, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m, 4H), 3.91 (s, 3H), 3.93 
(s, 3H), 4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 1H), 8.01 (s, 1H). ESI MS 
(-ve) m/z calcd. for C30H32NO14SNa [(M-Na)-)] 659.14, found 659.15 (M-Na)-.  
14: 1H NMR (D2O, 400 MHz) δ 2.40 (s, 3H), 3.24 (m, 8H), 3.67 (m, 8H), 3.81 (s, 3H), 3.92 (s, 
3H), 5.30 (s, 2H), 6.85 (s, 1H), 7.14 (s, 1H), 7.33 (s.1H), 7.43 (s, 1H). 13C NMR (D2O, 400 
MHz) δ 12.36, 42.55, 56.00, 56.40, 63.52, 66.17, 66.36, 96.23, 96.73, 107.16, 110.44, 113.33, 
115.29, 116.94, 117.92, 138.10, 143.04, 148.81, 149.45, 151.21, 151.81, 152.46, 156.38, 164.20, 
165.93. ESI HRMS (-ve) m/z calcd. for C30H31N2O13SNa [(M-Na)-)] 659.1422, found 659.1531 
(M-Na)-. 
17: 1H NMR (D2O, 400 MHz) δ 1.23 (m, 6H), 2.36 (s, 3H), 3.70 (s, 3H), 4.18 (m, 4H), 5.23 (s, 
2H), 6.96 (s, 1H), 7.03 (s, 1H), 7.53 (s, 1H), 7.62 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.4, 
13.51, 13.59, 56.30, 61.53, 62.08, 63.51, 96.28, 99.06, 108.05, 111.73, 114.48, 115.06, 117.13, 
119.54, 138.31, 138.82, 147.96, 150.23, 150.94, 152.02, 158.07, 164.50, 164.87, 165.60. ESI 
HRMS (-ve) m/z calcd. for C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0366 (M-Na)-.  
18: 1H NMR (D2O, 400 MHz) δ 1.55 (t, J=18 Hz, 3H),1.59 (t, J=18 Hz, 3H), 2.41 (s, 3H), 3.81 
(s, 3H), 4.18 (q, J=18 Hz, 2H), 4.23 (q, J=18 Hz, 2H), 5.18 (s, 2H), 6.71 (s, 1H), 6.89 (s, 1H), 
7.65 (s, 1H), 7.91 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.47, 13.61, 13.63, 56.32, 61.53, 62.18, 
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63.61, 96.28, 99.16, 108.01, 111.53, 114.48, 115.06, 117.13, 119.54, 138.31, 138.82, 147.96, 
150.23, 150.84, 152.12, 158.17, 164.53, 164.77, 165.60. ESI HRMS (-ve) m/z calcd. for 
C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0277 (M-Na)-.  
19: 1H NMR (CDCl3, 300 MHz) δ 1.39 (m, 6H), 2.67 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 4.36 (m, 
4H), 5.55 (s, 2H), 7.22 (s, 1H), 7.23 (s, 1H), 7.43 (s, 1H), 8.07 (s, 1H). 13C NMR (CD3OD, 400 
MHz) δ 13.25, 13.38, 13.52, 55.66, 55.77, 60.25, 60.79, 63.16, 95.63, 99.17, 103.95, 108.76, 
112.48, 115.58, 117.27, 120.11, 139.90, 146.40, 148.00, 148.45, 152.15, 152.23, 158.27, 163.04, 
163.59, 164.61. ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found 
577.1100 (M-Na)-. 
 
Synthesis of 15 
To a solution of 12a (100 mg, 0.16 mmol) in 2 mL of methanol was added LiOH (20 mg, 0.8 
mmol) and stirred for 5 h at RT. After completion, the reaction mixture was concentrated and 
purified using HPLC (see Appendix, Page 301 for NMR spectra). 1H NMR (D2O, 400 MHz) δ 
2.66 (s, 3H), 3.84 (s, 3H), 3.89 (s, 3H), 5.52 (s, 2H), 7.11 (s, 1H), 7.27 (s, 1H), 7.41 (s, 1H), 8.01 
(s, 1H). 13C NMR (CD3OD, 400 MHz) δ 13.43, 61.67, 63.73, 95.54, 95.63, 109.19, 112.32, 
115.57, 117.40, 118.31, 139.89, 145.50, 149.74, 152.08, 152.20, 158.54, 162.57, 164.51, 165.48. 
ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 521.0322, found 521.1496 (M-Na)-. 
 
Synthesis of 6 from 2a 
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To a solution of 2a (0.5 mmol) in toluene was added lithium aluminum hydride (2.5 mmol) and 
stirred for 4 hours at RT. The reaction was quenched by adding water. The reaction mixture was 
extracted with ethyl ether twice. The organic layer was concentrated under vacuum and purified 
by flash chromatography using ethyl acetate in hexanes (0-40%). The reduced form of 2a was 
sulfated by method described previously in this chapter (see Appendix, Page 250 for NMR 
spectra). 
2a-reduced: 1H NMR (CDCl3, 300 MHz) δ 2.75 (s, 3H), 3.96 (s, 3H), 5.58 (s, 2H), 6.98 (s, 1H), 
7.36 (s, 1H).  
6: 1H NMR (CD3OD, 300 MHz) δ 2.61 (s, 3H), 3.86 (s, 3H), 6.88 (s, 2H), 7.15 (s, 1H), 7.86 (s, 
1H). 13C NMR (CD3OD, 300 MHz) δ 10.85, 55.78, 59.93, 95.76, 110.69, 112.67, 120.71, 
138.55, 150.48, 151.65, 154.22.  
 
Synthesis of 7 from 3a 
 
 
To a solution of 3a (0.5 mmol) in toluene was added lithium aluminum hydride (4 mmol) and 
stirred for 4 hours at RT. The reaction was quenched by adding water. The reaction mixture was 
extracted with ethyl ether twice. The organic layer was concentrated under vacuum and purified 
by flash chromatography using ethyl acetate in hexanes (0-40%). The reduced form of 3a is 
sulfated by method described previously in this chapter (see Appendix, Page 250 for NMR 
spectra). 
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3a-reduced: 1H NMR (CDCl3, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H), 
5.58 (s, 2H), 6.98 (s, 1H), 7.36 (s, 1H). 13C NMR (CDCl3, 300 MHz) δ 4.48, 12.29, 18.70, 26.02, 
55.88, 56.04, 95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81. 
7: 1H NMR (CD3OD, 300 MHz) δ 0.44 (s, 6H), 1.02 (s, 9H), 2.75 (s, 3H), 3.96 (s, 3H), 6.68 (s, 
2H), 6.98 (s, 1H), 7.36 (s, 1H). 13C NMR (CD3OD, 300 MHz) δ 4.48, 12.29, 18.70, 26.02, 55.88, 
56.04, 95.47, 109.94, 114.31, 120.84, 142.03, 149.32, 149.40, 151.81. 
 
Synthesis of 10 from 4a 
 
To the solution of 4a (0.3 mmol) in DMF was added Morpholine (0.4 mmol) and cesium 
carbonate (0.4 mmol) and stirred for 8 hrs at RT. The reaction was quenched by adding 
methylene chloride and extracted with brine. The organic layer was concentrated and purified by 
flash chromatography using ethyl acetate in hexanes (0-40%). To the solution of intermediate 4a-
1 (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid (10 µL). The reaction 
mixture was stirred for 5 hours. The reaction was quenched by methylene chloride and extracted 
with brine solution. The organic layer was combined and dried over magnesium sulfate and 
concentrated. The solid was precipitated using methanol to obtain intermediate 4a-2 in 90% 
 84 
 
yield. Compound 10 was obtained by the sulfation reaction previously described (see Appendix, 
Page 252 and 255 for NMR spectra) 
4a-1: 1H NMR (CDCl3, 400 MHz) δ 1.44 (t, J=18 Hz, 4H), 2.63 (s, 4H), 3.74 (s, 4H), 4.11 (s, 
2H), 4.39 (q, J=18 Hz, 3H), 7.02 (s, 1H), 7.48 (s, 1H). 
4a-2: 1H NMR (CDCl3, 400 MHz) δ 1.45 (t, J=18 Hz, 3H), 2.67 (m, 4H), 3.76 (m, 4H), 3.94 (s, 
3H), 4.15 (s, 2H), 4.40 (q, J=18 Hz, 3H), 7.03 (s, 1H), 7.48 (s, 1H).  
10: 1H NMR (D2O, 400 MHz) δ 1.47 (t, J=18 Hz, 3H), 2.71 (m, 4H), 3.81 (m, 4H), 3.95 (s, 3H), 
4.02 (s, 2H), 4.39 (q, J=18 Hz, 2H), 7.25 (s, 1H), 7.74 (s, 1H). 13C NMR (D2O, 400 MHz) δ 
13.45, 52.47, 52.64, 56.34, 61.82, 66.07, 96.24, 111.83, 114.82, 117.14, 137.95, 150.45, 151.64, 
159.30, 164.77. ESI HRMS (-ve) m/z calcd. for C17H20NO9SNa [(M-Na)-)] 414.0933, found 
414.0847 (M-Na)-. 
 
Synthesis of 13 from 4a 
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To a solution of 4a-2 (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium 
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under 
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride 
and extracted with brine. The organic layer was dried over magnesium sulphate and 
concentrated. Purification was done by using flash chromatography on silica gel using 0-70% 
ethyl acetate in hexanes. The product 4a-3 was obtained in 60% yield. The deprotection step 
followed by sulfation (performed as explained previously) yielded the product 13 (see Appendix, 
Page 252 and 266 for NMR spectra). 
4a-3: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.03 (s, 9H), 1.39 (m, 6H), 2.62 (m, 4H), 3.65 
(m, 4H), 3.73 (s, 3H), 3.82 (s, 3H),  4.36 (m, 6H), 5.61 (s, 2H), 7.00 (s, 1H), 7.06 (s, 1H), 7.45 (s, 
1H), 7.62 (s, 1H). 
4a-3 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m, 
4H), 3.91 (s, 3H), 3.93 (s, 3H),  4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 
1H), 7.59 (s, 1H). 
13: 1H NMR (CD3OD, 400 MHz) δ 1.38 (m, 6H), 2.60 (m, 3H), 3.71 (m, 4H), 3.91 (s, 3H), 3.93 
(s, 3H), 4.37 (m, 6H), 5.62 (s, 2H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 1H), 8.01 (s, 1H). ESI MS 
(-ve) m/z calcd. for C30H32NO14SNa [(M-Na)-)] 659.14, found 659.15 (M-Na)-.  
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Synthesis of 16 from 11a 
 
To a solution of 11a (200 mg, 0.32 mmol) in 10 mL of dry THF was added LiAlH4 (65 mg, 1.6 
mmol) and stirred for 6 hours under nitrogen. After completion, the reaction was quenched by 
adding 30 mL of water and extracted with 100 mL of ethyl ether twice. The organic layer was 
concentrated down and purified with flash chromatography using ethyl acetate in hexanes (0-
50%). The reduced form of 11a was sulfated using the general sulfation procedure explained 
previously (see Appendix, Page 270 for NMR spectra). 
11a-reduced: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 2.71 (s, 3H), 3.87 (s, 
3H), 3.91 (s, 3H), 5.51 (s, 2H), 5.55 (s, 2H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H,), 7.42 (s, 1H), 
7.55 (s, 1H).  
16. 1H NMR (CD3OD, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 2.71 (s, 3H),  3.87 (s, 3H), 3.91 (s, 
3H), 5.51 (s, 2H), 6.65 (s, 2H), 6.69 (s, 2H), 7.01 (s, 1H), 7.04 (s, 1H), 7.37 (s, 1H), 7.45 (s, 1H). 
13C NMR (CDCl3, 300 MHz) δ 4.47, 12.31, 18.70, 26.00, 55.45, 55.81, 55.94, 56.58, 94.60, 
95.48, 103.35, 114.35, 118.34, 120.39, 121.24, 142.32, 142.65, 144.82, 148.21, 149.73, 152.05. 
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Synthesis of 17 from 4a and 1a 
 
To a solution of 1a (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium 
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under 
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride 
and extracted with brine. The organic layer was dried over magnesium sulfate and concentrated 
in vacuo. Purification was done by using flash chromatography on silica gel using (0-70) % ethyl 
acetate in hexanes. The product 4a-4 was obtained in 60% yield. The deprotection step followed 
by the sulfation step (performed as explained previously) yielded the product 17 (see Appendix, 
Page 264 and 275 for NMR spectra). 
4a-4: 1H NMR (CDCl3, 400 MHz) δ 0.03 (s, 6H), 0.04 (s, 6H), 0.96 (s, 9H), 0.97 (s, 9H), 1.36 
(m, 6H), 2.72 (s, 3H), 3.81 (s, 3H), 4.15 (m, 4H), 5.34 (s, 2H), 6.78 (s, 1H), 6.80 (s, 1H), 7.22 (s, 
1H), 7.37 (s, 1H). 
Deprotected 4a-4: 1H NMR (CDCl3, 400 MHz) δ 1.36 (m, 6H), 2.70 (s, 3H), 3.86 (s, 3H), 4.35 
(m, 4H), 5.54 (s, 2H), 6.98 (s, 1H), 7.00 (s, 1H), 7.42 (s, 1H), 7.57 (s, 1H). 
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17: 1H NMR (D2O, 400 MHz) δ 1.23 (m, 6H), 2.36 (s, 3H), 3.70 (s, 3H), 4.18 (m, 4H), 5.23 (s, 
2H), 6.96 (s, 1H), 7.03 (s, 1H), 7.53 (s, 1H), 7.62 (s, 1H). 13C NMR (D2O, 400 MHz) δ  13.4, 
13.51, 13.59, 56.30, 61.53, 62.08, 63.51, 96.28, 99.06, 108.05, 111.73, 114.48, 115.06, 117.13, 
119.54, 138.31, 138.82, 147.96, 150.23, 150.94, 152.02, 158.07, 164.50, 164.87, 165.60. ESI 
HRMS (-ve) m/z calcd. for C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0366 (M-Na)-.  
 
Synthesis of 8a & 8b from 3a 
 
To a solution of trimethyl aluminum (1.5 mmol) in THF was added Morpholine or 4-methyl 
Piperidine (1.5 mmol). The solution was stirred for 1 hour at RT. The solution of 3a (1 mmol) in 
THF was added to drop wise to the above solution over the time of 30 mins. The reaction 
mixture was stirred at 70 oC for 24 hours. The reaction was quenched by adding ethyl acetate and 
extracted with brine. The organic layer was concentrated and purified by flash chromatography 
using ethyl acetate and hexanes (0-70 %) (See Appendix, Page 256 for NMR spectra). 
8a: 1H NMR (CDCl3, 400 MHz) δ 0.13 (s, 6H), 1.00 (s, 9H), 2.48 (s, 3H), 3.64 (m, 8H), 3.78 (s, 
3H), 6.84 (s.1H), 6.93 (s, 1H). 
8b: 1H NMR (CDCl3, 400 MHz) δ 0.11 (s, 6H), 0.97 (d, J=18 Hz, 3H), 0.98 (s, 9H), 1.65 (m, 
4H), 2.44 (s, 3H), 2.88 (m, 2H), 2.98 (m, 2H), 3.80 (s, 3H), 6.86 (s, 1H), 6.93 (s, 1H). 
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Synthesis of 9a and 9b 
 
The deprotection step followed by the sulfation step (performed as explained previously) yielded 
the product 9a and 9b (see Appendix, Page 248 for NMR spectra). 
8a-1: 1H NMR (CDCl3, 400 MHz) δ 2.48 (s, 3H), 3.69 (m, 8H), 3.91 (s, 3H), 6.91 (s, 1H), 6.94 
(s, 1H). 
8b-1: 1H NMR (CDCl3, 400 MHz) δ 0.97 (d, J=18 Hz, 3H), 1.67 (m, 4H), 2.46 (s, 3H), 2.88 (m, 
2H), 2.98 (m, 2H), 3.80 (s, 3H), 6.86 (s, 1H), 6.93 (s, 1H). 
9a: 1H NMR (D2O, 400 MHz) δ 2.47 (S, 3H), 3.55-3.90 (m, 8H), 3.91 (s, 3H), 7.25 (s, 1H), 7.41 
(s, 1H). 13C NMR (D2O, 400 MHz) δ 12.48, 42.76, 47.82, 56.43, 66.41, 66.79, 96.68, 110.52, 
112.70, 118.31, 137.35, 149.74, 151.36, 156.79, 166.23. ESI HRMS (-ve) m/z calcd. for 
C15H16NO8SNa [(M-Na)-)] 370.0544, found 370.0652 (M-Na)-. 
9b: 1H NMR (D2O, 400 MHz) δ 0.89 (d, J=17 Hz, 3H), 1.01 (m, 1H), 1.61-1.81 (m , 4H), 2.39 
(s, 3H), 2.92 (m, 1H), 3.08 (m, 1H), 3.56 (m, 1H), 3.92 (s, 3H), 4.45 (m, 1H), 7.27 (s, 1H), 7.64 
(s, 1H). 13C NMR (D2O, 400 MHz) δ 12.47, 12.55, 14.88, 20.89, 30.17, 55.67, 56.59, 96.67, 
111.46, 112.63, 118.67, 137.67, 149.82, 151.26, 155.45, 165.32. ESI HRMS (-ve) m/z calcd. for 
C17H20NO7SNa [(M-Na)-)] 482.1022, found 382.0847 (M-Na)-.  
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Synthesis of 14 from 8a 
 
To a solution of 8a (1 mmol) in THF (20 mL) was added NBS (1 mmol) and the mixture was 
refluxed at 65 oC under a halogen lamp for 1 hour. The reaction mixture was cooled and 
extracted using hexanes and water. The organic layer was concentrated and product 8a-Br was 
obtained in 90% yield. 
To a solution of 8a-1 (0.3 mmol) and 8a-Br (0.4 mmol) in ethyl acetate (4 mL) were added 
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred 
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene 
chloride and extracted with brine. The organic layer was dried over magnesium sulphate and 
concentrated in vacuo. Purification was done by using flash chromatography on silica gel using 
(0-70) % ethyl acetate in hexanes. The product 4a-4 was obtained in 60% yield. The deprotection 
step followed by the sulfation step (performed as explained previously) yielded the product 14 
(see Appendix, Page 268 and 276 for NMR spectra). 
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8a-Br: 1H NMR (CDCl3, 400 MHz) δ 0.14 (s, 6H), 1.01 (s, 9H), 3.72 (m, 8H), 3.85 (s, 3H), 4.69 
(s, 2H), 6.85 (s, 1H), 6.99 (s, 1H). 
8a-2:1H NMR (CDCl3, 400 MHz) δ 0.14 (s, 6H), 1.01 (s, 9H), 2.49 (s, 3H), 3.74 (m, 16H), 3.85 
(s, 3H), 3.87 (s, 3H), 5.24 (s, 2H), 6.90 (s, 1H), 7.00 (s, 1H), 7.02 (s.1H), 7.11 (s, 1H). 
8a-2 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 2.48 (s, 3H), 3.74 (m, 16H), 3.87 (s, 
3H), 3.96 (s, 3H), 5.25 (s, 2H), 6.99 (s, 1H), 7.04 (s, 1H), 7.09 (s.1H), 7.12 (s, 1H). 
14: 1H NMR (D2O, 400 MHz) δ 2.40 (s, 3H), 3.24 (m, 8H), 3.67 (m, 8H), 3.81 (s, 3H), 3.92 (s, 
3H), 5.30 (s, 2H), 6.85 (s, 1H), 7.14 (s, 1H), 7.33 (s,1H), 7.43 (s, 1H). 13C NMR (D2O) δ 12.36, 
42.55, 56.00, 56.40, 63.52, 66.17, 66.36, 96.23, 96.73, 107.16, 110.44, 113.33, 115.29, 116.94, 
117.92, 138.10, 143.04, 148.81, 149.45, 151.21, 151.81, 152.46, 156.38, 164.20, 165.93. ESI 
HRMS (-ve) m/z calcd. for C30H31N2O13SNa [(M-Na)-)] 659.1422, found 659.1531 (M-Na)-. 
 
Synthesis of 18 from 1a 
 
 
The protection of the free phenolic groups of 1a with TBDMSCl (as per procedure for synthesis 
of 3a ̶ 3f) followed by the introduction of the bromo group (as per procedure for synthesis of 4a ̶ 
4f) leads to synthesis of intermediate 1a-2. Coupling intermediate 1a-2 with 2a using the 
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procedure described above (synthesis of 5a ̶ 5f) leads to formation of intermediate 1a-3. The 
deprotection step followed by the sulfation step (performed as explained previously) yielded the 
product 18 (see Appendix, Page 256, 260, 266 and 280 for NMR spectra). 
1a-1: 1H NMR (CDCl3, 400 MHz) δ 0.12 (s, 12H), 1.05 (s, 18H), 1.37 (t, J=18 Hz, 3H), 2.71 (s, 
3H), 4.40 (q, J=18 Hz, 2H), 6.95 (s, 1H), 7.30 (s, 1H). 
1a-2: 1H NMR (CDCl3, 400 MHz) δ 0.10 (s, 12H), 1.05 (s, 18H), 1.34 (t, J=18 Hz, 3H), 4.21 (q, 
J=18 Hz, 2H), 6.99 (s, 1H), 7.23 (s, 1H). 
1a-3: 1H NMR (CDCl3, 400 MHz) δ 0.04 (s, 6H), 0.09 (s, 6H), 1.01 (s, 9H), 1.05 (s, 9H), 1.43 
(m, 6H), 2.62 (s, 3H), 3.81 (s, 3H), 4.15 (m, 4H), 5.34 (s, 2H), 6.88 (s, 1H), 6.96 (s, 1H), 7.22 (s, 
1H), 7.37 (s, 1H). 
1a-3 (deprotected form): 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 6H), 2.71 (s, 3H), 3.84 (s, 
3H), 4.37 (m, 4H), 5.52 (s, 2H), 6.98 (s, 1H), 7.12 (s, 1H), 7.35 (s, 1H), 7.47 (s, 1H). 
18: 1H NMR (D2O, 400 MHz) δ 1.55 (t, J=18 Hz, 3H),1.59 (t, J=18 Hz, 3H), 2.41 (s, 3H), 3.81 
(s, 3H), 4.18 (q, J=18 Hz, 2H), 4.23 (q, J=18 Hz, 2H), 5.18 (s, 2H), 6.71 (s, 1H), 6.89 (s, 1H), 
7.65 (s, 1H), 7.91 (s, 1H). 13C NMR (D2O, 400 MHz) δ 13.47, 13.61, 13.63, 56.32, 61.53, 62.18, 
63.61, 96.28, 99.16, 108.01, 111.53, 114.48, 115.06, 117.13, 119.54, 138.31, 138.82, 147.96, 
150.23, 150.84, 152.12, 158.17, 164.53, 164.77, 165.60. ESI HRMS (-ve) m/z calcd. for 
C25H22O14S2Na [(M-Na)-)] 665.0121, found 665.0277 (M-Na)-.  
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Synthesis of 19 
 
To a solution of 2a’ (0.3 mmol) and 4a (0.4 mmol) in ethyl acetate (4 mL) were added cesium 
carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred under 
nitrogen for 15 hours at room temperature. The reaction was quenched with methylene chloride 
and extracted with brine. The organic layer was dried over magnesium sulphate and concentrated 
in vacuo. Purification was done by using flash chromatography on silica gel using 0-70% ethyl 
acetate in hexanes. The product 2a’-1 was obtained in 60% yield. The deprotection step followed 
by the sulfation step (performed as explained previously) yielded the product 19 (see Appendix, 
Page 270 and 277 for NMR spectra).  
2a’: 1H NMR (CDCl3, 300 MHz) δ 1.48 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.94 (s, 3H), 4.40 (q, J=6 
Hz, 2H, CH2), 7.03 (s, 1H), 7.43 (s, 1H). 
2a’-1: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H),  1.41 (m, 6H), 2.70 (s, 3H),  3.83 
(s, 3H), 3.92 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.99 (s, 1H), 7.21 (s, 1H), 7.43 (s, 1H), 7.44 (s, 
1H).13C NMR (CDCl3) δ 4.50, 14.46, 14.63, 14.78, 18.72, 25.97, 55.97, 56.62, 60.42, 60.93, 
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63.47, 95.47, 98.39, 103.77, 109.21, 112.25, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95, 
148.08, 150.20, 150.99, 157.66, 162.77, 164.07, 164.79. 
2a’-1 (deprotected form): 1H NMR (CDCl3, 300 MHz) δ 1.43 (t, J=6 Hz, 6H), 2.72 (s, 3H), 
3.92 (s, 6H), 4.39 (m, 4H), 5.60 (s, 2H), 7.00 (s, 1H), 7.19 (s, 1H), 7.41 (s, 1H), 7.44 (s, 1H). 13C 
NMR (CDCl3) δ 14.57, 14.63, 14.77, 56.52, 56.65, 60.42, 61.01, 63.57, 94.71, 98.55, 103.83, 
106.24, 109.21, 112.35, 118.39, 120.08, 143.81, 146.34, 147.95, 148.12, 149.07, 157.99, 162.82, 
164.06, 164.80. 
19: 1H NMR (CDCl3, 300 MHz) δ 1.39 (m, 6H), 2.67 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 4.36 (m, 
4H), 5.55 (s, 2H), 7.22 (s, 1H), 7.23 (s, 1H), 7.43 (s, 1H), 8.07 (s, 1H). 13C NMR (CD3OD, 300 
MHz) δ 13.25, 13.38, 13.52, 55.66, 55.77, 60.25, 60.79, 63.16, 95.63, 99.17, 103.95, 108.76, 
112.48, 115.58, 117.27, 120.11, 139.90, 146.40, 148.00, 148.45, 152.15, 152.23, 158.27, 163.04, 
163.59, 164.61. ESI HRMS (-ve) m/z calcd. for C26H25O13SNa [(M-Na)-)] 577.1011, found 
577.1100 (M-Na)-. 
 
 
 
3.4.3 Determination of Purity by HPLC Method: 
HPLC purification was carried out on a Jasco chromatography system using a Varian Dynamax 
microsorb C4 column of size 250*10 mm. The mobile phase consisted of acetonitrile – water 
mixture run at a constant flow rate of 3 mL/min. Absorbance was recorded by a Jasco MD-2010 
plus UV-VIS detector at 300 nm. The following HPLC method was used: 
 
 
 95 
 
Table 5. Method used for purity determination 
Time Solvent A (water) Solvent B (Acetonitrile) 
0 95% 5% 
5 95% 5% 
15 50% 50% 
20 0% 100% 
25 0% 100% 
30 95% 5% 
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Table 6. Purity of compounds synthesized 
Compound Retention time (mins) % purity 
5a 16.21 98.12 
5b 15.38 98.09 
5c 16.64 98.56 
5d 14.69 96.56 
5e 15.85 98.34 
5f 16.32 97.87 
5g 12.23 78.11 
5h 11.60 76.85 
5i 16.31 95.15 
5j 16.04 98.08 
9a 11.22 98.27 
9b 11.72 97.59 
10e 13.34 98.52 
12a 12.72 99.01 
12b 12.01 96.64 
12c 13.37 96.22 
12d 11.20 95.37 
12e 12.97 99.05 
12f 13.50 97.52 
13 10.34 98.43 
14 11.1 98.15 
15 8.01 99.13 
17 8.34 97.59 
18 8.61 98.36 
19 12.65 98.27 
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Chapter 4 Identification of a Novel Binding Site for Allosteric Regulation of Thrombin 
 
 
4.1 Introduction  
In this work, we present the enzyme inhibition and Michaelis-Menten kinetic studies for 
the library of sulfated benzofuran monomers and dimers, synthesized as described in an earlier 
chapter, that display a range of inhibition potentials and an allosteric mechanism of inhibition. In 
this study, we also propose a binding site for sulfated benzofuran dimers (SBDs) based on 
detailed biochemical studies on the interaction of one of the potent SBDs with thrombin 
combined with molecular modeling techniques. This will encourage for further rational structure-
based drug design. Our work reveals that the SBD interacts with exosite II of thrombin, but in a 
manner dramatically different from all previously known exosite II ligands, including full-length 
heparin, heparin octasaccharide, sucrose octasulfate, γ’-fibrinogen peptide, and sulfated LMWLs. 
The identification of a new site of binding on thrombin together with the molecular size, the 
novelty of inhibitor structures, the nature of their inhibition and allosteric modulation of 
thrombin, may lead to a powerful alternative to the competitive inhibitors approved to date. This 
work puts forward a distinct direction in the terms of the site of binding and thrombin inhibitor 
structures that will re-direct the search for allosteric modulators of coagulation enzymes, 
especially thrombin. 
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4.2 Results 
4.2.1 Thrombin Inhibition Potential of Designed Sulfated Benzofuran Monomers and 
Dimer  
Inhibition of thrombin by the designed benzofurans (in Chapter 3) was measured through 
Spectrozyme TH hydrolysis assay, as described earlier.213, 214 This assay relies on the decrease in 
the initial rate of substrate hydrolysis in the presence of the sulfated benzofuran derivative as a 
quantitative measure of the inhibition. The fractional decrease in the initial rate of hydrolysis 
typically shows a sigmoidal profile on a semi-log plot, which is then fitted by a dose – response 
equation 1 (see experimental section 4.4.2) to derive IC50, HS, Y0 and YM parameters for each 
potential inhibitor.  
Figure 18 shows the semi-log inhibition curves observed for selected benzofuran 
monomers and dimers from the library shown in Figure 17 (See Chapter 3). Of the 28 potential 
inhibitors studied in this work, only 11 molecules exhibited reasonable inhibition of human α-
thrombin at pH 7.4 and 25 °C. These included the sulfated monomer 5i and dimers 12a – 12f, 13, 
and 17 – 19 (Tables 7 and 8). Within this group, inhibitors 12b, 12c, and 12f were the only 
molecules exhibiting IC50 less than 50 µM. The t-butyl derivative 12c was found to be the most 
potent thrombin inhibitor with an IC50 of 7.3 µM under physiologically relevant conditions. 
The range of inhibition efficacy was found to vary considerably with the structure of the 
inhibitor. For example, the sulfated dimer 12e displayed essentially complete inhibition of 
thrombin (95%, Table 8), while dimer 15 with two carboxylic acid groups inhibited to the extent 
of only 14% (Table 8). Nearly 85% of the inhibitors displayed 60% or more thrombin inhibition 
suggesting good overall efficacy for sulfated benzofurans. 
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Figure 18. Direct inhibition of thrombin by designed sulfated benzofuran monomers and dimers. 
The inhibition of human thrombin was determined spectrophotometrically through a 
Spectrozyme TH hydrolysis assay at pH 7.4 and 25 °C. Solid lines represent sigmoidal fits to the 
data to obtain IC50, YM, and YO (equation 1), as described in the experimental section (4.4.2).  
 
Comparison of the two series of benzofuran molecules shows that dimers tend to inhibit 
thrombin several-fold better than monomers. Of the 15 sulfated monomers studied in this work 
and 17 sulfated and unsulfated monomers studied earlier,218 only 5i inhibited thrombin with 
measurable potency (~500 µM, Table 7). By contrast, most sulfated dimers displayed thrombin 
inhibition (Table 8). This suggested that larger scaffolds may exhibit higher potency. This also 
rationalizes the nanomolar potency observed for sulfated LMWL inhibition of thrombin.213 
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Table 7. Inhibition of Human α-Thrombin by Sulfated Benzofuran Monomers 
 R R’ log IC50  (M) IC50  (µM) ∆Y 
      
5a OCH2CH3 CH3 ndb >2500c - 
5b OCH3 CH3 nd >3000c - 
5c OC(CH3)3 CH3 nd >3000c - 
5d OCH2 CH2OCH3 CH3 nd >2000c - 
5e OCH2CH3 CH2CH3 -1.7±0.2d 20560±8500 0.60 
5f OCH2CH3 CH(CH3)2 -1.9±0.3 13650±10400 0.75 
5g OCH2CH3 CH2OCH3 nd >16000c - 
5h OCH2CH3 Morpholine-4-carbonyl nd >25,000c - 
5i OCH2CH3 Benzoyl-p-methoxy -3.3±0.2 520±280 0.54 
5j OCH2CH=CH2 CH3 nd >3000 - 
9a N-morpholino CH3 nd >2000c - 
9b N-piperidino CH3 nd >2000c - 
10e CH2CH3 CH3 nd >7000c - 
aThrombin inhibition was measured in spectrophotometric assay through initial rate of 
Spectrozyme TH hydrolysis as described in Experimental section. bNot determined due to 
incomplete and/or poor inhibition. cEstimates on the basis of the highest concentration used in 
experiment. dstandard error shown is ±1 S.E. e10 contains a morpholine group at the allylic 
position (instead of a –CH3 group).  
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Table 8. Inhibition of Human α-Thrombin by Sulfated Benzofuran Dimers 
 R R’ log IC50  (M) IC50  (µM) ∆Y 
      
12a OCH2CH3 CH3 -4.22±0.16b 60±22 0.75 
12b OCH3 CH3 -4.43±0.12 37±11 0.68 
12c OC(CH3)3 CH3 -5.14±0.18 7.3±3.1 0.84 
12d OCH2 CH2OCH3 CH3 -3.42±0.13 375±109 0.80 
12e OCH2CH3 CH2CH3 -3.92±0.05 121±14 0.95 
12f OCH2CH3 CH(CH3)2 -4.52±0.19 30±13 0.72 
13 nac Na -3.89±0.20 129±60 0.62 
14 N-morpholino CH3 Incompleted >7100 nac 
15 OH CH3 -3.43±0.37 ~374e 0.14 
17 nac Na -3.12±0.35 ~764e 0.95 
18 nac Na -3.44±0.06 365±57 0.79 
19 nac Na -4.05±0.26 89±54 0.70 
 
aThrombin inhibition was measured in spectrophotometric assay through initial rate of 
Spectrozyme TH hydrolysis as described in Experimental section. bstandard error shown is ±1 
S.E. cNot applicable. See complete structures of 13, 14, 15, 17, 18 and 19 in Figure 17. dFull 
inhibition profile was not measured. eThe error in IC50 could not be accurately defined because 
of insufficient number of data points. 
 
The distinct groups at the 2, 3, 5 and 6- positions on the benzofuran ring result in 
interesting structure–activity relationships. The sulfate group at the 5- position was found to be 
the key basis for thrombin inhibition, since all unsulfated precursors studied in this work, 
monomers as well as dimers, did not inhibit thrombin. Such a high level of dependence on one 
sulfate group is striking. It also appears to be unusual because thrombin is known to be 
considerably forgiving in recognizing ligands. For example, ligands as different as heparin and 
RNA are known to bind in exosite II.224, 225 Similarly, hirudin, which contains a sulfated tyrosine, 
as well as de-sulfated hirudin, i.e., desirudin, binds in exosite I with excellent affinities.79, 209, 226  
 102 
 
The stringent requirement for 5-sulfate led to the expectation that multiple sulfate groups 
on the benzofuran scaffold may induce higher potency. Yet, dimers 17 and 18, which bear two 
sulfate groups (5 and 5’, and 5 and 6- positions, respectively) inhibited thrombin approximately 
6–17-fold weaker (Table 8). Furthermore, the IC50 of 15, which contains the 5-sulfate as well as 
a carboxylate at each of the 3- positions of the benzofuran rings, also decreases 6.2-fold from its 
parent 12a. This implies that any additional anionic group on the benzofuran scaffold is counter-
productive, which is contrary to what one would predict on the basis of the thrombin – heparin 
system.212, 224, 226 
Comparison of the IC50s of 12a, 12b and 12c shows that as lipophilicity of the 3-ester 
increases, the inhibition potency improves 8.2-fold (Table 8). Likewise, change in substitution 
from ethyl to isopropyl at the 6- position, as in 12e and 12f, also increases the potency nearly 4-
fold. This implies that hydrophobicity of the scaffold plays an important role in thrombin 
recognition. In support of this, increase in hydrophilicity of groups markedly decreases potency. 
For example, the 3-methoxyethyl ester containing 12d is a 6.2-fold weaker inhibitor of thrombin 
than the 3-ethyl containing 12a (Table 8). More importantly, introduction of an N-morpholinyl 
ring (dimer 14) increased IC50 to >2000 µM, which represents a more than 270-fold loss of 
affinity from a comparable t-butyl ester containing dimer 2c. 
While the above discussion suggests fairly stringent structural requirements on the 
benzofuran scaffold, two interesting results highlight the possible variances. Dimer 13 containing 
a morpholine ring at the 2-allylic position displays IC50 of 129 µM, which is only 2.2-fold higher 
than that of 12a. This suggests that introduction of a hydrophilic and sterically bulkier group at 
the terminus opposite the 5-sulfate is not detrimental. Likewise, dimer 19 displays no change in 
IC50 from its comparable parent 12a (Table 8). Dimer 19 contains a 2-CH2O-6 inter-monomeric 
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linkage as compared to a 2-CH2O-5 linkage present in dimer 12a. An essentially identical 
inhibition potency of 19 as compared to 12a indicates that a change as drastic as a ring flip, or 
regioisomerism, is well tolerated. 
 
4.2.2 Mechanism of Thrombin Inhibition By Sulfated Benzofuran Dimer 12a  
To elucidate the nature of thrombin inhibition by the designed sulfated benzofurans, the 
kinetics of Spectrozyme TH hydrolysis by thrombin at pH 7.4 in the presence and absence of 12a 
was studied. Spectrozyme TH has been routinely used as a chromogenic substrate of thrombin.213 
The initial rate of amidolysis as a function of the substrate concentration displayed a hyperbolic 
profile, as expected (Figure 19), from which the Michaelis constant (KM) and maximal velocity 
of the reaction (VMAX) were derived. The KM and VMAX for Spectrozyme TH in the absence of 
12a was found to be 18.9 µM and 100 mAUmin-1µM-1, respectively. In the presence of 1.5, 3.0, 
10.5 and 30 µM 12a, the KM of substrate was found to be 12.6 ± 4.7, 15.5 ± 5.5, 15.9 ± 7.4, and 
15.5 ± 3.7 µM. In contrast, the VMAX was measured to be 97 ± 13, 107 ± 14, 73 ± 13 and 66 ± 6 
mAUmin-1µM-1 in these experiments. This corresponds to ~34% decrease in maximal velocity of 
reaction upon approximately 50% saturation of the enzyme. This suggests that the presence of 
12a does not significantly affect the binding of the chromogenic substrate to the active site of the 
enzyme, while significantly reducing its catalytic efficiency.  
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Figure 19. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by human thrombin in the 
presence of dimer 12a. The initial rate of hydrolysis at various substrate concentrations was 
measured spectrophotometrically in pH 7.4 buffer as described in ‘Experimental Procedures’. 
The concentrations of 12a chosen for study include 0 (), 3.0 (), 10.5 (▲), and 30 µM (). 
Solid lines represent non-linear regressional fits to the data by the standard Michaelis-Menten 
equation to yield KM and VMAX. 
 
The above Michaelis–Menten kinetics result indicates a non-competitive, allosteric 
mechanism of thrombin inhibition by 12a and, by analogy, other sulfated benzofuran molecules. 
The reduction in catalytic efficiency by these novel inhibitors is primarily brought about by the 
slow conversion of the thrombin–Spectrozyme TH Michaelis complex, which may arise from the 
intrinsic change in the rate of chemical reaction or by a change in the structure of the catalytic 
triad induced by the allosteric inhibitors. 
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4.2.3 Prolongation of Plasma Clotting Time by Sulfated Benzofurans  
 Two plasma clotting assays are typically used to assess the anticoagulant potential of 
new coagulation inhibitors. These are the prothrombin and activated partial thromboplastin time 
assays (PT and APTT, respectively), which attempt to measure the effect of an inhibitor on the 
extrinsic and intrinsic flux of coagulation. The concentrations of the inhibitors required to double 
the PT and APTT were measured, as described earlier for sulfated LMWLs.215, 216 The 
prolongation of plasma clotting time as a function of the concentration of the sulfated 
benzofurans followed a pattern typical of other well-studied anticoagulants (Figure 20), except 
for the range of active concentrations. A 2-fold increase in PT required 850 – 2100 µM 
concentration of 5i, 12a or 12b (Table 9). In a similar manner, the doubling of APTT required 
355 – 1250 µM of 5i, 12a, 12c, or 12e (Table 9). Most other monomers or dimers were found to 
be not effective. These results suggest that the designed small, sulfated benzofurans are about 
100 – 250-fold less potent in human plasma than the oligomeric sulfated LMWLs from which 
they were designed.216 This is not too unexpected considering that thrombin inhibition by the 
smaller synthetic molecules is nearly 400-fold weaker than that of the parent oligomers. Yet, 
interesting similarities and differences are discernible. For example, dimers are better 
anticoagulants in plasma than monomers. Within the group of dimers 12a, 12c and 12e, which 
inhibit thrombin well, are also the best in terms of prolonging APTT. Interestingly, 12b, which is 
comparable to 12a in thrombin inhibition, does not affect APTT at all (Table 9) and the reason 
for this behavior is not clear. Overall, the plasma studies suggest the feasibility of designing 
sulfated benzofurans that will function as anticoagulants in vivo. 
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Table 9. Effect of Designed Sulfated Benzofurans on Human Plasma Clotting Time 
 
 APPT PT 
 
(µM) (µM) 
 
  
5i 1,250 1,200 
5g >1,200 neb 
5c >2,000 ne 
12a 740 2,100 
12b >1,000 850 
12c 355 ne 
12d >1,000 ne 
12e 530 ne 
14 >1,000 ndc 
15 >1,000 ne 
 
a
 PT and APTT values were deduced in in vitro human plasma experiments where the clot 
initiator is either thromboplastin or ellagic acid, respectively. See Methods for details. b no effect. 
c not determined. 
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Figure 20. Prolongation of clotting time as a function of concentration of sulfated benzofuran 
monomers and dimers in either activated partial thromboplastin time assay (A) or prothrombin 
time assay (B). Solid lines are trend lines, and not non-linear regressional fits. Error bars in the 
range of symbol size have been omitted. APTT and PT assays were performed as described in 
the experimental section. 
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4.2.4 Complementary Biochemical Studies (Studies performed by Dr. Aiye Liang and Ms. 
May H. Abdel Aziz) 
1) To test whether dimers bind in exosite I, competition studies with the hirugen analog, 
[5F]-Hir[54-65](SO3-), were performed. The presence of [5F]-Hir[54-65](SO3-) did not 
significantly affect the thrombin inhibition profiles indicating that the dimer does not 
appear to bind in the anion-binding exosite I of thrombin. 
2) To test whether dimers bind in exosite II, competition studies with three different exosite 
II binding ligands; porcine unfractionated, heparin, H8, and γ’fibrinogen peptide were 
performed. A distinct shift in the profiles is observed as the concentration of the 
γ’fibrinogen peptide increases, suggesting full competition between the two ligands for 
thrombin binding. This indicates that the dimer and γ’fibrinogen peptide compete for 
exosite II of thrombin. However, no change in inhibition profile was observed with 
increasing concentration of heparin octasaccharide H8 and a slight change in inhibition 
profile was observed with heparin. This indicates that the dimer and H8 do not compete 
with each other, whereas partial competition is observed with UFH. 
3) To identify the basic residues that might play an important role in dimer recognition, we 
studied the inhibition of five thrombin mutants containing single and triple replacements 
of Arg/Lys to Ala. The dose – response profiles for three of the four single point mutants 
(Arg175Ala, Lys169Ala, and Lys235Ala) and one triple mutant (Arg93, 97,101Ala) 
studied in this work were essentially identical to the recombinant wild type enzyme. In 
striking contrast, the Arg173Ala mutant displayed a 22-fold increase in IC50 compared to 
the wild type enzyme, suggesting its importance for thrombin binding and inhibition by 
12a and related sulfated benzofuran derivatives. 
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4.2.5 Molecular Docking Identifies a Single Plausible Binding Geometry for 12a on 
Thrombin  
To identify a plausible binding geometry of sulfated benzofuran dimers on thrombin for 
structure-based design, we employed a molecular docking and scoring approach. We have 
previously utilized a similar approach using the automated docking routine GOLD to understand 
how highly sulfated oligosaccharides recognize proteins.227, 228 This approach was also exploited 
to study the recognition of antithrombin by sulfated LMWLs,229 which are the parent molecules 
for the sulfated benzofuran dimers being studied here. Hence, we chose to employ a GOLD-
based identification of plausible binding sites and geometries of 12a on human thrombin. 
The GOLD-based docking and scoring approach utilizes a genetic algorithm (GA) to 
iteratively derive the best binding geometry for each ligand in a pre-defined binding site. Our 
recent work on the recognition of sulfated LMWLs binding to thrombin mutants revealed that 
hydrophobic patches in the vicinity of Arg93 may be involved.230 Considering this, we 
hypothesized that hydrophobic region(s) near Arg173, which has been implicated by the 
Arg173Ala thrombin mutant studies presented here, would be important for recognition of 12a 
and its related sulfated benzofurans. Several GA docking runs were thus performed to assess 
how well 12a could be recognized by the binding site regions surrounding Arg173. Each docking 
run was performed using a constraint that encouraged the guanidine group of Arg173 to 
hydrogen bond with the sulfate group of SBD. Only one particular binding site was consistently 
found to provide a surface complementary to 12a in which the ligand is bound in an extended, 
flat conformation. This binding domain was located between Arg173 and the active site of 
human thrombin, exhibits a high degree of shape complementarity with the ligand and consists 
of hydrophobic areas suitable for recognizing the benzofuran rings and their substituents. To 
 110 
 
more rigorously test whether low occupancy, alternate binding site(s) are possible, a ‘diverse-
docking’ experiment was performed in which GOLD was forced to identify solutions with 
alternative binding sites of 12a that differ by at least 1.5 Å from the binding mode described 
above. With this directive, GOLD identified binding sites vastly different from that shown in 
Figure 21 but with no complementarity to 12a. This was also reflected in very poor GOLD 
scores for these alternative geometries. Additionally, the reproducibility of these geometries was 
poor, suggesting that the algorithm was not able to converge on a plausible binding pose.  
On the basis of these initial docking results as well as the FibP and Arg173Ala thrombin 
studies described above, we concluded that the class of sulfated benzofuran dimers being studied 
here do recognize this highly complementary domain. To test this prediction further, the library 
of sulfated benzofuran dimers studied earlier was docked onto human thrombin.231 Three crystal 
structures of human thrombin (PDB ID = 3EQ0, 1H8D and 2UUF)232, 233 with resolution 
between 1.5 and 2.5 Å were used to test the consistency of binding of the entire library. Each 
thrombin crystal structure was bound by both an active site inhibitor and a hirudin peptide in 
exosite II. All of the residues within reach of an Arg173-associated SBD were completely 
resolved in these three thrombin structures. Overall, the three structures were similar in terms of 
the resolution of residues in exosite II (backbone RMSD = 0.2 Å; Figure 22). 
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Figure 21. Connolly surface of thrombin (PDB ID = 3EQ0), showing the location of several 
electropositive basic residues, including those contributing to exosite II and the γ‘-fibrinogen 
peptide binding site (purple patches).  The putative binding site and mode of the lead sulfated 
benzofuran dimer 12a is rendered as a yellow surface and shows the high degree of shape 
complementarity with its putative binding site. The thrombin light chain (yellow ribbon) and 
hirudin peptide denoting the location of exosite-I (red ribbon) are also shown. B) The same 3D 
image rotated by 90°, further highlighting the high degree of shape complementarity between the 
ligand dimer and its proposed binding site. The active site is displayed with a hydropathic 
potential map (blue = hydrophilic, green = amphipathic, brown = hydrophobic) with the 
nucleophilic serine S195 shown as a red patch. The S1 and S4 substrate specificity pockets are 
indicated; the hydrophobic S4 pocket is occluded because it is occupied by the ethyl group of the 
3’-ethyl ester of 12a. 
 
  
Figure 22. GOLD binding site definitions for 3EQ0, 1H8D and 2UUF (22 Å radius about R173) 
highlighting the conformational similarity among the three proteins. The thrombin heavy chain is 
shown as a colored ribbon (red = helix, blue = sheet/strand, yellow = coil) and t
rendered as capped sticks (white carbon atoms, 3EQ0; orange carbon atoms, 1H8D; green carbon 
atoms, 2UUF). The inter-heavy chain backbone RMSD among the three proteins is 0.2 Å.
 
For the inhibitors studied as a part of the docking library, 
Arg173 and the active site was found to satisfy known thrombin inhibition characteristics. In 
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the binding site between 
 
he residues are 
 
 113 
 
addition, the GOLDScores of the compounds in the library showed a modest correlation with 
their inhibitory activity; compounds with significant, minimal and no inhibitory activity were 
effectively distinguished (Tables 10 and Figure 23). The docking pose of 12a onto 3EQ0 
thrombin could be used explain interactions at an atomic level. For example, in this pose the 4-
sulfate group of 12a forms a bidentate hydrogen-bond with Arg173, which supports the 
observation that all molecules devoid of 4-sulfate group are completely devoid of thrombin 
inhibition activity.231 This consistency was expected due to the inclusion of the Arg173 
hydrogen-bond docking constraint.  In the proposed binding mode, the Arg173 side chain is in 
fact surrounded by atoms of the first monomer: the sulfate group forms a double hydrogen-bond 
salt bridge with the guanidinium group, the 3-ethyl ester group is in a sterically unhindered 
region adjacent to the guanidinium group and may engage in pi-stacking interactions with it, and 
the benzofuran core is closely associated with the alkyl portion of the Arg173 side chain. 
 
Table 10. Comparison of GOLD scores obtained from docking studies and IC50 obtained from 
experimental data. 
Inhibitor GoldScore IC50 (µM) 
12a 64.37 60±22 
12b 62.92 37±11 
12c 64.01 7.3±3.1 
12d 59.94 375±109 
12e 64.60 121±14 
12f 64.37 30±13 
13 63.16 129±60 
14 56.70 >7100 
15 59.43 ~374 
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Figure 23. Scatter Plot of GOLDScore vs. pIC50 Values for Docked SBDs. 
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Figure 24. Expanded view of the interaction of 12a with it putative binding site. The ligand is 
rendered as a ball-and-stick figure and binding site residues rendered as capped sticks. All 
binding site side chains within 5 Å of 12a are displayed. Hydrogen bonds between Arg173 and 
the ligand sulfate group are shown as green dotted lines. 
 
Additionally, the 3’-ethyl ester group on the second monomeric unit binds in a shallow 
hydrophobic pocket lined by Asn98, Ile174, Ile176 and Trp215 (i.e., the S4 substrate specificity 
pocket). Interaction of the 3’-ester group here is consistent with the higher potency of inhibitors 
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12a, 12b, and 12c (see Table 11 for structures). As the hydrophobic character of groups at the 3’- 
position increases, the potency possibly also increases because of more favorable interactions in 
the hydrophobic S4 pocket. In contrast, inhibitors 12d, 14 and 15, which contains larger and/or 
polar groups at this position have poorer thrombin inhibition potential.231 
 
Table 11. Structure of sulfated benzofuran dimers 12a ̶ f and 13 ̶ 15 found to potently inhibit 
human thrombin.  
 
 
The 6-methoxy group of 12a is suggested to bind in a region lined by the amide 
backbones of Arg175, Glu97A, and Ile174, whereas the 6’-methoxy group binds in region 
formed largely by Asp217 and Lys224 side chains. Both these pockets appear to possess a 
R’ R R”
12a -CH3 -OC2H5 -H
12b -CH3 -OCH3 -H
12c -CH3 -OC(CH3)3 -H
12d -CH3 -OC2H4OCH3 -H
12e -C2H5 -OC2H5 -H
12f -CH(CH3)2 -OC2H5 -H
13 -CH3 -OC2H5 N-morpholino
14 -CH3 N-morpholino -H
15 -CH3 -OH -H
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combination of hydrophobic and polar properties and are significantly sterically unhindered, 
which implies they can accommodate larger groups. In fact, the inhibition potency increases as 
we move from 12a to 12b to 12c, which display increasing homologation at these positions. 
The 2’-allylic position is located in an amphiphilic region near Trp215 between the S1 
and S4 substrate binding pockets and is oriented toward S1. The model indicates that this region 
is moderately sterically constrained, which helps us understand why inhibitor 13 containing a 2’-
morpholino ring substituent is essentially inactive. The larger and much more polar morpholine 
ring at 2’-region is likely to prevent the SBD from binding in this pocket resulting in loss of 
activity. 
A key aspect of this binding geometry is that the benzofuran scaffold appears to be an 
effective core structure because it places its substituents into stereoelectronically favorable 
pockets on thrombin. It remains to be seen whether or not other planar hydrophobic scaffolds can 
improve inhibitor potency. Thus, at present it is difficult to discount the value of benzofuran 
rings to inhibition potency. 
 
4.2.6 Screening Against Other Serine Proteases  
The library of sulfated benzofuran monomers and dimers was screened against the panel 
of coagulation proteases. It includes factors VIIa, IXa, Xa, XIa and XIIa, which are involved in 
either the intrinsic or extrinsic pathways. The assay is based on hydrolysis of a chromogenic 
substrate by the protease, the rate of which is decreased in the presence of inhibitor. Screening 
was performed at single concentration of inhibitors using substrate hydrolysis assay in 96 well-
plates. This assay is based on the decrease in the initial rate of substrate hydrolysis in the 
presence of inhibitor. The decrease in initial rate of hydrolysis typically provides the fractional 
 118 
 
residual activity of enzyme. The details of experimental conditions are provided in the 
Experimental Section (4.4.6).  
Tables 12 and 13 show the percentage residual activity of all proteases at a final 
concentration of 365 µM of each inhibitor. Seven representative monomers were selected to 
cover a range of substitutions from hydrophobic to polar characteristics as well as the number of 
sulfate groups. None of these monomers inhibited the factors VIIa, IXa, Xa and XII more than 
20% at the concentration of 365 µM. This was expected as monomers showed very poor potency 
for thrombin except 5i (IC50 ~ 500 µM). The inhibitor 5i was not able to inhibit any protease 
except factor XIa greater than 20% at the given concentration. 5i completely inhibited factor XIa 
at given concentration, showing its higher potency (Figure 25).  
Similarly, seven representative molecules were selected from the library of dimers. None 
of the dimers inhibited factors VIIa, IXa and XIIa greater than 30% at given concentration 
showing selectivity of the designed benzofuran dimer derivatives against these proteases (Figure 
26). The molecules 12a, 12e and 20 inhibited factor Xa activity more than 40%. It is 
hypothesized that these molecules have the potential to inhibit factor Xa that moderates potency. 
It has been observed from data on thrombin inhibition that a library of dimers was only able to 
inhibit thrombin 60% or less. Beside factor Xa, 12e and 21 were also able to completely inhibit 
factor XIa at the given concentration. The results are again consistent with the library of 
monomers and dimers, which showed inhibition potential for both thrombin and factor XIa. 
Thus, it can be concluded that sulfated benzofuran derivatives bind at a site that have high 
homology in thrombin and factor XIa. 
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Table 12. Residual activity of various proteases obtained by screening the library of monomers 
 
Factor IXa Factor Xa Factor VIIa Factor XIa Factor XIIa 
5c 92±2.7 73±3.9 102±4.2 92±3 100±2 
5f 90±1.3 94±1.6 105±5.6 85±4 102±6 
5g 104±7 101±5 96±4 96±3.5 104±4 
5i 104±5.5 113±16 56±3.2 7±4.1 102±3.3 
9a 127±9.9 104±7.8 97±3.2 100±3 105±6 
9b 117±22 112±10 100±2.5 106±6 100±4 
5j 121±9 106±8 75±3.5 65±3 90±2.5 
 
 
Table -13. Residual activity of various proteases obtained by screening the library of monomers 
 
Factor IXa Factor Xa Factor VIIa Factor XIa Factor XIIa 
12a 81±3 61±2 100±3.5 88±2 100±3 
12e 89±3 59±4 101±6 6±2 103±6 
14 82±3.5 100±4 90±2 89±2 91±1 
12d 96±6 114±17 83±3 77±1.6 94±5 
15 91±4 101±3 91±2 85±4 94±5 
20 82±3 57±3.5 87±1 103±6 96±5 
21 83±2 108±10 85±2 51±3 104±5 
  
 Figure 25. Bar graph showing the % residual activity of given proteases at single concentration 
of each inhibitor 
 
 Figure 26. Bar graph showing the % residual activity of given proteases at single concentration 
of each inhibitor 
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4.3 Discussion 
The range of thrombin inhibition potency and efficacy discovered for sulfated 
benzofurans suggests that the designed sulfated benzofuran scaffold may be an excellent lead in 
developing anticoagulants radically different from those studied to-date. The β-5 inter-monomer 
linkage is only one of the many units present in sulfated LMWLs,213, 216 which implies that 
computational structure-based design may be necessary to identify the most appropriate ‘small’ 
structure from the large number of potential molecules. One such strategy, e.g., combinatorial 
virtual library screening, has been put forward for highly sulfated molecules228 and also been 
found useful for sulfated lignins binding to antithrombin.234 
This work presents small synthetic sulfated aromatic structures as novel allosteric 
modulators of thrombin function. Allosteric exosite II-based modulators of thrombin are of 
special interest because they afford the possibility of controlled inhibition of this key protease 
that takes part in a number of physiological processes.79 Excess inhibition could, in principle, be 
reversed by highly sulfated small molecules, e.g., sucrose octasulfate, that are also expected to 
bind in this region without inducing significant reduction in thrombin’s catalytic activity. 
Allosteric exosite II-mediated inhibitors with nanomolar potency, other than sulfated LMWLs,213 
have not been designed as yet and thus, sulfated benzofurans represent first molecules in a new 
class of thrombin modulators. 
Although the potency of our first allosteric inhibitors is not high, it is not a major concern 
because rational design of these molecules from the parent polymers invoked a rather drastic 
reduction in molecular weight. Whereas sulfated LMWLs are oligomeric chains with an average 
molecular weight of 5000, sulfated benzofurans range from 500 to 1000.215 Thus, a relatively 
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easy approach to higher potency would be to prepare appropriate tri- and tetramers of sulfated 
benzofurans.  
This work suggests that SBDs utilize a hydrophobic cavity, which overlaps with the S4 
binding pocket (see Figure 21). Although designed as mimetics of heparin, SBDs do not engage 
the traditional exosite II ligand residues including Arg101, Arg126, Lys235, Lys236 and Lys240. 
SBDs recognize Arg173, a heparin-binding residue. Yet, the predicted binding mode and 
orientation of 12a (see Figure 21 and 24) is likely to be dramatically different from that of 
polymeric heparin with its chain oriented along the highly electropositive surface.224 In fact, 12a 
binds in a region different from that predicted for sulfated LMWLs, which appear to bind in a 
linear hydrophobic segment present in exosite II on either sides of residues Arg93 and 
Arg101.235 The competition of 12a with FibP coupled with the known structure of FibP – 
thrombin complex bodes well for designing peptidomimetics based on the FibP sequence that 
recognizes the new binding site.236 These peptidomimetics are likely to possess structures 
different from our SBDs. 
Molecule 12a does not compete with the chromogenic substrate and yet reduces the rate 
of substrate hydrolysis231 suggesting that the new binding site is energetically coupled to the 
active site. The affinity of 12a for thrombin at pH 7.4 and 25 °C is approximately 6 µM, which 
implies a reasonably high affinity interaction. In fact, other than the antithrombin-binding 
heparin pentasaccharide, which binds with an affinity of ~50 nM,237 no small, sulfated molecule 
is known to bind with such high affinity. A recent study of a group of synthetic heparin 
octasaccharides that target herpes virus glycoproteins with ~20 µM affinity further support this 
observation. The reason for the very high affinity of antithrombin-binding heparin 
pentasaccharide is marvelous engineering by nature over millions of years. Thus, the ~6 µM 
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affinity of 12a, which is ~1000-fold higher than that of its monomer precursor,238 is a good lead. 
In fact, the putative binding site presents excellent opportunities advancing the design. For 
example, Lys224 and Arg221A are within 5 to 8 Å of the carboxylic acid ester. Likewise, several 
hydrophobic residues are also available for targeting. 
Molecule 12a reduces thrombin’s catalytic activity approximately 50% in comparison to 
known inhibitors that target the active site and exosite I.20, 197 This implies that 12a does not 
completely inhibit the procoagulant signal. Whereas this could be traditionally considered as a 
defect of design, considering the problems of over-anticoagulation induced by thrombin 
inhibitors, the less than perfect reduction in catalytic activity of thrombin may serve to foster the 
fine balance between procoagulant and anticoagulant signals. More importantly, detailed 
inhibition profiles reveal that some SBDs exhibit efficacies of greater than 50%, while only 
between 10 and 20% for others.231 This implies that the SBD binding site may be a ‘tunable’ 
binding site and appropriate molecules may be designed with variable efficacies to treat varying 
levels of procoagulant tendencies.  
Finally, this work also highlights the opportunity of exploring allosteric modulators of 
other coagulation enzymes, e.g., factors Xa, IXa and XIa, through sulfated lignin scaffolds. 
Considering the wealth of structural diversity accessible with the lignin scaffold, it may be 
possible to design allosteric inhibitors that target these enzymes in a highly specific manner. 
 
4.4 Experimental Section 
4.4.1 Enzyme and Chemicals for Biological Experiments   
 Human α-thrombin, factors Xa, XIa, IXa, VIIa and recombinant tissue factor were 
purchased from Haematologic Technologies (Essex Junction, VT). Factor XIIa was purchased 
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from Enzyme Research Laboratories (South Bend, IN). Stock solutions of thrombin were 
prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl. The 
chromogenic substrates Spectrozyme TH, Spectrozyme FXa, Spectrozyme FXIIa, Spectrozyme 
FIXa (299), Spectrozyme VIIa, and Spectrozyme CTY were obtained from American 
Diagnostica (Greenwich, CT). Citrated human plasma for coagulation time assays was purchased 
from Valley Biomedical (Winchester, VA). Thromboplastin and ellagic acid were obtained from 
Fisher Diagnostics (Middletown, VA). 
 
4.4.2 Inhibition of Thrombin   
 Direct inhibition of thrombin by sulfated benzofuran derivatives was measured through a 
chromogenic substrate hydrolysis assay.213, 214 The buffer used in these experiments was 20 mM 
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% polyethylene 
glycol (PEG) 8000. Benzofuran derivatives (2 to 30 µL) at concentrations ranging from 4 µg/mL 
to 5 mg/mL were diluted with the appropriate volume of assay buffer in PEG 20,000-coated 
acrylic cuvettes at 25 °C. To this solution was added 5 µL of thrombin solution to give 
approximately 5 nM initial thrombin concentration. After 10 min of incubation, 20 µL of 1 mM 
Spectrozyme TH was rapidly added and the residual thrombin activity was measured from the 
initial rate of increase in absorbance at 405 nm. Relative residual thrombin activity at each 
concentration of the inhibitor was calculated from the ratio of thrombin activity in the presence 
and absence of inhibitor. Logistic equation 1 was used to fit the dose-dependence of residual 
proteinase activity to obtain the IC50 and the efficacy ∆Y (= YM – Y0) of inhibition. 
 =  +

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                              Equation 1 
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In this equation, Y is the ratio of residual thrombin activity in the presence of inhibitor to 
that in its absence (fractional residual activity), YM and YO are the maximum and minimum 
possible values of the fractional residual proteinase activity, IC50 is the concentration of the 
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill Slope, which was 
set constant at 1. A current version of SigmaPlot (SPSS, Inc. Chicago, IL) was used to perform 
non-linear curve fitting in which YM, YO and IC50 were allowed to float. 
 
4.4.3 Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis  
The initial rate of Spectrozyme TH hydrolysis by 5 – 10 nM thrombin was monitored 
from the linear increase in absorbance at 405 nm corresponding to less than 10% consumption of 
the substrate, as described earlier.213, 214 The initial rate was measured as a function of various 
concentrations of the substrate (10 to 600 µM) in the presence of fixed concentration of dimer 
12a (0–30 µM) in 20 mM Tris-HCl buffer, pH 7.4, at 37 °C. The data were fitted by Michaelis-
Menten equation 2 to determine KM and VMAX. 
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                               Equation 2 
 
4.4.4 Prothrombin Time and Activated Partial Thromboplastin Time   
Clotting time was measured in a standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD), as described previously.215, 216 For PT 
assays, thromboplastin was reconstituted according to manufacturer’s directions and warmed to 
37 °C. A 10 µL sample of the sulfated benzofuran, to give the desired concentration, was brought 
up to 100 µL with citrated human plasma, incubated for 30 s at 37 ºC followed by addition of 200 
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µL pre-warmed thromboplastin. Clotting time in the absence of an anticoagulant was determined 
using 10 µL deionized water. For the APTT assay, 10 µL inhibitor was mixed with 90 µL 
citrated human plasma and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid). After 
incubation for 4 minutes, clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 ºC) and 
time to clot was noted. Each clotting assay was performed in duplicate. The data were fit to a 
quadratic trendline, which was used to determine the concentration of the inhibitor necessary to 
double the clotting time, 2×APTT or 2×PT. 
 
4.4.5 Molecular Modeling Studies  
Molecular docking studies to identify potential binding poses require an accurate 3D 
crystal structure of thrombin with high resolution and well-defined side chains. The crystal 
structure of thrombin bound to its allosteric exosite I ligand hirugen at 1.53 Å resolution was 
obtained from the Protein Data Bank (PDB ID = 3EQ0), as well as two additional thrombin 
structures (PDB IDs = 1H8D and 2UUF).29,30 All the residues in region of Arg173 were 
manually inspected to insure that the side chains were completely resolved. Each of the acidic 
and basic residues was modeled in its most predominant ionization state at physiological pH (i.e., 
anionic Asp and Glu; cationic Arg and Lys). The inorganic salts and water molecules were 
deleted from the crystal structure, and hydrogen atoms were added using SYBYL 8.1 (Tripos 
International, St. Louis, MO). To prepare the structure for docking and scoring protocol, the 
newly-added hydrogen atoms were energy-minimized using the Tripos Force Field (Gasteiger–
Hückel charges; termination criterion of 0.05 kcal/(mol×Å) or 1 × 105 iterations; distance-
dependent dielectric constant ε = 4.0). 
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Substituted benzofuran-based dimers 12a–f and 13–15, each studied previously, 24 were 
prepared in SYBYL for virtual library screening. Using in-house SYBYL Programming 
Language (SPL) scripts, compounds contained in the resulting virtual library were post-
processed to (1) assign appropriate atom types to the sulfate groups (sulfur atom = S.o2; terminal 
oxygen atoms = O.co2); (2) assign an initial set of 3D coordinates using the CONCORD module 
within SYBYL; (3) add missing hydrogen atoms and (4) energy-minimize the resulting 
structures using the Tripos Force Field as described for the protein (vide supra). 
Docking of the synthesized inhibitors onto the defined binding site of the thrombin was 
performed using GOLD 4.1 (Cambridge Crystallographic Data Centre, Cambridge, UK). The 
binding site was defined to include all atoms within 22 Å around the Arg173 Cα atom. Default 
parameters were employed during the GOLD docking runs with the following exceptions: a 
protein hydrogen bonding constraint was added such that the score was reduced by 10.0 
GoldScore units if the ligand did not form an H-bond with the guanidinium group of Arg173. 
Amide bonds were allowed to flip. The number of GA runs was increased to 30 in order to more 
accurately screen all possible binding geometries, and early termination was disabled. The 
docking was driven by the GOLDScore fitness function and the docked solutions were ranked 
based on the unmodified GOLDScore obtained. To assess the reproducibility of the docked 
poses, the docking runs were performed in triplicate. 
 
4.4.6 Screening for other proteases 
Screening of library for Factor VIIa inhibition - Direct inhibition of factor VIIa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
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containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02% 
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 75 µL 
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was 
added 10 µL of factor VIIa solution to give approximately 80 nM initial factor VIIa 
concentration and 5 µL of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL 
of 20 mM Spectrozyme factor VIIa was rapidly added and the residual factor VIIa activity was 
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a 
microplate reader (FlexStation III, Molecular Devices). Relative residual factor VIIa activity was 
calculated from the ratio of thrombin activity in the presence and absence of inhibitor. The 
percent residual activity was calculated using the equation 3: 
% Residual Activity = [(slope of blank – slope of well with inhibitor)/slope of blank] x 100 
A cut off of 40% was selected, and those compounds which showed a % residual activity lower 
than 40% were selected for full inhibition profile. 
 
Screening of library for Factor IXa inhibition - Direct inhibition of factor IXa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000, 0.02% Tween 
80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at concentrations 20 mM were 
diluted with 80 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To 
this solution was added 5 µL of factor IXa solution to give approximately 1780 nM initial factor 
IXa concentration. After 10 min of incubation, 10 µL of 8.5 mM Spectrozyme factor IXa was 
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rapidly added and the residual factor IXa activity was measured from the initial rate of increase 
in absorbance at 405 nm. The plate was read using a microplate reader (FlexStation III, 
Molecular Devices). Relative residual factor IXa activity was calculated from the ratio of 
thrombin activity in the presence and absence of inhibitor. The percent residual activity was 
calculated using the equation 3. 
Screening of library for Factor Xa inhibition - Direct inhibition of Factor Xa by the library of 
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02% 
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL 
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was 
added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa concentration. 
After 10 min of incubation, 5 µL of 5 mM Spectrozyme factor Xa was rapidly added and the 
residual factor Xa activity was measured from the initial rate of increase in absorbance at 405 
nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative 
residual factor Xa activity was calculated from the ratio of thrombin activity in the presence and 
absence of inhibitor. The percent residual activity was calculated using the equation 3. 
Screening of library for Factor XIa inhibition - Direct inhibition of factor XIa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80. 
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 85 µL volume of assay 
buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL of 
 130 
 
factor XIa solution to give approximately 15.3 nM initial factor XIa concentration. After 10 min 
of incubation, 5 µL of 6.6 mM Spectrozyme factor XIa was rapidly added and the residual factor 
XIa activity was measured from the initial rate of increase in absorbance at 405 nm. The plate 
was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual factor 
XIa activity was calculated from the ratio of thrombin activity in the presence and absence of 
inhibitor. The percent residual activity was calculated using the equation 3. 
Screening of library for Factor XIIa inhibition - Direct inhibition of factor XIIa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80. 
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL volume of 
assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL 
of factor XIIa solution to give approximately 200 nM initial factor XIIa concentration. After 10 
min of incubation, 5 µL of 5 mM Spectrozyme factor XIIa was rapidly added and the residual 
factor XIIa activity was measured from the initial rate of increase in absorbance at 405 nm. The 
plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual 
factor XIIa activity was calculated from the ratio of thrombin activity in the presence and 
absence of inhibitor. The percent residual activity was calculated using the equation 3. 
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Chapter 5 Synthesis and Biochemical Evaluation of 2nd Generation Sulfated Benzofurans 
 
 
5.1 Introduction 
The previous chapters describe the successful design and synthesis of small molecules 
that display an antithrombotic effect through an allosteric mechanism.23, 12, 18 Those were the first 
reported small molecules that reduced the catalytic efficiency of thrombin by binding to an 
allosteric site. In order to improve the potency of benzofuran dimeric units, we designed a library 
of 2nd generation compounds. From the SAR studies of the sulfated benzofuran monomers and 
dimers, we found that substitution at the 2’-allylic position of the sulfated benzofuran dimer does 
not have a detrimental effect on potency.231 This led us to design a second generation library 
containing three linked benzofuran units as the backbone scaffold and various substitutions at the 
first benzofuran unit to improve the potency and solubility of the compounds. In this work, we 
report the synthesis, biological activity, mechanistic and blood plasma studies of a library of 
eleven sulfated benzofuran trimers and tetramer. Based on substrate hydrolysis assay and 
through Michaelis-Menten kinetic studies, we can state that these molecules are potent small 
synthetic allosteric inhibitors of thrombin. The strong competition with heparin suggests that 
 132 
 
these molecules bind at exosite II. Finally, plasma studies showed that these molecules are potent 
anticoagulants in whole human plasma.  
5.2 Results and Discussion 
5.2.1 Design and Synthesis of the 2nd Generation Sulfated Benzofuran Scaffold 
Previously, we reported that the sulfated low molecular weight lignins (LMWLs) are 
potent allosteric inhibitors of thrombin and are structurally very different from heparin with less 
anionic charge and a more hydrophobic scaffold.239 Similar to heparin, LMWLs are constituted 
of a mixture of different structures arising from varying inter-residue linkages and degrees of 
sulfations. It is well known that the β-5 linkage is the most abundant linkage present in natural 
lignins.200, 202 Based on this assumption and its synthetic feasibility, the benzofuran scaffold was 
designed. In preliminary work, we synthesized a diverse library of sulfated benzofuran 
monomers and dimers to study the effects of various substitutions on their potency of thrombin 
inhibition.231 Among the members of this library, a few structures were found to inhibit thrombin 
with moderate potency in the range of 5-50 µM. A mechanistic study divulged that these 
molecules inhibit the catalytic efficiency of thrombin in an allosteric fashion, similar to the 
parent LMWLs. SAR studies revealed very interesting findings and guided the design 2nd 
generation compounds. It had been known that one sulfate group at the 5- position is optimal for 
potency. In addition, any increase in the number of anionic charges, either from sulfate or 
carboxylate, is detrimental. The presence of hydrophobic groups at the 3-ester and 6-hydroxy 
positions is favorable. The most striking feature in the SAR that leads to the design of 2nd 
generation compounds was tolerance of steric group at the 2’-allylic position of sulfated 
benzofuran dimer.231 Along with this, a 1000-fold improvement in potency on moving from 
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monomers to dimers led us to add an additional substituted benzofuran unit to the existing 
dimeric scaffold.   
Incorporating the above, a pilot 2nd generation library of ten sulfated benzofuran trimers 
was designed and synthesized. In this library, the terminal two benzofuran units were kept the 
same and variations were made at 3, 4 and 5- positions of the first benzofuran units. The 
variation at the 3-carboxylate ester position included both hydrophilic and bulky hydrophobic 
groups, while the position and number of anionic group and hydrophobic groups at 6- position 
were also varied. 
 
5.2.2 Chemistry 
Syntheses of β-5-like trimeric units were described in Figure 27-30. Figure 27 described 
the synthesis of various reactive handles T4a ̶ T4h starting from the readily available catechol. 
The first step leads to formation of 5, 6-dihydroxy-benzofuran-3-carboxylic acid esters using 
conditions published previously.231 The highly functionalized benzofuran unit T1a ̶ T1e was 
synthesized in one step using an oxidative-Michael addition reaction. The selective mono-
alkylation of the 6-hydroxy group of compounds T1a ̶ T1e was achieved under basic condition 
to afford T2a ̶ T2g in 60% yield. This reaction also resulted in formation of another regio-isomer 
T2h in minor amounts (< 10 %), causing an unfortunate difficulty in purification. The separation 
can be achieved by careful purification using flash chromatography. Subsequently, protection of 
the 5-hydroxy group was achieved by t-butyltrimethylsilyl chloride in the presence of imadazole, 
this led to formation of T3a ̶ T3h in very high yield. The bromination of the allylic position in 
the presence of N-bromosuccinimide leads to the synthesis of reactive handles T4a ̶ T4h.  
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Figure 27. Description of synthesis of a library reactive handles T4a ̶ T4h for synthesis of 
library of sulfated benzofuran trimers. Reactions: a) Alkyl aceto-acetate, NaIO4, DIPEA, ethanol: 
water (3:1); b) Cs2CO3, alkyl or acyl halide, anh. DMF; c) TBDMSCl, Imidazole, DMF; d) NBS, 
CCl4. 
 
 
As shown in Figure 28, synthesis of compound T5a ̶ T5b was afforded by nucleophilic 
displacement of the allylic bromide of T4a by a free phenolic group at the 5- position of T2a and 
T2e under basic condition. The coupling reaction was low yielding <50% due to steric 
interference around both nucleophilic (allylic bromide) and electrophilic (phenolic group) 
positions. The required handle T6a ̶ T6b was achieved by removal of the protecting silyl group 
from 5- position using potassium fluoride and a catalytic amount of glacial acetic acid.  
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Figure 28. Description of synthesis of reactive handles T6a ̶ T6b for synthesis of library of 
sulfated benzofuran trimers. Reactions: e) Cs2CO3, T2a & T2e; DMF; f) KF, CH3COOH, DMF. 
 
Figure 29 describes the synthesis of the nine desired sulfated trimeric units T9a ̶ T9h and 
T14. The coupling of the two reactive handles T4a ̶ T4h and T6a ̶ T6b were achieved using 
microwave radiation to afford trimeric units T7a ̶ T7h. Unlike the coupling reactions for dimeric 
unit T5a ̶ T5b, coupling for trimers failed at room temperature due to solubility and steric issues. 
Microwave-based coupling reaction afforded the desired compounds in a reaction time of 80 
minutes with 50% yield. The compounds T8a ̶ T8h were obtained by removal of the protecting 
silyl group similar to condition used above (synthesis of T6a ̶ T6b, Figure 27). The selective 
hydrolysis of the allyl ester of T8e is achieved by a catalytic amount of Pd(PPh3)3 in the presence 
of base to give T13 in good yield. The targeted compounds T9a ̶ T9h and T14 were accessed by 
addition of a sulfate group using the microwave-based conditions previously developed in our 
laboratory.222 The cation exchange from triethylamine to sodium was performed using weak 
cation exchange resin and purified using flash chromatography. In Figure 30, intermediate T8a 
and T4a were coupled together under basic conditions using the microwave method described 
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above in synthesis of T7a ̶ T7h. This followed by removal of the protecting group and sulfation 
afforded the desired compound T12.  
 
 
Figure 29. Description of synthesis of library of sulfated benzofuran trimers T9a ̶ T9h and T14. 
Reactions: g) Cs2CO3, 2; DMF; h) KF, CH3COOH, DMF; i) Et3N:SO3, CH3CN: DMF (4:1), 
MW; j) Pd(PPh3)3, PPh3, pyrrolidine. 
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Figure 30..Description of synthesis of sulfated benzofuran tetramer T12. Reactions: k) Cs2CO3, 
T2a; DMF; L) KF, CH3COOH, DMF; M) Et3N:SO3, CH3CN: DMF (4:1). 
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5.2.3 Substrate Hydrolysis Assay 
The inhibition potencies of sulfated benzofuran trimers and tetramer for thrombin were 
measured using the Spectrozyme TH hydrolysis-based assay.202 This assay measures the decrease 
in the initial rate of substrate hydrolysis in the presence of the inhibitors as a quantitative 
measure of the inhibition. The fractional decrease in the initial rate of hydrolysis typically gives a 
sigmoidal curve on a semi-log plot, which is then fitted by a dose - response equation 4 (see 
Experimental Section 5.4.3) to calculate IC50, HS and ∆Y parameters for each potential inhibitor.  
The semi-log inhibition profile observed for sulfated benzofuran trimers are shown in 
Figure 31. From the library of 11 inhibitors, ten molecules demonstrated potent inhibition of 
human α-thrombin at pH 7.4 and 25 °C. These include sulfated trimers T9a ̶ T9h, T14 and the 
sulfated tetramer T12 (Tables 14). The inhibitor T9a showed the most potent inhibition with an 
IC50 of 670 nM under physiologically relevant conditions. The range of inhibition efficacy (45 to 
95 %, Table 14) was found to vary considerably with the structure of the inhibitor. Nearly all of 
the inhibitors studied inhibited thrombin to more than 50% suggesting reasonably good overall 
efficacy in this series of sulfated benzofurans. 
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Table 14. Inhibition of human thrombin by sulfated benzofuran trimers 
 
R’ R log IC50  (M) IC50  (µM) ∆Y 
   
 
  
T9a OCH2CH3 CH3 -3.17 ± 0.02 0.67 ± 0.04 44.1 
T9b OCH3 CH3 -2.59 ± 0.12 2.5 ± 0.2 54.9 
T9c OC(CH3)3 CH3 -0.77 ± 0.03 149.24 ± 0.04 92.8 
T9d OCH2 CH2OCH3 CH3 -1.05 ± 0.01 88.49 ± 0.01 67.8 
T9f OCH2CH3 CH2CH3 -2.29± 0.01 5.1 ± 0.1 41.4 
T9g OCH2CH3 CH(CH3)2 -0.48± 0.01 324 ± 0.1 83.8 
T9e OCH2CHCH2 CH3 -1.12 ± 0.04 75.64 ± 0.02 64.3 
T9h na na -0.79 ± 0.3 162 ± 1 88.6 
T12 na na -0.97 ± 0.25 107 ± 1 50.88 
T13 na na 
 
>500 
 
T14 OH CH3 -0.84 ± 0.03 143 ± 0.04 47.72 
Spectrozyme TH was used as the substrates and the residual enzyme activity in the presence of 
the trimer was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Equation 
3 was used to fit the dose dependence of the residual enzyme activity to obtain log IC50, Y0, and 
YM values.  
 
  
Figure 31. Direct inhibition of thrombin by designed sulfated benzofuran trimers and tetramer. 
The inhibition of human thrombin was determined spectrophotometrically through a 
Spectrozyme TH hydrolysis assay at pH 7.4 and 25 °C. 
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T9b, T9c, T9d and T9e shows that as the size of the 3
s by 30 to 60-fold (Table 14). For example, 
 t-butyl is 60-fold less potent than 
 in the cases of T9d and T9e, having methoxy methyl and allyl 
-fold.  Although the potency of inhibition is decreased 
well than hydrophobic groups of the same size. 
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Similarly for T9f and T9g potency decreased 65-fold by changing the substitution from 
ethyl to isopropyl at the 6- position. These imply that Hydrophobicity, as well as the size of the 
substitution at the 6- position, plays an important role. Increasing the anionic charge, as seen in 
T14, decreases the potency by 220-fold. This suggests that the terminal benzofuran unit binds in 
a hydrophobic pocket that cannot tolerate the highly charged carboxylate group. This is a 
significant finding about the nature of this binding pocket. The trimer unit was found to be 
optimal for activity. Increasing the oligomeric chain to the tetramer as in T12 decreased activity 
by 150-fold. 
Comparing the effect of the sulfate group with the carboxylate group, it was found that 
the carboxylate group is not polar enough to solubilize the aromatic trimer scaffold. The 
molecule T13 was found to precipitate at a higher concentration, thus causing problems in 
determination of the full inhibition profile. Thus, we can conclude that carboxylate group cannot 
successfully replace the sulfate group in this series for direct thrombin inhibition. 
 
5.2.4 Biochemical Studies 
1) Michaelis-Menten studies show no change in KM, while there are significant changes in 
VMax with increasing concentration of inhibitor. This suggests that the presence of the 
trimer does not affect the binding of the chromogenic substrate to the active site of the 
enzyme, but significantly reduces its catalytic efficiency. This indicates an 
uncompetitive, allosteric mechanism of thrombin inhibition by the trimer.  
2) To test whether trimers binds in exosite I, competition studies with the hirugen analog, 
[5F]-Hir[54-65](SO3-), were performed. The presence of [5F]-Hir[54-65](SO3-) did not 
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significantly affect the thrombin inhibition profiles indicating that the trimer does not 
appear to bind in the anion-binding exosite I of thrombin. 
3) To test whether trimers binds in exosite II, competition studies with three different 
exosite II binding ligands; porcine unfractionated heparin, H8, and γ’Fibrinogen peptide 
were performed. A distinct shift in these profiles is observed as the concentration of the 
UFH increases, suggesting competition between the two ligands for thrombin binding. 
This indicates that the trimer and full-length heparin compete for exosite II of thrombin. 
However, there was no change in inhibition profile observed with increasing 
concentration of heparin octasaccharide H8 and γ’Fibrinogen peptide. This indicates that 
the trimer and H8 do not compete with each other, although both are exosite II ligands.   
 
5.2.5 Prolongation of Plasma Clotting Time by T9a 
Typically, two plasma clotting assays are performed to evaluate the anticoagulant 
potency in plasma for new coagulation inhibitors. Prothrombin time (PT) and activated partial 
thromboplastin time (APTT) assays are used to measure the effect of an inhibitor on the extrinsic 
and intrinsic flux of coagulation, respectively. The concentrations of the inhibitors required to 
double the PT and APTT were measured and reported as described earlier (Chapter 4) for our 
first generation compounds (see Table 15).  
A 2-fold increase in PT required 568 µM concentration of T9a. In a similar manner, the 
doubling of APTT required 139 µM of T9a. The higher potency for the APTT assay as 
compared to the PT assay suggests a more profound effect on intrinsic pathway. These results 
also suggest that the 2nd generation library of sulfated trimeric benzofurans is 10-fold more 
potent in human plasma than 1st generation compounds. These results were expected and prove 
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the validity of our design. The 2nd generation compounds are only 10 times less potent than our 
LMWLs, from which the benzofuran scaffold was designed. To further evaluate the mechanism 
of anticoagulation of these inhibitors in plasma, we performed plasma studies on various factor-
deficient human plasmas. When the APTT test was performed on factors IX and XI-deficient 
human plasma, we measured that concentrations required to double the APTT time were 135 µM 
and 120 µM respectively (see Table 15). There was no significant change in 2ˣAPPT time 
compared to normal human plasma suggesting a less significant role factors IX and XI with 
respect to the anticoagulation effect of these inhibitors. Similarly, 2ˣPT value for factor VII 
deficient plasma was 518 µM, which is not significantly different from normal human plasma. 
Thus, we can conclude that our designed inhibitors are not inhibiting factors IX, XI and VII in 
human whole plasma. Overall, the plasma studies suggest the feasibility of designing sulfated 
benzofurans that will function as anticoagulants in vivo. 
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Figure 32 Prolongation of clotting time as a function of concentration of sulfated benzofuran 
trimer and tetramer in either activated partial thromboplastin time assay (top) or prothrombin 
time assay (bottom). Solid lines are trend lines, and not non-linear regressional fits.  
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Table 15. The PT and APTT assay results for T9a in normal as well as factor deficient plasma 
APTT Assay 2ˣPT (µM) 2ˣAPTT 
Normal Plasma 568 139 
Factor XI Deficient Plasma NA 135 
Factor IX Deficient Plasma NA 120 
Factor VII deficient Plasma 518 NA 
PT and APTT values were deduced in in vitro human plasma experiments where the clot initiator 
is either thromboplastin or ellagic acid, respectively.  
 
5.2.6 Screening against Other Serine Proteases  
The library of sulfated benzofuran trimers was screened against the panel of coagulation 
proteases including factors VIIa, IXa, Xa, XIa and XIIa, all of which are either involved in 
intrinsic or extrinsic pathways of the coagulation cascade. These assays are based on the rate of 
hydrolysis of a chromogenic substrate by the protease, which decreases in the presence of an 
inhibitor. Screening was performed at a single concentration of inhibitors using a substrate 
hydrolysis assay in 96-well plates. The decrease in initial rate of hydrolysis provided the 
fractional residual activity of enzyme. The details of experimental conditions are provided in the 
Experimental Section (5.4.6).  
Table 16 shows the residual activity of all proteases at a final concentration of 365 µM of 
each inhibitor. The library of trimers contains molecules with varying substitutions ranging from 
hydrophobic to polar as well multiple anionic groups. None of these trimers inhibited factor XIIa 
more than 20% at this concentration. In the screening against factor VIIa, molecules T9b and 
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T9e inhibited factor VIIa activity more than 70%, this showing potential for potent inhibition. 
These two molecules were selected for further inhibition study. Similarly, several trimers showed 
higher potential for inhibition of factor IXa. Molecules T9a, T9b, T9e, T9f, T12 and T15 
inhibited factor IXa activity greater than 80% at the given concentration. These inhibitors were 
selected for detailed inhibition profile and thus have potential for the design into better inhibitors 
of factor IXa.  
 
Table 16. Residual activity of proteases (in %) at single concentration (365 µM) of each 
inhibitor 
 
Factor VIIa Factor IXa Factor Xa Factor XIa Factor XIIa 
T9a 72±3 1±1.5 84±2 2±3 103±5 
T9b 26±3.5 3±3 38±3 3±5 86±3 
T9c 92±3.5 103±6 31±2 11±1 92±3 
T9e 37±3 16±2 69±2 1±1.5 93±3 
T9f 98±4 31±2 73±3 5±7 98±6 
T9g 101±3 82±3 85±3 39±2.5 98±3 
T9h 104±7 96±6 76±2 6±2 96±4 
T12 100±6 11±6 66±3 3±2.5 86±2 
T14 74.±1 103±8 102±4 11±5 47±1.5 
T15 100±4 17±1 70±3 4±3 99±3.5 
 
In screening against factor Xa, with the exception of inhibitors T9b and T9c, the majority 
of trimers showed minimal activity against factor Xa. Although the inhibitory abilities of T9b 
and T9c are just 40%, which were much less as compared to inhibition by other proteases, these 
molecules were selected for detailed inhibition profiles. As expected from the results of 
inhibition by monomers and dimers, the library of trimers showed potent inhibition against factor 
  
XIa. The trimers inhibited the factor 
The entire library of trimers was selected for detailed inhibition profile.
Figure 33. Bar graph showing the % residual activity of given proteases at single concentration 
of each inhibitor 
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inhibition potency for factor VIIa. T9e is the most potent with an IC50 of 82.5 ± 0.1 µM, while 
T9b exhibited an IC50 of 239 ± 1 µM under physiologically relevant conditions. Although T9b 
displayed lower potency compared to T9e, it showed a better inhibition efficacy (85%, Table 17) 
than T9e (45%, Table 17). Although this study is too small to predict SAR, these molecules can 
still serve as potential leads to design inhibitors for factor VIIa. 
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Figure 34. Direct inhibition of factor VII by inhibitors T9e and T9b. The inhibition of human 
factor VIIa was determined spectrophotometrically through a Spectrozyme factor VIIa 
hydrolysis assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to obtain 
IC50, YM, and YO, as described in the experimental section.  
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Table 17. Inhibition of sulfated benzofuran trimers 
 
Log IC50 IC50 (µM) ∆Y 
T9b -3.62 ± 0.01 239 ± 0.02 83.6 
T9e -4.08 ± 0.01 82.4 ± 0.02 45.3 
 
 
5.2.8 Factor IXa Inhibition Potential of Designed Sulfated Benzofuran Trimers  
Figure 35 shows the semi-log inhibition curves observed obtained from the selected 
sulfated trimers. The selected trimer molecules exhibited reasonable inhibition of human factor 
VIIa at pH 7.4 and 37 OC. Out of the library of 10 trimers, five trimers exhibited moderate 
inhibition potency for factor VIIa. T9f is most potent with an IC50 of 9.2 µM and displayed 
complete inhibition efficacy (95%, Table 18). The other trimers T9c, T9d, T12 and T15 
displayed potencies of 25.7 µM, 22.3 µM, 65.5 µM and 23.8 µM, respectively. These trimers 
displayed inhibition efficacy of 80-90% (Table 18). However, a clear trend of SAR is not 
observed from this small library of molecules. However, more hydrophobic scaffolds displayed 
higher potency and efficacy for inhibition of factor IXa. The most potent inhibitor T9f has a 
hydrophobic isopropyl group at the 6- position. Similarly, T9c, T9d and T15 with hydrophobic 
substitutions at the 6- and 3- positions displayed similar potency. The presence of a terminal 
carboxylate group in T15 is well tolerated. Increasing the chain length with additional 
benzofuran units (T12) reduces the inhibition potency by 2-fold. Thus, it can be concluded that 
the trimer is optimal with hydrophobic substitutions at the first unit. 
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Figure 35. Direct inhibition of factor IXa by inhibitors T9c, T9d, T9f, T12 and T15. The 
inhibition of human factor IXa was determined spectrophotometrically through a Spectrozyme 
factor IXa hydrolysis assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to 
obtain IC50, YM, and YO, as described in the Experimental Section (5.4.8).  
 
Table 18. Inhibition of human factor IXa by sulfated benzofuran trimer 
 
Log IC50 IC50 (µM) ∆Y 
T9c -4.59 ± 0.02 25.7 ± 0.04 81.3 
T9d -4.65 ± 0.01 22.2 ± 0.01 67 
T9f -5.03 ± 0.01 9.2 ± 0.02 95.8 
T12 -4.18 ± 0.01 65.5 ± 0.01 82.2 
T15 -4.62 ± 0.01 23.7 ± 0.02 81.3 
 
5.2.9 Factor Xa Inhibition Potential of Designed Sulfated Benzofuran Trimers  
Figure 36 shows the semi-log inhibition curves obtained from selected sulfated trimers. The 
selected trimer molecules exhibited reasonable inhibition of human factor Xa at pH 7.4 and 37 
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°C. Out of a library of 10 trimers, only T9b and T9d exhibited moderate inhibition potency. T9b 
is the most potent with an IC50 of 61 µM and T9d displayed a potency of 103 µM (Table 19). 
These molecules displayed inhibition efficacy of 80-100%. Although this study is too small to 
predict any SAR, these molecules can serve as potential lead to design inhibitors for factor Xa. 
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Figure 36. Direct inhibition of factor Xa by inhibitors T9b, and T9d. The inhibition of human 
factor Xa was determined spectrophotometrically through a Spectrozyme factor Xa hydrolysis 
assay at pH 7.4 and 37 °C. Solid lines represent sigmoidal fits to the data to obtain IC50, YM, and 
YO, as described in the Experimental Section (5.4.7).  
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Table 19 Inhibiton of human factor Xa by sulfated benzofuran trimers 
 
Log IC50 IC50 (µM) ∆Y 
T9b -4.21 ± 0.02 61.1 ± 0.03 68.9 
T9d -3.98 ± 0.04 103.0 ± 0.05 99 
 
5.3 Significance 
This work presents a library of small homogenous sulfated aromatic scaffolds as novel 
inhibitors of thrombin with an allosteric mode of action. These are the first known small 
aromatic molecules as allosteric inhibitors of thrombin with nanomolar potency. The allosteric 
inhibition of thrombin offers advantages of controlled inhibition and ease of design of antidote.  
Finally, the successful design of allosteric inhibitors of thrombin opens a path for 
designing allosteric inhibitors for other upstream proteases of the coagulation cascade. The 
recognization of the heparin binding site by these aromatic inhibitors may extend the inhibition 
activity for other proteases that are known to bind heparin.  By exploring the other structural 
features of lignins, it may be possible find scaffolds inhibiting other proteases in highly specific 
manners.  
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5.4 Experimental Procedures 
5.4.1 Chemicals, Reagents and Analytical Chemistry 
Reagents, chemicals and solvents were purchased either from Sigma-Aldrich 
(Milwaukee, WI) or Fisher (Pittsburgh, PA) and were used as received. Reagent solutions and 
chemicals were handled under inert nitrogen atmosphere using syringe techniques for liquid and 
dried spatula for solids. All glassware was dried in the oven overnight before use. All organic 
layers obtained during work-up were dried using anhydrous sodium sulfate. Reaction progress 
was monitored using analytical thin layer chromatography (TLC) using UNIPLATETM silica gel 
GHLF 250 µm pre-coated plates (ANALTECH, Newark, DE) and detected by UV (254 nm). 
Column chromatography was performed using Teledyne ISCO (Lincoln, NE) Combiflash RF 
system and disposable normal silica cartridges of 30 – 50 µm particle size, 230 – 400 mesh size 
and 60 Å pore size. Sodium exchange chromatography was performed using SP Sephadex C-25 
sodium cation exchange resin from GE Healthcare Life Sciences (Piscataway, NJ). 
Approximately 100 mg of each sulfated sample was loaded onto 10 g of the cation exchanger in 
a 10 × 460 mm column and eluted with water at 0.5 mL/min. Microwave-based sulfation and 
coupling reactions were performed using a CEM-Discover synthesizer (Matthews, NC) in sealed 
reaction vessels (7 mL) at 50 W. Temperature of the reaction was maintained at the desired 
setting using cooled nitrogen (45 psi) flow.  
1H and 13C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or 
Bruker UltrashieldTMPlus) in appropriate deuterated solvents including CDCl3, DMSO-d6, or 
D2O. All signals are reported in ppm with the internal chloroform, DMSO, and D2O signals at 
7.26, 2.50, 2.05, and 4.79, respectively, as standards. The data is reported as chemical shifts 
(ppm) and splitting pattern is described as (s = singlet, d = doublet, t = triplet, m = multiplet) 
with coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all 
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synthesized molecules using a Micromass ZMD4000 single quadrupole mass spectrometer with 
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples, 
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source 
block temperature and the probe temperature were typically held at 100 and 120 °C, respectively, 
while corona and cone voltages were selected through manual optimization. The desolvation 
nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from 110 to 1000 
Daltons at 400 amu/sec. 
Chromogenic substrate Spectrozyme TH (H-D-hexahydrotyrosol-Ala-Arg-p-nitroanilide) 
was purchased from American Diagnostica (Greenwich, CT). Unfractionated porcine heparin 
was purchased from Sigma (St. Louis, MO). Heparin octasaccharide H8 was purchased from V-
Labs (Covington, LA). All other chemicals were analytical reagent grade from either Sigma 
Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as such.  
 
5.4.2 Synthesis Protocols 
Synthesis of 5, 6-dihydroxy-2-methylbenzofuran-3-carboxylate esters (T1a ̶ T1e). 
 
 
To a solution of catechol (20 mmol) in 75 mL of ethanol were added ester of acetoacetate (20 
mmol) and N, N-Diisopropylethylamine (40 mmol). The reaction mixture was stirred for 5 min. 
To this mixture was added sodium iodate (20 mmol) and the solution stirred vigorously for 5 min 
and then 25 mL of water was added. The reaction mixture was stirred for 10 hours at room 
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temperature and quenched with 400 mL of ethyl acetate and extracted with 150 mL of brine and 
30 mL of 0.5 N HCl. The organic layer was dried over magnesium sulfate and concentrated. The 
product was purified by passing through a plug of silica (1 inch in height) using 2% methanol in 
methylene chloride. The product was concentrated and dried under vacuum to provide a yield of 
40%. 
T1a: 1H NMR (Acetone-d6, 300 MHz) δ 1.36 (t, J =3 Hz, 3H), 2.63 (s, 3H), 4.31 (q, J =6 Hz, 
2H), 6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83, 
117.56, 144.09, 144.92, 147.79, 161.79, 164.48. 
T1b: 1H NMR (CDCl3, 300 MHz) δ 2.65 (s, 3H), 3.97 (s, 3H), 6.99 (s, 1H), 7.43 (s, 1H). 
T1c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 6.96 (s, 1H), 7.39 (s, 1H). 
T1d: 1H NMR (CDCl3, 300 MHz) 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 4.46 (t, J=12 
Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
T1e: 1H NMR (CDCl3, 300 MHz) 2.71 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 (d, 2H), 6.00 (m, 
1H), 6.91 (s, 1H), 7.46 (s, 1H). 
 
Synthesis of 5-hydroxy-6-alkoxy-2-methylbenzofuran-3-carboxylate esters (T2a ̶T2h) 
 
 
To a solution of T1a ̶ T1e (1.44 mmol) in DMF (12 mL) were added cesium carbonate (0.72 
mmol) and acyl or alkyl halide (1.44 mmol) and stirred for 15 hours under an N2 atmosphere. 
The reaction was quenched by adding 0.5 N HCl and extracted with ethyl acetate. The organic 
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extract was dried over magnesium sulfate, concentrated and  purified on silica gel (0-25% ethyl 
acetate in hexanes) to give product in 53% yield.  
T2a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6 
Hz, 2H), 5.58 (s, 1H), 6.95 (s, 1H), 7.37 (s, 1H). 13C NMR (CDCl3) δ 14.60, 14.66, 56.54, 60.43, 
94.33, 106.04, 109.23, 119.19, 143.37, 145.18, 147.86, 162.87, 164.88. 
T2b: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 6.95 (s, 1H), 7.44 (s, 
1H). 
T2c: 1H NMR (CDCl3, 300 MHz) δ 1.60 (s, 9H), 2.63 (s, 3H), 3.92 (s, 3H), 6.92 (s, 1H), 7.39 (s, 
1H). 
T2d: 1H NMR (CDCl3, 300 MHz) δ 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, J=12 Hz, 2H), 3.82 (s, 
3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
T2e: 1H NMR (CDCl3, 300 MHz) δ 2.71 (s, 3H), 3.83 (s, 3H), 4.85 (d, 2H), 5.22 (d, 1H), 5.36 
(d, 2H), 6.00 (m, 1H), 6.91 (s, 1H), 7.46 (s, 1H). 
T2f: 1H NMR (CDCl3, 400 MHz) δ 1.45 (s, 6H), 2.70 (s, 3H), 4.13 (d, 2H), 4.36 (d, 2H), 6.93 (s, 
1H), 7.43 (s, 1H). 13C NMR (CDCl3) δ 14.34, 14.43, 14.76, 31.42, 36.45, 60.15, 65.02, 76.69, 
77.00, 77.32, 94.97, 105.73, 109.04, 118.95, 143.34, 144.13, 147.63, 162.50, 162.58, 164.63. 
T2g: 1H NMR (CDCl3, 300 MHz) δ 1.40 (d, J=1.5 Hz, 6H), 1.43 (t, J=1.8 Hz, 3H), 2.71 (s, 3H), 
4.38 (t, J=1.8 Hz, 2H), 4.58 (m, 1H), 6.96 (s, 1H), 7.44 (s, 1H). 
T2h: 1H NMR (CDCl3, 300 MHz) δ 1.46 (t, J=6 Hz, 3H), 2.75 (s, 3H), 3.96 (s, 3H), 4.39 (q, J=6 
Hz, 2H), 5.58 (s, 1H), 7.01 (s, 1H), 7.31 (s, 1H). 
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Synthesis of 5-((t-butyldimethylsilyl)oxy)-6-alkoxy-2-methylbenzofuran-3-carboxylate ester 
(T3a ̶ T3h). 
 
 
To a solution of T2a ̶ T2f (3.63 mmol) in DMF (30 mL) were added imidazole (18.15 mmol) and 
TBDMSCl (21.83 mmol) and the mixture was stirred. After 16 hours the reaction mixture was 
quenched with water and extracted with diethyl ether. The organic layer was dried over 
magnesium sulfate, concentrated and purified by flash chromatography on silica gel (0-15% 
EtOAc in hexanes) to obtain product in yield of 85-90 %.  
T3a: 1H NMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H),  1.46 (t, J=6 Hz, 3H), 2.69 (s, 
3H),  3.87 (s, 3H), 4.39 (q, J=6 Hz, 2H), 7.05 (s, 1H) and 7.41 (s, 1H). 13C NMR (CDCl3) δ 4.5, 
14.47, 18.73, 22.25, 25.96, 55.99, 61.00, 95.23, 111.31, 112.77, 118.07, 143.56, 149.97, 151.43, 
157.60, 163.69. 
T3b: 1H NMR (CDCl3, 300 MHz) δ 1.16 (s, 6H), 1.02 (s, 9H), 2.70 (s, 3H), 3.83 (s, 3H), 3.91 (s, 
3H), 6.93 (s, 1H), 7.37 (s, 1H). 
T3c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.03 (s, 9H), 1.62 (s, 9H), 2.69 (s, 3H), 3.83 (s, 
3H), 6.92 (s, 1H), 7.36 (s, 1H). 
T3d: 1H NMR (CDCl3, 300 MHz) δ 0.13 (s, 6H), 1.01 (s, 9H), 2.63 (s, 3H), 3.41 (s, 3H), 3.72 (t, 
J=12 Hz, 2H), 3.82 (s, 3H), 4.46 (t, J=12 Hz, 2H), 6.96 (s, 1H), 7.39 (s, 1H). 
T3f:1H NMR (CDCl3, 400 MHz) δ 0.11(s, 6H), 1.04 (s, 9H), 1.46 (s, 6H), 2.71 (s, 3H), 4.03 (d, 
2H), 4.35 (d, 2H), 6.93 (s, 1H), 7.40 (s, 1H). 
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T3g: 1H NMR (CDCl3, 400 MHz) δ 0.19 (s, 6H), 1.04 (s, 9H), 1.37 (d, 6H), 1.42 (t, 3H), 2.71 (s, 
3H), 4.40 (d, 2H), 6.94 (s, 1H), 7.40 (s, 1H). 
T3h: 1HNMR (CDCl3, 300 MHz) δ 0.17 ( s, 6H), 1.01 (s, 9H),  1.46 (t, J=6 Hz, 3H), 2.69 (s, 
3H),  3.87 (s, 3H), 4.39 (q, J=6 Hz,, 2H),  7.08 (s, 1H) 7.35 (s, 1H). 
 
Synthesis of 2-(bromomethyl)-5-((tert-butyldimethylsilyl)oxy)-6-alkoxybenzofuran-3-
carboxylate ester (T4a ̶ T4h). 
 
 
To a solution of T3a ̶ T3f (1 mmol) in THF (20 mL) was added NBS (1 mmol) and the solution 
was refluxed at 65 oC under a halogen lamp for 1 hour. The reaction mixture was cooled and 
quenched with water and extracted with hexanes. The organic layer was concentrated and 
product was obtained in 90-95 % yield. 
T4a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H), 
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.05 (s, 1H), 7.41 (s, 1H). 
T4b: 1H NMR (CDCl3, 300 MHz) δ 1.17 (s, 6H), 1.02 (s, 9H), 3.83 (s, 3H), 3.91 (s, 3H), 4.91 (s, 
2H), 6.93 (s, 1H), 7.37 (s, 1H). 
T4c: 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H), 1.01 (s, 9H), 1.65 (s, 9H), 3.85 (s, 3H), 4.93 (s, 
2H), 6.96 (s, 1H), 7.40 (s, 1H). 
T4d: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 3.45 (s, 3H), 3.76 (t, J=12 Hz, 
2H), 3.86 (s, 3H), 4.50 (t, J=12 Hz, 2H), 4.96 (s, 2H), 6.98 (s, 1H), 7.45 (s, 1H). 
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T4f: 1H NMR (CDCl3, 400 MHz) δ 0.11(s, 6H), 1.04 (s, 9H,), 1.46 (s, 6H,), 4.03 (d, 2H,), 4.35 
(d, 2H), 4.96 (s, 2H), 6.93(s, 1H), 7.40(s, 1H). 
T4g: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.38 (d, 6H), 1.43 (t, 3H), 4.48 (d, 
2H), 4.57 (s, 2H), 6.97 (s, 1H), 7.41 (s, 1H). 
T4h: 1HNMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H), 1.46 (t, J=6 Hz, 3H), 3.87 (s, 3H), 
4.39 (q, J=6 Hz, 2H), 4.93 (s, 2H), 7.08 (s, 1H) 7.35 (s, 1H). 
 
 
Synthesis of ethyl 5-((tert-butyldimethylsilyl)oxy)-2-(((3-(ethoxycarbonyl)-6-methoxy-2-
methylbenzofuran-5-yl)oxy)methyl)-6-methoxybenzofuran-3-carboxylate (T5a ̶ T5b). 
 
OH3CO
TBDMSO
OC2H5
O
O
H3CO O
OR"
O
OH3CO
TBDMSO
OC2H5
O
Br Cs2CO3
5a: R" = -C2H5
5b: R" = -CH2CHCH2
 
To a solution of T2a or T2e (0.3 mmol) and T4a (0.4 mmol) in ethyl acetate (4 mL) were added 
cesium carbonate (0.3 mmol) and anhydrous DMF (1 mL). The reaction mixture was stirred 
under nitrogen for 15 hours at room temperature. The reaction was quenched with methylene 
chloride and extracted with brine. The organic layer was dried over magnesium sulfate and 
concentrated. Purification was done by using flash chromatography on silica gel using (0-20) % 
ethyl acetate in hexanes. The product was obtained in 60-65 % yield. 
T5a: 1H NMR (CDCl3, 300 MHz) δ 0.17 (s, 6H), 1.01 (s, 9H),  1.46 (m, 6H), 2.71 (s, 3H),  3.87 
(s, 3H), 3.91 (s, 3H), 4.39 (m, 4H), 5.60 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 
1H). 13C NMR (CDCl3) δ 4.55, 14.41, 14.73, 14.68, 18.92, 25.57, 55.77, 56.62, 60.62, 61.93, 
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64.47, 95.27, 98.31, 103.47, 109.31, 112.55, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95, 
148.08, 151.20, 150.69, 157.66, 162.67, 164.17, 164.83. 
T5b: 1H NMR (CDCl3, 400 MHz) δ 0.15 (s, 6H), 1.00 (s, 9H), 1.37 (t, J=10.2 Hz, 3H), 2.70 (s, 
3H), 3.82 (s, 3H), 3.85 (s, 3H), 4.35 (q, J=10.2 Hz, 2H), 4.80 (d, J=5.6 Hz, 2H), 5.20 (m, 1H), 
5.38 (m, 1H), 5.57 (s, 2H), 5.99 (m, 1H), 6.97 (s, 1H), 6.98 (s, 1H), 7.24 (s, 1H), 7.44 (s, 1H), 
7.59 (s, 1H). 13C NMR (CDCl3) δ 4.72, 14.20, 14.46, 18.49, 25.75, 55.77, 56.31, 60.52, 63.93, 
64.78, 95.32, 107.68, 108.93, 11.88, 118.33, 132.39, 143.07, 145.83, 148.91, 149.09, 149.94, 
150.70, 157.79, 162.62, 163.67. 
 
 
Synthesis of ethyl 5-(hydroxy)-2-(((3-(ethoxycarbonyl)-6-methoxy-2-methylbenzofuran-5-
yl)oxy)methyl)-6-methoxybenzofuran-3-carboxylate (T6a ̶T6b). 
 
 
To a solution of T5a – T5b (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid 
(10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene 
chloride and extracted with brine solution. The aqueous layer was again extracted with fresh 
methylene chloride. The organic layer was combined and dried over magnesium sulfate and 
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90% 
yield. 
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T6a: 1H NMR (CDCl3, 300 MHz) δ 1.46 (m, 6H), 2.71 (s, 3H), 3.80 (s, 3H), 3.85 (s, 3H), 4.39 
(m, 4H), 5.35 (s, 2H), 6.95 (s, 1H), 6.99 (s, 1H), 7.42 (s, 1H), 7.55 (s, 1H). 13C NMR (CDCl3) δ 
14.41, 14.73, 14.68, 25.57, 55.77, 56.62, 60.62, 61.93, 64.47, 95.27, 98.31, 103.47, 109.31, 
112.55, 112.73, 117.90, 119.98, 143.29, 146.34, 147.95, 148.08, 151.20, 150.69, 157.66, 162.67, 
164.17, 164.83. 
T6b: 1H NMR (CDCl3, 400 MHz) δ 1.39 (t, J=10.2 Hz, 3H), 2.71 (s, 3H), 3.87 (s, 3H), 3.3 (s, 
3H), 4.36 (q, J=10.2 Hz, 2H), 4.80 (d, J=5.6 Hz, 2H), 5.23 (m, 1H), 5.38 (m, 1H), 5.60 (s, 2H), 
5.99 (m, 1H), 6.98 (s, 1H), 7.02 (s, 1H), 7.50 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3) δ 14.15, 
14.37, 56.26, 60.64, 64.02, 84.81, 64.91, 94.63, 95.37, 105.85, 106.05, 107.84, 118.09, 118.28, 
132.25, 143.70, 145.69, 146.51, 147.68, 148.80, 148.88, 149.11, 157.92, 162.72, 162.81, 163.82. 
 
 
 
 
 
 
Synthesis of T7a ̶ T7h 
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 R R’ R” 
T7a -C2H5 - CH3 -H 
T7b - CH3 - CH3 -H 
T7c -C(CH3)3 - CH3 -H 
T7d -C2H4OCH3 - CH3 -H 
T7e -C2H5 -CH3 -CH2CHCH2 
T7f -C2H5 - C2H5 -H 
T7g -C2H5 - CH(CH3)2 -H 
T7h -C2H5 -CH3 -H 
 
To a solution of T6a-T6b (0.3 mmol) and T4a ̶ T4h (0.4 mmol) in ethyl acetate (3 mL) were 
added cesium carbonate (0.3 mmol) and anhydrous DMF (0.5 mL) in a microwave tube (10 mL). 
The reaction mixture was stirred under microwave radiation at 90 °C for 80 minutes. The 
reaction was quenched with methylene chloride and extracted with brine. The organic layer was 
dried over magnesium sulfate and concentrated. Purification was by using flash chromatography 
on silica gel using 20-60) % ethyl acetate in hexanes. The product was obtained in 50 % yield 
(see Appendix, Page 318-325 for NMR spectra).  
T7a: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.37 (m, 9H), 2.71 (s, 3H), 3.83 
(s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.35 (m, 6H), 5.59 (s, 2H), 5.60 (s, 2H), 6.98 (s, 1H), 7.00 (s, 
1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3) δ 4.73, 14.20, 
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14.23, 14.28, 14.36, 14.39, 25.74, 55.76, 56.25, 56.29, 60.11, 60.56, 60.70, 63.77, 64.02, 95.28, 
95.53, 106.05, 107.59, 107.82, 109.10, 111.93, 112.04, 112.52, 117.72, 117.86, 118.39, 143.08, 
145.66, 146.07, 148.86, 149.10, 149.84, 149.94, 150.14, 150.72, 157.68, 157.89, 162.37, 163.49, 
163.68, 164.40. 
T7b: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.35 (m, 6H), 2.70 (s, 3H), 3.83 
(s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.91 (s, 3H), 4.34 (s, 4H), 5.58 (s, 2H), 5.59 (s, 2H), 6.98 (s, 
1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.43 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C  NMR (CDCl3, 400 
MHz) δ 4.72, 14.23, 14.37, 14.39, 18.49, 25.76, 51.63, 55.71, 56.26, 56.31, 60.11, 60.57, 63.86, 
64.06, 95.23, 95.32, 95.56, 107.74, 107.89, 109.12, 111.78, 112.03, 112.44, 117.77, 117.86, 
118.42, 143.15, 145.68, 146.05, 148.89, 149.12, 149.88, 149.95, 150.75, 157.67, 157.91, 162.38, 
163.49, 163.78, 164.40. 
T7c: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.35 (m, 6H), 1.58 (s, 9H), 2.70 
(s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.33 (m, 4H), 5.57 (s, 2H), 5.59 (s, 2H), 6.97 (s, 
1H), 6.99 (s, 1H), 7.05 (s, 1H), 7.42 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3, 400 
MHz) δ 4.74, 14.25, 14.37, 14.39, 18.47, 25.75, 28.33, 55.74, 56.24, 56.31, 60.12, 60.56, 63.91, 
64.05, 81.41, 95.23, 95.32, 95.53, 107.64, 107.90, 109.12, 112.05, 112.66, 113.14, 117.75, 
118.08, 118.42, 142.91, 145.68, 146.23, 148.89, 149.12, 149.87, 150.14, 150.59, 157.34, 157.88, 
162.38, 162.51, 162.86, 163.50, 164.40. 
T7d: 1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.02 (s, 9H), 1.33 (m, 6H), 2.70 (s, 3H), 3.37 (s, 
3H), 3.71 (m, 2H), 3.83 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.34 (m, 4H), 4.45 (m, 2H), 5.58 (s, 
2H), 5.61 (s, 2H), 6.97 (s, 1H), 6.99 (s, 1H), 7.05 (s, 1H), 7.46 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 
13C NMR (CDCl3, 400 MHz) δ 4.7, 14.25, 14.28, 14.38, 18.49, 25.76, 55.70, 56.27,56.32, 58.94, 
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60.12, 60.57, 63.51, 63.75, 64.07, 70.40, 95.28, 95.33, 95.56, 107.47, 107.90, 109.12, 111.77, 
112.50, 112.60, 117.75, 117.83, 118.43, 143.16, 145.69, 146.13, 148.90, 149.12, 149.82, 149.97, 
150.32, 157.89, 157.97, 162.38, 163.49, 163.60, 164.40. 
T7e: 1H NMR (CDCl3, 400 MHz) δ 0.02 (s, 6H), 1.02 (s, 9H), 1.37 (m, 6H), 2.72 (s, 3H), 3.84 (s, 
3H), 3.86 (m, 2H), 3.88 (s, 3H), 4.26 (m, 4H), 4.62 (m, 2H), 5.22 (s, 1H), 5.25 (s, 1H), 5.58 (s, 
2H), 5.62 (s, 2H), 6.01 (m, 1H),  6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.60 (s, 
1H), 7.64 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 4.72, 14.20, 14.24, 14.47, 18.49, 25.75, 55.76, 
56.26, 56.31, 60.56, 63.79, 64.00, 64.78, 95.30, 95.33, 95.56, 107.64, 107.76, 108.92, 111.94, 
112.08, 112.53, 117.75, 117.89, 118.11, 118.33, 132.37, 143.09, 145.76, 146.09, 148.91, 149.11, 
149.86, 149.95, 150.16, 150.73, 157.70, 157.82, 162.63, 163.47. 
T7f: 1H NMR (CDCl3, 400 MHz) δ -0.17 (s, 6H), 1.03 (s, 9H), 1.34 (m, 12H),  2.71 (s, 3H), 3.86 
(s, 3H), 3.87 (s, 3H), 4.18 (m, 2H), 4.35 (m, 6H), 5.58 (s, 3H), 5.60 (s, 3H), 6.98 (s, 1H), 6.99 (s, 
1H), 7.05 (s, 1H), 7.45 (s, 1H), 7.58 (s, 1H), 7.64 (s, 1H). 13C NMR (CDCl3) δ 4.71, 14.21, 
14.23, 14.27, 14.29, 14.36, 14.38, 25.71, 55.77, 56.27, 56.30, 60.14, 60.56, 60.72, 63.77, 64.12, 
95.30, 95.52, 95.99, 106.05, 107.61, 107.82, 109.13, 111.83, 112.10, 112.52, 117.62, 117.84, 
118.44, 143.08, 145.61, 146.17, 148.76, 149.11, 149.83, 149.94, 150.14, 150.72, 157.68, 157.89, 
162.33, 163.43, 163. 65,164.42. 
T7g: 1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.35 (m, 15H),  2.70 (s, 3H), 3.85 
(s, 3H), 3.87 (s, 3H), 4.35 (m, 6H), 4.58 (m, 1H), 5.58 (s, 3H), 5.60 (s, 3H), 6.97 (s, 1H), 6.99 (s, 
1H), 7.05 (s, 1H), 7.43 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 4.74, 
14.24, 14.27, 14.28, 14.30, 14.36, 14.35, 25.71, 55.75, 56.27, 56.31, 60.14, 60.58, 60.72, 63.74, 
64.12, 95.31, 95.55, 95.91, 106.05, 107.61, 107.85, 109.13, 111.83, 112.13, 112.52, 117.64, 
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117.84, 118.44, 143.12, 145.61, 146.11, 148.76, 149.19, 149.73, 149.94, 150.24, 150.72, 157.58, 
157.89, 162.33, 163.43, 163.67, 164.48. 
T7h:1H NMR (CDCl3, 400 MHz) δ 0.16 (s, 6H), 1.00 (s, 9H), 1.35 (m, 9H), 2.70 (s, 3H), 3.86 (s, 
3H), 3.87 (s, 9H), 4.35 (m, 6H), 5.58 (s, 4H), 6.97 (s, 1H), 7.03 (s, 1H), 7.05 (s, 1H), 7.44 (s, 
1H), 7.57 (s, 1H), 7.64 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 4.72, 14.26, 14.37 (2C), 18.49, 
25.70, 28.26, 55.88, 56.26, 56.31, 60.11, 60.57, 60.59, 60.66, 64.07, 95.33, 95.57, 103.47, 
103.61, 103.85, 103.95, 107.91, 107.95, 109.12, 111.99, 112.03, 117.78, 118.43, 119.08, 144.71, 
145.69, 146.10, 148.90, 149.13, 149.58, 149.95, 150.23, 157.70, 157.93, 162.38, 163.70, 164.40. 
 
Synthesis of T8a ̶ T8g 
 
 
To a solution of T7a ̶ T7g (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid 
(10 µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene 
chloride and extracted with brine solution. The aqueous layer was again extracted with 
methylene chloride. The organic layer was combined and dried over magnesium sulfate and 
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90% 
yield (see Appendix, Page 326-332 for NMR spectra). 
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T8a: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 9H), 2.72 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 3.93 
(s, 3H), 4.35 (m, 6H), 5.58 (s, 2H), 5.62 (s, 2H), 6.97 (s, 1H), 7.02 (s, 1H), 7.15 (s, 1H), 7.39 (s, 
1H), 7.51 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.22, 14.31, 14.36, 14.39, 56.24, 
56.31, 60.11, 60.56, 60.64, 63.83, 64.06, 94.49, 95.33, 95.58, 106.07, 107.71, 107.90, 
109.12,112.02, 117.76, 118.35, 118.42, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12, 
149.75, 150.46, 157.93, 158.12, 162.39, 163.37, 163.68, 164.43. 
T8b: 1H NMR (CDCl3, 400 MHz) δ 1.34 (m, 6H), 2.70 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 3.92 
(s, 3H), 3.93 (s, 3H), 4.34 (m, 4H), 5.58 (s, 2H), 5.61 (s, 2H), 6.97 (s, 1H), 7.01 (s, 1H), 7.05 (s, 
1H), 7.49 (s, 1H), 7.56 (s, 1H), 7.62 (s, 1H).  13C NMR (CDCl3, 400 MHz) δ 14.21, 14.36, 14.39, 
51.63, 56.28, 56.31, 60.11, 60.57, 63.80, 64.06, 94.49, 95.33, 95.58, 106.05, 107.76, 107.90, 
109.11, 111.85, 112.02, 117.77, 118.27, 118.43, 143.66, 145.68, 145.98, 146.16, 148.82, 148.89, 
149.12, 149.86, 150.17, 157.93, 158.05, 162.39, 162.69, 163.47, 164.08, 164.40. 
T8c: 1H NMR (CDCl3, 400 MHz) δ 1.34 (m, 6H), 1.57 (s, 9H), 2.70 (s, 3H), 3.85 (s, 3H), 3.86 
(s, 3H), 3.92 (s, 3H), 4.34 (m, 4H), 5.58 (s, 2H), 5.59 9s, 2H), 6.97 (s, 1H), 7.00 (s, 1H), 7.05 (s, 
1H), 7.46 (s, 1H), 7.58 (s, 1H), 7.61 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.23, 14.36, 14.38, 
28.33, 56.25, 56.28, 56.32, 60.12, 60.56, 64.00, 64.05, 81.58, 94.43, 95.34, 95.56, 106.08, 
107.79, 107.91, 109.12, 112.04, 113.19, 117.77, 118.43, 118.61, 143.49, 145.68, 146.00, 146.16, 
148.71, 148.90, 149.12, 149.89, 150.16, 157.48, 157.90, 162.38, 162.66, 162.85, 163.47. 
T8d: 1H NMR (CDCl3, 400 MHz) δ 1.33 (m, 6H), 2.70 (s, 3H), 3.37 9s, 3H), 3.70 (m, 3H), 3.85 
(s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 4.34 (m, 4H), 4.47 (m, 2H), 5.58 (s, 2H), 5.61 (s, 2H), 6.97 (s, 
1H), 7.01 (s, 1H), 7.05 (s, 1H), 7.50 (s, 1H), 7.56 (s, 1H), 7.62 (s, 1H). 13C NMR (CDCl3, 400 
MHz) δ 14.22, 14.37, 28.25, 35.48, 56.29, 58.93, 60.12, 60.58, 63.47, 63.81, 64.08, 70.38, 70.46, 
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94.43, 95.34, 95.56, 106.07, 107.54, 107.93, 109.12, 111.82, 112.04, 117.78, 118.34, 118.44, 
143.70, 145.70, 146.09, 146.19, 148.84, 148.91, 149.13, 149.81, 150.13, 157.91, 158.17, 162.38, 
162.64, 163.46, 164.40. 
T8e: 1H NMR (CDCl3, 400 MHz) δ 1.31 (t, J=6.8 Hz, 3H), 1.39 (t, J=6.8 Hz, 3H),  2.71 (s, 3H), 
3.87 (s, 3H), 3.88 (s, 3H), 3.92 (s, 3H), 4.37 (m, 4H), 4.79 (d, J=5.6 Hz, 2H), 5.22 (m, 2H), 5.33 
(m, 2H), 5.57 (s, 2H), 5.62 (s, 2H), 6.00 (m, 1H), 6.97 (s, 1H), 7.01 (s, 1H), 7.04 (s, 1H), 7.49 (s, 
1H), 7.59 (s, 1H), 7.62 (s, 1H). 13C NMR (CDCl3) δ 14.20, 14.24, 14.47, 25.75, 55.76, 56.26, 
56.31, 60.56, 63.79, 64.00, 64.78, 95.30, 95.33, 95.56, 107.64, 107.76, 108.92, 11.94, 112.08, 
112.53, 116.05, 117.79, 119.11, 119.93, 131.35, 143.09, 145.76, 146.09, 148.59, 149.01, 149.53, 
148.75, 151.06, 151.71, 157.38, 167.92, 163.61, 164.07. 
T8f: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 12H),  2.71 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 4.17 
(m, 2H), 4.35 (m, 6H), 5.58 (s, 3H), 5.62 (s, 3H), 6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 1H), 7.50 (s, 
1H), 7.57 (s, 1H), 7.62 (s, 1H). ). 13C NMR (CDCl3) δ 14.20, 14.24, 14.29, 14.31, 14.36, 14.38,  
55.78, 56.29, 56.32, 60.15, 60.57, 60.74, 63.77, 64.19, 95.34, 95.52, 95.89, 106.15, 107.61, 
107.85, 109.13, 111.73, 112.10, 112.42, 117.65, 117.84, 118.44, 143.08, 145.65, 146.17, 148.76, 
149.21, 149.83, 149.94, 150.14, 150.72, 157.68, 157.85, 162.33, 163.47, 163.65, 164.42. 
T8g: 1H NMR (CDCl3, 400 MHz) δ 1.37 (m, 15H),  2.70 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 4.36 
(m, 6H), 4.58 (m, 1H), 5.58 (s, 3H), 5.62 (s, 3H), 6.97 (s, 1H), 7.02 (s, 1H), 7.05 (s, 1H), 7.49 (s, 
1H), 7.57 (s, 1H), 7.63 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.21, 14.25, 14.27, 14.34, 14.36, 
14.38,  55.79, 56.25, 56.40, 60.12, 60.56, 60.62, 63.77, 64.12, 95.40, 95.52, 95.79, 106.15, 
107.51, 107.72, 109.43, 111.63, 112.10, 112.52, 117.52, 117.83, 118.44, 143.08, 145.51, 146.17, 
148.66, 149.11, 149.53, 149.64, 150.24, 150.72, 157.88, 157.92, 162.33, 163.33, 163.65, 164.32. 
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T8h: 1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 9H), 2.72 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 3.93 
(s, 3H), 4.35 (m, 6H), 5.58 (s, 2H), 5.62 (s, 2H), 6.97 (s, 1H), 7.02 (s, 1H), 7.15 (s, 1H), 7.39 (s, 
1H), 7.51 (s, 1H), 7.59 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ 14.22, 14.31, 14.36, 14.39, 56.24, 
56.31, 60.11, 60.56, 60.64, 63.83, 64.06,  94.49, 95.33, 95.58, 106.07, 107.71, 107.90, 
109.12,112.02, 117.76, 118.35, 118.42, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12, 
149.75, 150.46, 157.93, 158.12, 162.39, 163.37, 163.68, 164.43. 
 
Synthesis of T13 
 
To a solution of T8e (0.19 mmol) in methylene chloride (1.5 mL) were added Pd(PPh3)4 (0.009 
mmol) and PPh3 (0.018 mmol). The reaction mixture was stirred for 10 minutes in ice bath to 
bring temperature down. To this mixture was added pyrrolidine (0.21 mmol) and it was stirred 
for 30 minutes. The reaction was quenched by methylene chloride and extracted with brine 
solution. The aqueous layer was again extracted with methylene chloride. The organic layer was 
combined and dried over magnesium sulfate and concentrated in vacuum. The solid obtained was 
washed with hexane several times to remove excess of PPh3 and purified by flash 
chromatography using ethyl acetate and hexanes (40% to 80%) as the solvent system (see 
Appendix, Page 331 for NMR spectra).  
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T13: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (t, J=7.2 Hz, 3H), 1.30 (t, J=7.2 Hz, 3H), 2.66 (s, 
3H), 3.78 (s, 3H), 3.82 (s, 6H), 4.29 (m, 4H), 5.50 (s, 2H), 5.52 (s, 2H), 7.26 (s, 1H), 7.30 (s, 
1H), 7.32 (s, 1H), 7.41 (s, 1H), 7.48 (s, 2H). 13C NMR (DMSO-d6, 400 MHz) δ 13.85, 13.96, 
54.85, 55.95, 55.99, 56.04, 60.38, 60.50, 62.62, 62.74, 95.67, 95.95, 96.17, 105.93, 106.24, 
108.95, 111.22, 111.43, 116.59, 116.99, 117.95, 144.82, 145.06, 145.63, 147.89, 147.97, 148.30, 
148.36, 149.32, 149.61, 157.17, 157.59, 161.68, 162.58, 162.90, 165.02. MS (-ve) m/z calcd. for 
C39H37O15 [(M-H)-)] 717.37, found 717.26 (M-H)-. 
 
Synthesis of T9a ̶ T9g and T14 
 
 
To a solution of T8a ̶ T8g (0.07 mmol) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube 
were added triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The 
reaction mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum 
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C-
25 cation exchange resin and eluted with water. Fractions containing the sulfated product were 
lyophilized to obtain a solid residue, which was further purified on flash chromatography using 
0-20% methanol in methylene chloride (see Appendix, Page 334-342 for NMR spectra and page   
344-348 for Mass Spectra). 
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T9a: 1H NMR (DMSO-d6, 400 MHz) δ 1.24 (m, 12H), 2.65 (s, 3H), 3.77 (s, 6H), 3.80 (s, 3H), 
4.26 (m, 6H), 5.49 (s, 2H), 5.53 (s, 2H), 7.30 (s, 1H), 7.32 (s, 1H), 7.36 (s, 1H), 7.41 (s, 1H), 
7.46 (s, 1H), 8.03 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.84, 14.01, 14.16, 14.29, 56.04, 
56.11, 60.23, 60.59, 60.74, 63.73, 64.16,  94.56, 95.44, 95.58, 106.17, 107.71, 107.94, 
109.12,112.12, 117.44, 118.35, 118.22, 143.59, 145.68, 146.04, 146.09, 148.72, 148.88, 149.12, 
149.75, 150.46, 156.93, 157.12, 161.39, 162.37, 162.68, 163.43. MS (-ve) m/z calcd. for 
C39H37O18S [(M-Na)-)] 825.17, found 825.23 (M-Na)-. 
T9b: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 6H), 2.68 (s, 3H), 3.80 (s, 6H), 3.84 (s, 3H), 
3.86 (s, 3H), 4.27 (m, 4H), 5.52 (s, 2H), 5.56 (s, 2H), 7.32 (s, 1H), 7.34 (s, 1H), 7.40 (s, 1H), 
7.43 (s, 1H), 7.49 (s, 1H), 8.00 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.85, 14.00, 48.56, 
51.76, 56.04, 56.09, 59.92, 60.47, 62.80, 62.97, 95.97, 96.06, 96.23, 106.53, 106.73, 108.26, 
111.35, 111.39, 113.15, 116.28, 116.60, 117.31, 140.86, 145.10, 145.54, 148.51, 148.62, 149.39, 
149.65, 150.21, 150.85, 157.63, 157.82, 162.07, 162.62, 163.18, 163.34. MS (-ve) m/z calcd. for 
C38H35O18S [(M-Na)-)] 811.15, found 811.43 (M-Na)-. 
T9c: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 6H), 1.50 (s, 9H), 2.68 (s, 3H), 3.80(s, 3H), 
3.81 (s, 3H), 3.82 (s, 3H), 4.27 (m, 4H), 5.51 (s, 2H), 5.53 (s, 2H), 7.31 (s, 1H), 7.32 (s, 1H), 
7.40 (s, 1H), 7.43 (s, 1H), 7.48 (s, 1H), 8.11 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.87, 
14.01, 14.04, 27.76, 56.01, 56.04, 56.07, 59.70, 59.92, 60.46, 62.93, 63.07, 95.60, 96.06, 96.23, 
106.75, 106.84, 108.29, 111.38, 112.69, 113.08, 116.64, 116.74, 117.33, 140.86, 145.10, 145.70, 
148.51, 148.64, 149.45, 149.74, 149.96, 150.52, 156.98, 157.83, 161.92, 162.05, 162.61, 163.34. 
HRMS (-ve) m/z calcd. for C41H41O18S [(M-Na)-)] 853.20, found 853.46 (M-Na)-. 
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T9d: 1H NMR (DMS0-d6, 400 MHz) δ 1.24 (m, 6H), 2.65 (s, 3H), 3.21 (s, 3H), 3.76 (m, 3H), 
3.83 (s, 3H), 3.86 (s, 3H), 3.96 (s, 2H), 4.24 (m, 4H), 4.57 (m, 2H), 5.51 (s, 2H), 5.59 (s, 2H), 
7.31 (s, 1H), 7.34 (s, 1H), 7.38 (s, 1H), 7.40 (s, 1H), 7.44 (s, 1H), 8.05 (s, 1H). 13C NMR 
(DMSO-d6, 400 MHz) δ 13.57, 14.17, 28.15, 35.41, 57.29, 58.83, 60.22, 60.51, 63.27, 63.61, 
64.18, 70.48, 70.56, 94.73, 95.44, 95.66, 106.17, 107.54, 107.93, 109.12, 111.82, 112.04, 117.78, 
118.34, 118.44, 143.70, 145.70, 146.09, 146.19, 148.84, 148.91, 149.13, 149.81, 151.13, 157.61, 
158.11, 162.28, 162.44, 163.36, 164.10. MS (-ve) m/z calcd. for C39H37O19S [(M-Na)-)] 841.16 
found 841.42 (M-Na)-. 
T9e: 1H NMR (DMSO-d6, 400 MHz) δ 1.29 (m, 6H), 2.68 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H), 
3.84 (s, 3H), 4.30 (m, 4H), 5.46 (s, 2H), 5.55 (s, 2H), 7.30 (s, 1H), 7.34 (s, 1H), 7.48 (s, 1H), 
7.50 (s, 1H), 7.57 (s, 1H), 8.05 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.52, 13.89, 13.92, 
14.05, 48.56, 52.81, 56.03, 56.05, 60.48, 60.53, 62.85, 63.22, 95.77, 96.06, 96.26, 96.36, 106.42, 
107.37, 108.75, 111.42, 111.55, 113.19, 116.44, 116.63, 117.64, 140.85, 145.24, 145.63, 148.37, 
148.62, 148.77, 149.40, 149.66, 150.17, 150.77, 157.45, 157.56, 157.67, 159.52, 162.24, 162.60, 
162.68. MS (-ve) m/z calcd. for C40H37O18S [(M-Na)-)] 837.16, found 837.42 (M-Na)-. 
T9f: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 12H), 2.66 (s, 3H), 3.81 (s, 3H), 3.89 (s, 3H), 
4.12 (m, 2H), 4.25 (m, 6H), 5.51 (s, 3H), 5.58 (s, 3H), 7.30 (s, 1H), 7.32 (s, 1H), 7.35 (s, 1H), 
7.39 (s, 1H), 7.42 (s, 1H), 8.02 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.86, 14.04, 14.19, 
14.23, 14.31, 14.34,  56.78, 56.99, 57.32, 60.35, 60.59, 60.84, 63.47, 64.59, 95.84, 95.92, 96.19, 
106.55, 107.41, 107.84, 109.43, 111.763, 112.13, 113.42, 117.65, 117.84, 118.44, 143.08, 
145.65, 146.17, 148.56, 149.01, 149.73, 149.84, 150.74, 151.72, 156.68, 156.85, 161.33, 163.27, 
163. 45,164.22. MS (-ve) m/z calcd. for C40H339O18S [(M-Na)-)] 839.18, found 839.41 (M-Na)-. 
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T9g: 1H NMR (DMSO-d6, 400 MHz) δ 1.27 (m, 15H), 2.64 (s, 3H), 3.81 (s, 3H), 3.87 (s, 3H), 
4.26 (m, 6H), 4.42 (m, 1H), 5.52 (s, 3H), 5.59 (s, 3H), 7.30 (s, 1H), 7.32 (s, 1H), 7.37 (s, 1H), 
7.39 (s, 1H), 7.43 (s, 1H), 8.00 (s, 1H). 13C NMR (DMS0-d6, 400 MHz) δ 13.88, 14.15, 14.26, 
14.31, 14.33, 14.37,  56.79, 57.25, 57.40, 60.62, 60.76, 60.68, 63.57, 64.33, 95.63, 95.72, 95.89, 
107.15, 107.58, 107.92, 109.83, 112.63, 112.90, 113.52, 117.52, 117.83, 118.44, 143.08, 145.51, 
146.17, 148.66, 149.11, 149.53, 149.64, 150.24, 151.72, 158.88, 158.92, 162.63, 163.13, 163. 
45,164.12. MS (-ve) m/z calcd. for C41H41O18S [(M-Na)-)] 853.20, found 853.47 (M-Na)-. 
T9h: 1H NMR (DMSO-d6, 400 MHz) δ 1.25 (m, 9H), 2.64 (s, 3H), 3.82 (s, 3H), 3.87 (s, 3H), 
3.91 (s, 3H), 4.25 (m, 6H), 5.51 (s, 2H), 5.58 (s, 2H), 7.31 (s, 1H), 7.34 (s, 1H), 7.35 (s, 1H), 
7.41 (s, 1H), 7.46 (s, 1H), 8.02 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.82, 14.11, 14.26, 
14.31, 56.84, 56.91, 60.41, 60.76, 60.94, 63.63, 64.16,  94.79, 95.93, 96.18, 106.27, 107.74, 
107.98, 109.52,112.02, 117.76, 118.35, 118.42, 141.59, 144.68, 144.84, 145.09, 148.12, 148.48, 
149.02, 149.75, 150.36, 157.63, 157.92, 162.49, 163.07, 163.48, 164.13. MS (-ve) m/z calcd. for 
C39H37O18S [(M-Na)-)] 825.17, found 825.29 (M-Na)-. 
T14: 1H NMR (DMSO-d6, 400 MHz) δ 1.29 (m, 6H), 2.68 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H), 
3.84 (s, 3H), 4.30 (m, 4H), 5.46 (s, 2H), 5.55 (s, 2H), 7.30 (s, 1H), 7.34 (s, 1H), 7.48 (s, 1H), 
7.50 (s, 1H), 7.57 (s, 1H), 8.05 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.52, 13.89, 13.92, 
14.05, 48.56, 52.81, 56.03, 56.05, 60.48, 60.53, 62.85, 63.22, 95.77, 96.06, 96.26, 96.36, 106.42, 
107.37, 108.75, 111.42, 111.55, 113.19, 116.44, 116.63, 117.64, 140.85, 145.24, 145.63, 148.37, 
148.62, 148.77, 149.40, 149.66, 150.17, 150.77, 157.45, 157.56, 157.67, 159.52, 162.24, 162.60, 
162.68. MS (-ve) m/z calcd. for C37H33O18S [(M-Na)-)] 793.13, found 793.27 (M-Na)-. 
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Synthesis of T10 
OH3CO
TBDMSO
OC2H5
O
O
H3CO O
OC2H5
O
O
O
OC2H5
O
H3CO O
O
OC2H5O
H3CO
T8a + T4a
 
To a solution of T8a (0.3 mmol) and T4a (0.4 mmol) in ethyl acetate (3 mL) were added cesium 
carbonate (0.3 mmol) and anhydrous DMF (0.5 mL) in a microwave tube (10 mL). The reaction 
mixture was stirred under microwave radiation at 90 °C for 80 minutes. The reaction was 
quenched with methylene chloride and extracted with brine. The organic layer was dried over 
magnesium sulfate and concentrated. Purification was done by using flash chromatography on 
silica gel using 30-70% ethyl acetate in hexanes. The product was obtained in 50 % yield (see 
Appendix, Page 341 for NMR spectra). 
1H NMR (CDCl3, 400 MHz) δ 0.17 (s, 6H), 1.02 (s, 9H), 1.35 (m, 12H), 2.71 (s, 3H), 3.83 (s, 
3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 4.35 (m, 8H), 5.58 (s, 2H), 5.60 (s, 2H), 5.61 (s, 
2H), 6.98 (s, 1H), 7.00 (s, 1H), 7.05 (s, 2H), 7.45 (s, 1H), 7.58 (s, 1H), 7.63 (s, 1H), 7.64 (s, 1H). 
13C NMR (CDCl3, 400 MHz) δ 4.71, 14.08 (2C), 14.20, 14.24, 14.37, 18.48, 25.75, 55.77, 56.27 
(2C), 56.23, 60.10, 60.55 (2C), 60.58, 63.86, 63.91, 64.09, 95.32 (2C), 95.36, 95.59, 107.77, 
107.97, 109.13, 111.93, 112.03, 112.13, 112.53, 117.72, 117.80, 117.91, 118.45, 143.12, 145.72, 
146.10, 146.15, 148.93, 149.14, 149.90, 149.95 (2C), 150.19 (2C), 150.74, 157.71 (2C), 157.75, 
157.95, 162.37, 163.47, 163.67, 164.38. 
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Synthesis of T11 
 
To a solution of T10 (0.3 mmol) in DMF (3 mL) were added KF (4 mmol) and acetic acid (10 
µL). The reaction mixture was stirred for 5 hours. The reaction was quenched by methylene 
chloride and extracted with brine solution. The aqueous layer was again extracted with 
methylene chloride. The organic layer was combined and dried over magnesium sulfate and 
concentrated in vacuum. The solid was precipitated using methanol to obtain product in 90% 
yield (see Appendix, Page 342 for NMR spectra). 
1H NMR (CDCl3, 400 MHz) δ 1.35 (m, 12H), 2.70 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 
3H), 3.93 (s, 3H), 4.35 (m, 8H), 5.58 (s, 2H), 5.59 (s, 2H), 5.62 (s, 2H), 6.98 (s, 1H), 7.02 (s, 
1H), 7.05 (s, 2H), 7.49 (s, 1H), 7.57 (s, 1H), 7.62 (s, 2H). 13C NMR (CDCl3, 400 MHz) δ 14.22, 
14.29 (2C), 14.36, 14.39, 56.28 (4C), 60.12, 60.57, 60.60 (2C), 60.64, 63.81 (2C), 64.03, 94.48 
(2C), 95.32, 95.56, 106.07 (2C), 107.66, 107.71, 107.84, 109.10, 112.00, 112.12, 117.68, 117.75, 
118.30, 118.41, 143.63 (2C), 145.67, 146.05, 146.16, 148.81 (2C), 148.87, 149.11, 149.87, 
150.16 (2C), 157.72, 157.91, 157.97 (2C), 162.38, 162.73, 163.46, 163.67. 
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Synthesis of T12 
 
To a solution of T11 (0.05 mmol) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were 
added triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The 
reaction mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum 
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C-
25 cation exchange resin and eluted with water. Fractions containing the sulfated product were 
lyophilized to obtain a solid residue, which was further purified on flash chromatography using 
0-20% methanol in methylene chloride (see Appendix, Page 343 for NMR spectra). 
1H NMR (DMSO-d6, 400 MHz) δ 1.30 (m, 12H), 2.66 (s, 3H), 3.79 (s, 6H), 3.81 (s, 3H), 3.82 (s, 
3H), 4.28 (m, 8H), 5.51 (s, 2H), 5.53 (s, 2H), 5.55 (s, 2H), 7.31 (s, 1H), 7.33 (s, 1H), 7.37 (s, 
2H), 7.42 (s, 2H), 7.49 (s, 1H), 8.05 (s, 1H). 13C NMR (DMSO-d6, 400 MHz) δ 13.79, 13.87, 
14.00, 14.01, 56.02 (4C), 56.08, 59.90, 60.60 (2C), 60.45, 62.89 (2C), 95.72 (2C), 96.07, 96.25, 
106.57 (2C), 106.67, 107.71, 107.84, 109.10, 112.00, 112.12, 117.68, 117.75, 118.30, 118.41, 
143.63 (2C), 145.67, 146.05, 146.16, 148.81 (2C), 148.87, 149.11, 149.87, 150.16 (2C), 157.42 
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162.08, 162.62, 162.68, 163.34. MS (-ve) m/z calcd. forC52H49O23S [(M-Na)-)] 1073.44, found 
1073.67 (M-Na)-. 
 
5.4.3 Substrate Hydrolysis Assay 
Thrombin activity in the presence of inhibitors was studied using a chromogenic substrate 
hydrolysis assay in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 
and 0.1 % polyethylene glycol (PEG) 8000 in PEG 20,000-coated acrylic cuvettes. Spectrozyme 
TH was used as substrate and the residual thrombin activity was quantified by measuring the 
initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a function of time. 
Briefly, a solution of 10 µL of the inhibitors to form final concentrations ranging from 4.5 – 900 
µM, was diluted with 970 µL of buffer and 5 µL of 1 µM thrombin (5 nM) and incubated. This 
was followed by addition of 15 µL of 2 mM Spectrozyme TH (30 µM) and the initial rate was 
quickly measured. Logistic equation 4 was used to fit the dose dependence of residual thrombin 
activity to obtain IC50.  
 =  +

	
	(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)×
                 Equation 4 
In this equation, Y is the ratio of residual thrombin activity in the presence of the inhibitor to that 
in its absence; YM and Y0 are the maximum and minimum possible values of the fractional 
residual thrombin activity, respectively; and IC50 is the concentration of inhibitors that results in 
50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc. Chicago, IL) was used to perform 
non-linear curve fitting in which YM, YO, and IC50 were allowed optimized. 
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5.4.4 Michaelis-Menten Kinetics of Substrate Hydrolysis by Thrombin in Presence of T9a 
The initial rate of Spectrozyme TH hydrolysis by 5 nM thrombin was monitored from the 
linear increase in absorbance at 405 nm corresponding to less than 10% consumption of the 
substrate. The initial rate was measured as a function of various concentrations of the substrate (2 
– 80 µM) in the presence of fixed concentrations of 9a (0–3.6 µM), from one or three different 
stock solutions, incubated with thrombin either overnight at 25°C or for two hours at 37°C in 20 
mM Tris-HCl buffer, pH 7.4, to ensure the prevention of aggregation at both conditions. The 
data was fitted by the standard Michaelis-Menten equation to determine KM and VMAX. 
 
5.4.5 Plasma Studies (Prothrombin Time and Activated Partial Thromboplastin Time) 
 For both PT and APTT assays, standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD) was used to measure the clotting time. 
For the APTT assay, 90 µL citrated human plasma, 10 µL inhibitor (or vehicle for blank test), 
and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid) were mixed and incubated for 4 
minutes. The clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 OC) and the time to 
clot was recorded. For Prothrombin (PT) assays, a 10 µL sample of the inhibitor (or vehicle for 
blank test), and 90 µL of citrated human plasma were mixed and incubated for 30 seconds at 37 
OC followed by addition of 200 µL pre-warmed thromboplastin (Reconstituted as per directions 
provided by manufacturer). Each clotting assay was performed in duplicate. The data were fit to 
a quadratic trend line, which was used to determine the concentration of the inhibitor necessary 
to double the clotting time, 2×APTT or 2×PT. 
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5.4.6 Screening Protocols 
Screening of library for Factor VIIa inhibition  ̶Direct inhibition of factor VIIa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02% 
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 75 µL 
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was 
added 10 µL of FVIIa solution to give approximately 80 nM initial FVIIa concentration and 5 µL 
of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL of 20 mM 
Spectrozyme factor VIIa was rapidly added and the residual factor VIIa activity was measured 
from the initial rate of increase in absorbance at 405 nm. The plate was read using a microplate 
reader (FlexStation III, Molecular Devices). Relative residual factor VIIa activity was calculated 
from the ratio of thrombin activity in the presence and absence of inhibitor. The percent residual 
activity was calculated using the equation 5. 
% Residual Activity = [(slope of blank – slope of well with inhibitor)/slope of blank] x 100 
A cut off of 40% was selected, and those compounds which showed a % residual activity lower 
than 40% were selected for full inhibition profile. 
 
Screening of library for Factor IXa inhibition  ̶Direct inhibition of factor IXa by the library of 
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000, 0.02% Tween 
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80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at concentrations 20 mM were 
diluted with 80 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To 
this solution was added 5 µL of factor IXa solution to give approximately 1780 nM initial factor 
IXa concentration. After 10 min of incubation, 10 µL of 8.5 mM Spectrozyme factor IXa was 
rapidly added and the residual factor IXa activity was measured from the initial rate of increase 
in absorbance at 405 nm. The plate was read using a microplate reader (FlexStation III, 
Molecular Devices). Relative residual factor IXa activity was calculated from the ratio of 
thrombin activity in the presence and absence of inhibitor. The percent residual activity was 
calculated using the equation 5. 
Screening of library for Factor Xa inhibition  ̶Direct inhibition of Factor Xa by the library of 
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 8000 and 0.02% 
Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL 
volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this solution was 
added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa concentration. 
After 10 min of incubation, 5 µL of 5 mM Spectrozyme factor Xa was rapidly added and the 
residual factor Xa activity was measured from the initial rate of increase in absorbance at 405 
nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative 
residual factor Xa activity was calculated from the ratio of thrombin activity in the presence and 
absence of inhibitor. The percent residual activity was calculated using the equation 5. 
Screening of library for Factor XIa inhibition  ̶Direct inhibition of factor XIa by the library of 
sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
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hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80. 
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 85 µL volume of assay 
buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL of 
factor XIa solution to give approximately 15.3 nM initial factor XIa concentration. After 10 min 
of incubation, 5 µL of 6.6 mM Spectrozyme factor XIa was rapidly added and the residual factor 
XIa activity was measured from the initial rate of increase in absorbance at 405 nm. The plate 
was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual factor 
XIa activity was calculated from the ratio of thrombin activity in the presence and absence of 
inhibitor. The percent residual activity was calculated using the equation 5. 
Screening of library for Factor XIIa inhibition  ̶Direct inhibition of factor XIIa by the library 
of sulfated benzofuran derivatives was measured through a one-point chromogenic substrate 
hydrolysis assay. The buffer used in these experiments was 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 0.1% polyethylene glycol (PEG) 8000 and 0.02% Tween 80. 
Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted with 185 µL volume of 
assay buffer in flat bottom 96 well-plates (BD Falcon) at 25 °C. To this solution was added 5 µL 
of factor XIIa solution to give approximately 200 nM initial factor XIIa concentration. After 10 
min of incubation, 5 µL of 5 mM Spectrozyme factor XIIa was rapidly added and the residual 
factor XIIa activity was measured from the initial rate of increase in absorbance at 405 nm. The 
plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative residual 
factor XIIa activity was calculated from the ratio of thrombin activity in the presence and 
absence of inhibitor. The percent residual activity was calculated using the equation 5. 
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5.4.7 Inhibition of Factor VIIa   
Direct inhibition of factor VIIa by the sulfated benzofuran trimer was measured through a 
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM Tris-
HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 
8000 and 0.02% Tween 80. Benzofuran derivatives (5 µL) at various concentrations were diluted 
with 75 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this 
solution was added 10 µL of factor VIIa solution to give approximately 80 nM initial factor VIIa 
concentration and 5 µL of tissue factor solution to give 800 nM. After 10 min of incubation, 5 µL 
of 20 mM Spectrozyme  factor VIIa was rapidly added and the residual factor VIIa activity was 
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a 
microplate reader (FlexStation III, Molecular Devices). Relative residual VIIa activity was 
calculated from the ratio of thrombin activity in the presence and absence of inhibitor. Equation 
6 was used to fit the dose-dependence of residual proteinase activity to obtain the IC50 and the 
efficacy ∆Y (= YM – Y0) of inhibition. 
																																																			 =  +

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                             Equation 6 
In this equation, Y is the ratio of residual thrombin activity in the presence of inhibitor to 
that in its absence (fractional residual activity), YM and YO are the maximum and minimum 
possible values of the fractional residual proteinase activity, IC50 is the concentration of the 
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill Slope, which was 
set constant at 1. A current version of SigmaPlot (SPSS, Inc. Chicago, IL) was used to perform 
non-linear curve fitting in which YM, YO and IC50 were optimized. 
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5. 4.8 Inhibition of Factor IXa   
Direct inhibition of factor IXa by sulfated benzofuran trimer was measured through a 
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM Tris-
HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 
8000, 0.02% Tween 80 and 33% v/v ethylene glycol. Benzofuran derivatives (5 µL) at 
concentrations 20 mM were diluted with 80 µL volume of assay buffer in flat bottom 96 well-
plates (BD Falcon) at 25 °C. To this solution was added 5 µL of factor IXa solution to give 
approximately 1780 nM initial factor IXa concentration. After 10 min of incubation, 10 µL of 8.5 
mM Spectrozyme factor IXa was rapidly added and the residual factor IXa activity was 
measured from the initial rate of increase in absorbance at 405 nm. The plate was read using a 
microplate reader (FlexStation III, Molecular Devices). Relative residual factor IXa activity was 
calculated as described in Experimental Section 5.4.7. 
 
5.4.9 Inhibition of Factor Xa   
Direct inhibition of factor Xa by sulfated benzofuran trimer was measured through a 
chromogenic substrate hydrolysis assay. The buffer used in these experiments was 20 mM Tris-
HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% polyethylene glycol (PEG) 
8000 and 0.02% Tween 80. Benzofuran derivatives (5 µL) at concentrations 20 mM were diluted 
with 185 µL volume of assay buffer in flat bottom 96 well-plates (BD Falcon) at 37 °C. To this 
solution was added 5 µL of factor Xa solution to give approximately 43.5 nM initial factor Xa 
concentration. After 10 min of incubation, 5 µL of 5 mM Spectrozyme Xa was rapidly added and 
the residual factor Xa activity was measured from the initial rate of increase in absorbance at 405 
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nm. The plate was read using a microplate reader (FlexStation III, Molecular Devices). Relative 
residual factor Xa activity was calculated as described in Experimental Section 5.4.7. 
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Chapter 6 Identification of Novel Allosteric Inhibitor by Exploring a Larger Chemical 
Space  
 
6.1 Introduction 
High throughput screening (HTS) and virtual screening (VS) are two most widely used 
techniques to discover new lead molecules.240 In the last few decades, there has been an 
enormous growth in the availability of databases of molecules, which in turn has led to increased 
screening costs and a reduction in hit rate making the HTS approach less appealing.241 
Computational methods such as VS may offer a time saving and cost saving solution for this 
problem.242 VS has been validated for performance in several studies for identifying hits.243 The 
increasing requirement for improvement in the drug discovery process has sparked the path away 
from traditional HTS to high speed and cost efficient VS methods.244 The main goal of VS is to 
come up with novel chemical structures with unique pharmacological profiles. Hence, VS can be 
called as rational alternative to traditional HTS.240 
VS can be classified into two categories: structure-based and ligand-based methods. 
Structure-based docking is used when the structure of the target is known. The success of this 
method is compromised, however, by the inability of available scoring functions to identify the 
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most appropriate binding mode.243 In addition, it is very time consuming and may not consider 
the flexibility of the binding site.245 In contrast to structure-based methods, ligand-based methods 
focus on specific key interactions responsible for protein-ligand binding to generate lead 
candidates.  The major disadvantage is its inability to consider the shape of the binding site. 
Thus, both of these methods face major drawbacks in terms of predictability. In order to 
overcome drawbacks associated with both methods, a combination approach may be used. 246 
The aim of this study is to utilize a combination of both ligand-based and docking-based 
VS approaches to identify new scaffolds in the design of potential allosteric inhibitors of 
thrombin. Virtual screening was performed based on the pharmacophore query developed from 
the SAR results of a library of sulfated benzofuran dimers (see Chapter 4). The hits generated 
from VS were further validated by docking to a crystal structure of thrombin to identify 
molecules having high predicted affinity and specificity for the binding site. Three molecules 
selected from these VS and docking studies were purchased and tested for thrombin inhibition. 
 
6.2 Results and Discussion 
6.2.1 Pharmacophore Generation  
 A pharmacophore was generated based on the results obtained from SAR studies of 
sulfated benzofuran dimers synthesized previously (Chapter 4),231 as shown in Figure 37. Based 
on this SAR, it was found that the potency of sulfated monomers improved 1000-fold on addition 
of one benzofuran unit. Thus, it can be concluded that at least two benzofuran (or aromatic) units 
are necessary for higher potency. The average distances between these two aromatic regions 
from their aromatic centroids were measured and found out to be 8.13 ± 0.5 Å. Additionally, 
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there was a requirement that a hydrophobic group be present at the 3- position on each unit. The 
average distance to these groups was measured to be 7.35±1 Å from the aromatic centroid. The 
most stringent requirement was the presence of negative charge (sulfate group) at the first 
aromatic unit. There are few molecules present in commercial libraries that contain negative 
charge in the form of sulfate group. To make the search successful, the sulfate group was 
replaced with a hydroxyl group, which can be later added both in silico and by synthesis to place 
negative charge in the specified region. Based on these features, the query for virtual screening 
was designed using the tools present in the UNITY search program. 
 
6.2.2 Virtual Screening  
 The virtual search was performed on the ZINC database (Shoichet Laboratory, UCSF, 
CA) containing around 1 million compounds. It was performed using the UNITY search tool 
present in SYBYL 8.1. To narrow down the drug like molecules, Lipinski’s rule of five was 
applied. The following constraints for Lipinski’s rule were applied; Maximum weight – 500, 
maximum donor – 5, maximum acceptor – 10, maximum LogP – 4.15. One deviation from the 
rule was allowed. The minimum gradient for tweak was set to 0.001.  In order to get maximum 
hits, rings were made flexible and no limit was placed on rotatable bonds. Using the 3D 
pharmacophore query, a flexible 3D search was performed on the entire ZINC database. Based 
on similarity in topological and electronic features, 4560 hits were obtained. These hits were pre-
processed to add sulfate group using a script that identifies the free phenolic group and performs 
an in silico sulfation. The modified database was used for molecular docking studies.  
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Figure 37. A) Represent atom of the common scaffold for the library of sulfated benzofuran 
dimers. B) 3D pharmacophore query used for virtual screening of ZINC database to identify the 
new scaffold with similar electronic and topological features. The query defines the important 
regions required for defining the activity of inhibitors like aromatic units, hydrophobic centers 
and the presence of an electron donating center. 
 
6.2.3 Docking Studies  
The docking studies were performed using a two-step method with the GOLD docking 
suite, shown in Figure 38. The aim of the first step is to narrow down the large library of hits 
obtained from virtual screening by identifying the structures having high affinity for thrombin. In 
A
B
 188 
 
this step, an initial single docking experiment was performed with the crystal structure of 
thrombin (PDB: 3EQO). The GA run was set to “10” and early termination was set “ON” to save 
the CPU time. The molecules were selected based on the GOLDScore. 138 structures were 
considered as high affinity based on GOLDScore (> 70). In the second step, docking studies 
were performed in triplicate to identify the structures which bind consistently in the same 
binding pose over three independent runs. The purpose of three independent runs was to gain 
confidence in binding geometry and to identify correct binding poses.  In three independent runs, 
GA was set to “30” and early terminal was set “OFF” to identify the best binding pose. The 
binding poses from three runs were superimposed to calculate the root mean square deviation 
(RMSD). The structures having RMSD < 2 were selected. Ten molecules were identified which 
met the requirement of both filters. These molecules have high GOLDScore, which correspond 
to high affinity for the binding site and consistent binding geometry over three independent runs. 
Based on this two-step docking study and commercial availability, three molecules were 
purchased. The molecules V1, V2 and V3 was purchased from Spec (RI, USA), ChemBridge 
Corporation (CA, USA) and ChemDiv (CA, USA), respectively. 
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Figure 38. Graphical representation of docking protocol using the two-step approach to identify 
new hits. Figure explains the two filters and cutoff limit to pass both filters. The figure is adapted 
from Raghuraman et al. (2006) J. Med. Chem. 49, 3553-3562.  
 
6.2.4 Chemistry  
  To meet the requirement of pharmacophore query, sulfate groups need to be added. In the 
final step, the sulfate group was added on the three purchased compound using the microwave-
based sulfation method developed in our laboratory.222 To the solution of unsulfated compound 
(typically 50 mg) in acetonitrile: DMF (4:1, 0.45 mL) in a microwave tube were added 
triethylamine (10 equiv) and trimethylamine-sulfur trioxide complex (15 equiv). The reaction 
mixture was exposed to microwaves (50 W) for 40 min at 100 °C followed by vacuum 
concentration to remove all solvent. The solid so obtained was directly loaded on a Sephadex C-
25 cation exchange resin and eluted with water. Fractions containing the sulfated product were 
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lyophilized to obtain a solid residue, which was further purified on reverse-phase gradient HPLC 
to remove residual unsulfated contaminants. The final molecules are obtained in good yield (see 
Appendix, Page 352-354 for NMR spectra). 
V1: 1H NMR (CDCl3, 400 MHz) δ 4.25 (s, 2H), 4.66 (s, 2H), 6.40 (d, J= 8.4 Hz, 1H), 6.64 (d, J= 
8.4 Hz, 2H), 6.85 (d, J=8.4 Hz, 1H), 6.90 (m, 2H), 6.95 (m, 4H), 7.04 (m, 2H). 
V1S:1HNMR (D2O, 400 MHz) δ 4.78 (s, 2H), 5.15 (s, 2H), 7.18 (d, J=8.8 Hz, 2H), 7.35 (m, 4H), 
7.40 (m, 1H), 7.47 (m, 1H), 7.66 (m, 2H), 7.92 (s, 1H). 
V2: 1H NMR (CDCl3, 400 MHz) δ 6.18 (m, 4H), 6.96 (m, 6H), 7.46 (m, 3H), 7.92 (m, 1H), 8.08 
(s, 1H), 9.32 (s, 1H), 9.66 (s, 1H). 
V2S: 1H NMR (D2O, 400 MHz) δ 7.23 (m, 4H), 7.48 (m, 4H), 7.51 (m, 2H), 7.72 (s, 1H), 7.79 
(m, 1H), 7.82 (d, J=8 Hz, 1H), 8.05 (s, 1H), 8.16 (m, 1H). 
V3: 1H NMR (DMSO-d6, 400 MHz) δ 2.27 (s, 3H), 3.77 (d, J=15 Hz, 1H), 4.93 (d, J=15 Hz, 
1H), 5.31 (s, 1H), 6.62 (t, J=2 Hz, 1H), 6.69 (m, 1H), 6.74 (m, 1H), 7.05 (m, 2H), 7.13 (m, 3H), 
7.55 (m, 1H), 7.88 (m, 2H), 8.03 (m, 1H). 
V3S: 1H NMR (DMSO, 400 MHz) δ 2.18 (s, 3H), 3.84 (d, J=15 Hz, 1H), 4.84 (d, J=15 Hz, 1H), 
5.35 (s, 1H), 6.97 (m, 4H), 7.05 (m, 2H), 7.18 (m, 1H), 7.29 (m, 1H), 7.49 (m, 1H), 7.76 (m, 
1H), 7.82 (m, 1H), 7.97 (m, 1H).  
  
 
Figure 39. Structures of a library of sulfat
thrombin.These molecules were purchased from Spec, Chembridge and ChemDiv and then 
sulfated.). Sulfation protocol is described in chemistry section.
 
 
6.2.5 Inhibition of Thrombin by Sulfated Molecules
Inhibition of thrombin by the 
hydrolysis assay. The assay is based
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pH 7.4 and 25 °C. The inhibitors V1S, V2S, and V3S exhibited IC50 65.9 µM, 192.9 µM and 
285.6 µM (see Table 20 and Figure 40). The potency for thrombin inhibition for these molecules 
is comparable to library of sulfated benzofuran dimers. Thus, these molecules can serve as 
additional lead structures for designing allosteric inhibitors of thrombin. 
 
Table 20. Inhibition of Human α-Thrombin by Sulfated molecules 
 log IC50  (M) IC50  (µM) ∆Y 
    
V1S -4.18±0.16 65.9±1.1 0.614 
V2S -3.71±0.12 192±11 0.425 
V3S -3.54±0.18 285.6±1.1 0.890 
Thrombin inhibition was measured in spectrophotometric assay through initial rate of 
Spectrozyme TH hydrolysis as described in Experimental section. Standard error shown is ±1 
S.E. 
 
  
Figure 40. Direct inhibition of thrombin by designed 
human thrombin was determined spectrophotometrically through a Spectrozyme TH hydrolysis 
assay at pH 7.4 and 25 °C. Solid lines represent sigmoidal fits to the data to obtain 
YO. 
 
6.2.6 Prolongation of Plasma Clotting Time
Two types of plasma clotting assays are performed to evaluate the anticoagulant potency 
in plasma for new coagulation inhibitors. Prothrombin 
time (APTT) assays are used to measure the effect of an inhibitor on the extrinsic and intrinsic 
flux of coagulation, respectively. The concentrations of the inhibitors required to double the PT 
and APTT were measured and reported, shown in 
µM concentrations of 1S. In a similar manner, the doubling of 
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IC50, YM, and 
µM of V1S. 
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These results suggest that the sulfated compound V1S is significantly potent in human plasma 
and hence proves our design and model for allosteric inhibition of thrombin.  
To further evaluate the effect of various factors in anticoagulation mechanism by 
inhibitor 1S in plasma, we performed plasma studies on various factor deficient human plasma. 
The APTT test was performed on factor IX and XI deficient human plasma; it was found that the 
concentration required to double the APTT time were 380 µM and 368 µM, respectively (see 
Table 21, Figure 41). These results suggest that there was no significant change in APTT time 
than normal human plasma; hence factors IX and XI do not play a role in the anticoagulation 
effect of these inhibitors. Similarly, the PT test was performed on factor VII deficient plasma 
giving 2*PT of 779.24 µM (see Table 21), which is significantly different from the value 
obtained in normal human plasma. Thus, we can conclude that our designed inhibitor V1S is 
interacting with factor VII in human plasma to show an anticoagulant effect. Overall, the plasma 
studies suggest the feasibility of designing small molecules that will function as anticoagulants in 
vivo. 
 
Table 21. Effect of Designed Sulfated Benzofurans on Human Plasma Clotting Time.a 
Plasma 2*PT (µM) 2*APTT (µM) 
Human Plasma 606.8 550 
FIX Deficient Plasma ndb 368.83 
FXI Deficient Plasma ndb 380 
FVII Deficient Plasma 779.24 ndb 
a
 PT and APTT values were deduced in in vitro human plasma experiments where the clot 
initiator is either thromboplastin or ellagic acid, respectively. b not determined. 
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Figure 41. Prolongation of clotting time as a function of concentration of V1S in either activated 
partial thromboplastin time assay (A) or prothrombin time assay (B). Solid lines are trend lines, 
and not non-linear regressional fits.  
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6.2.7 Screening against Other Serine Proteases  
The library of sulfated molecules obtained from virtual screening were screened against 
the panel of coagulation proteases including factors VIIa, IXa, Xa, XIa and XIIa, which are 
either involved in the intrinsic or extrinsic pathways. The assay is based on hydrolysis of a 
chromogenic substrate by the protease, the rate of which is decreased in the presence of inhibitor. 
Screening was performed at a single concentration of inhibitors using a substrate hydrolysis 
assay in 96 well-plates. This assay is based on the decrease in the initial rate of substrate 
hydrolysis in the presence of inhibitor. The decrease in initial rate of hydrolysis typically 
provides the fractional residual activity of enzyme.  
Table 22 shows the percentage residual activity of all proteases at the final concentration 
of 365 µM of each inhibitor. None of these molecules inhibited the factors VIIa, IXa, Xa and XII 
by more than 20% at the concentration of 365 µM (see Figure 42). In screening against factor 
XIa, molecules V1S and V2S completely inhibited factor XIa activity. These results were 
consistent with library of sulfated benzofuran dimers from which they are derived. Similar to 
dimers, these molecules showed selectivity against factors VIIa, IXa and XIIa and completely 
inhibited factor XIa. Thus, this selectivity filter further validates the computational model for 
designing the allosteric inhibitor of thrombin.  
 
 
 
 
  
Table 22. Residual enzyme activity for various proteases at 
 
Factor VIIa 
V1S 98±3 
V2S 100±2.5 
V3S 102±4 
 
 
Figure 42. Bar graph for residual activity for screening against various proteases
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This work presents the combination of ligand-based and docking-based approachs to 
identify and design small synthetic sulfated aromatic structures as novel allosteric modulators of 
thrombin function. The allosteric inhibitors of thrombin are advantageous in terms of their 
controlled inhibition of protease and the ability to reverse excess inhibition. The success of our 
computational model for allosteric inhibition of thrombin give us confidence to extend it toward 
for developing allosteric inhibitors for other proteases such as factors  VIIa, Xa, IXa and XIa. 
 
6.4 Experimental Section 
6.4.1 Protein preparation  
 The docking studies required an accurate 3D structure of thrombin with high resolution. 
The crystal structure of thrombin bound to its allosteric exosite I ligand hirugen with resolution 
of 1.53 Å was obtained from the protein data bank (ID: 3EQ0). All the heavy atoms in the region 
of Arg173 were resolved. The inorganic salts and water molecules were deleted. Hydrogen 
atoms were added to the protein using the “Add Hydrogen” function of Sybyl 8.1. The protein 
was minimized to adjust the hydrogen position using the minimizing tool in Sybyl 8.1,  by using 
the Tripos force field to reach the terminating gradient of 0.05 kcal/mol/Å or a maximum of 
100000 iterations. The Gasteiger-Huckel type charge was assigned to each atom. The thrombin 
binding site was defined to include all the amino acid residues in a radius of 22 Å around the Cα 
carbon of Arg173.  
6.4.2 Chemical database for virtual screening  
A virtual screening of the commercially available database “ZINC” using our pharmacophore 
was carried out. The ZINC database contains the structural information of approximately 1 
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million molecules. These molecules are supplied by various companies such as Key Organics, 
Maybridge, Chemdiv, Otava, Life Chemicals, Specs, Asinex, etc. The compound collection was 
obtained as Structure-Data files and stored. The virtual screening was performed using “Unity 
Search” available in Sybyl 8.1. The flexible 3D search option was used for screening the 
database against the pharmacophore query (Figure 37). To reduce the number of hits obtained 
from the search, constraints such as Lipinski rules, were applied.  
6.4.3 Docking Protocol  
 Docking of the potential hits obtained from virtual screening onto the defined binding 
site of the thrombin was performed with GOLD 4.1 (Cambridge Crystallographic Data Center, 
UK). The binding site is comprised of Arg173 and all the amino acid residues within a radius of 
22 Å around it. GOLD is a “soft docking” method that implicitly handles local protein flexibility 
by allowing a small degree of interpenetration, or van der Waals overlap, of ligand and protein 
atoms. GOLD optimizes the orientation of hydrogen-bond donating atoms on the residues such 
as Ser, Thr, Tyr, Lys and Arg as part of the docking process. Except for the automated number of 
iterations, the allowed amide bond flip and the prohibited early termination, default parameters 
were employed during the GOLD docking runs. Docking was driven by the GOLD scoring 
function and molecules were ranked based on the GOLDScore obtained. The protein hydrogen 
binding constraints were added for five hydrogen atoms of the guanidine group of Arg173 and 
penalty of 10 GOLD score units were assigned.  
Docking of the synthesized inhibitors onto the defined binding site of the thrombin were 
also performed with GOLD 4.1. Default parameters were employed with the following 
exceptions: A protein hydrogen bonding constraint was added such that the score was reduced by 
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10.0 GoldScore units if the ligand did not form an H-bond with the guanidinium group of 
Arg173. Again, amide bonds were allowed to flip. The number of GA runs was increased to 30 
to more accurately screen all possible binding geometries, and early termination was disabled. 
The docking was driven by the GOLDScore fitness function and the docked solutions were 
ranked based on the unmodified GOLDScore obtained. To assess the reproducibility of the 
docked poses, the docking runs were performed in triplicate. 
 
6.4.4 Chemicals, Reagents and Analytical Chemistry 
Reagents, chemicals and solvents were purchased either from Sigma-Aldrich 
(Milwaukee, WI) or Fisher (Pittsburgh, PA) and were used as received. Reagent solutions and 
chemicals were handled under inert nitrogen atmosphere using syringe techniques for liquid and 
dried spatula for solids. All glassware was dried in the oven overnight before use. Sodium 
exchange chromatography was performed using SP Sephadex C-25 cation exchange resin from 
GE Healthcare Life Sciences (Piscataway, NJ). Approximately 100 mg sulfated sample was 
loaded onto 10 g of the cation exchanger in a 10 × 460 mm column and eluted with either water 
at 0.5 mL/min. Microwave-based sulfation and coupling reactions were performed using a CEM-
Discover synthesizer (Matthews, NC) in sealed reaction vessels (7 mL) at 50 W. The temperature 
of the reaction was maintained at the desired setting using cooled nitrogen (45 psi) flow.  
1H and 13C NMR spectra were recorded at either 300 or 400 MHz (Varian Mercury or 
Bruker UltrashieldTM Plus) in appropriate deuterated solvents including CDCl3, DMSO-d6, or 
D2O. All signals are reported in ppm with the internal chloroform, DMSO, and D2O signals at 
7.26, 2.50, 2.05, and 4.79, respectively, as standards. The data is reported as chemical shifts 
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(ppm) and splitting pattern is described as (s = singlet, d = doublet, t = triplet, m = multiplet) 
with coupling constant(s) (Hz), and integration. Mass spectrometry was performed on all 
synthesized molecules using a Micromass ZMD4000 single quadrupole mass spectrometer with 
ESI ionization probe operating in negative ion mode (Waters Corp., Milford, MA). The samples, 
dissolved in acetonitrile containing formic acid (5% v/v), were infused at 10 µL/min. The source 
block temperature and the probe temperature were typically held at 100 and 120 °C, respectively, 
while corona and cone voltages were selected through manual optimization. The desolvation 
nitrogen flow was 500 L/hour. Mass spectra were acquired in the mass range from 110 to 1000 
Daltons at 400 amu/sec. The chromogenic substrate Spectrozyme TH (H-D-hexahydrotyrosol-
Ala-Arg-p-nitroanilide) was purchased from American Diagnostica (Greenwich, CT). 
Unfractionated porcine heparin was purchased from Sigma (St. Louis, MO). All other chemicals 
were analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher 
(Pittsburgh, PA) and used as such.  
 
6.4.5 Substrate hydrolysis assay  
Thrombin activity in the presence of inhibitors was studied using chromogenic substrate 
hydrolysis assay in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 
and 0.1% polyethylene glycol (PEG) 8000 in PEG 20,000-coated acrylic cuvettes. Spectrozyme 
TH was used as substrate and the residual thrombin activity was quantified by measuring the 
initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a function of time. 
Briefly, a solution of 10 µL of the inhibitors to form final concentrations ranging from 4.5 – 900 
µM, was diluted with 970 µL of buffer and 5 µL of 1µM thrombin (5 nM) and incubated. This 
was followed by addition of 15 µL of 2 mM Spectrozyme TH (30 µM) and the initial rate was 
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rapidly measured. Equation 6 was used to fit the dose dependence of residual thrombin activity 
to obtain IC50.  
              =  +

	
	()×
                                 Equation 6 
In this equation Y is the ratio of residual thrombin activity in the presence of the inhibitor 
to that in its absence; YM and Y0 are the maximum and minimum possible values of the 
fractional residual thrombin activity, respectively; and IC50 is the concentration of inhibitors that 
results in 50% inhibition of enzyme activity. Sigmaplot 8.0 (SPSS, Inc. Chicago, IL) was used to 
perform non-linear curve fitting in which YM, YO, and IC50 were optimized. 
6.4.6 Plasma studies (Prothrombin Time and Activated Partial Thromboplastin Time) 
For both PT and APTT assays, standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD) was used to measure the clotting time. 
For the APTT assay, 90 µL citrated human plasma, 10 µL inhibitor (or vehicle for blank test), 
and 100 µL of pre-warmed APTT reagent (0.2% ellagic acid) were mixed and incubated for 4 
minutes. The clotting was initiated by adding 100 µL of 25 mM CaCl2 (37 °C) and the time to 
clot was recorded. For prothrombin (PT) assays, 10 µL sample of the inhibitor (or vehicle for 
blank test) and 90 µL of citrated human plasma were mixed and incubated for 30 second at 37 °C 
followed by addition of 200 µL pre-warmed thromboplastin (reconstituted as per directions 
provided by manufacturer). Each clotting assay was performed in duplicate. The data were fit to 
a quadratic trend line, which was used to determine the concentration of the inhibitor necessary 
to double the clotting time, 2×APTT or 2×PT.   
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Chapter 7 Conclusion 
Designing allosteric inhibitors offers the opportunity to regulate thrombin for maintaining 
balance between its procoagulant and anticoagulant activities. Thus, allosteric inhibitors could 
help in overcoming the side effects such as enhanced risk of excessive bleeding and in 
eliminating the need for regular laboratory monitoring.  To design novel anticoagulants as 
allosteric inhibitors of thrombin based on the β-5 linkage of LMWLs, benzofuran-based sulfated 
monomers and oligomers were designed.  
A diversified library of monomers and dimers was synthesized and found to exhibit 
moderately potent inhibition of thrombin. From this library, 12c was found to be the most potent 
allosteric inhibitor designed so far. Interesting structure-activity relationships were observed. 
Sulfated dimers were found to be 1000-fold more potent than sulfated monomers. A strict 
requirement of a key sulfate group was found, as un-sulfated precursors were found to be 
inactive. However, increasing the number of anionic groups was found to be deleterious for 
potency. The presence of hydrophobic groups at 3- and 3′-positions improved potency, but 
substitution with hydrophilic and bulky groups at these positions led to a decrease in potency. 
Similarly, the presence of bulky and hydrophobic groups at 6 and 6′ positions improved the 
inhibition potency.  
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Michaelis-Menten kinetics study suggested a non-competitive, allosteric mode of 
inhibition by these inhibitors. Screening of sulfated monomers and dimers against the panel of 
coagulation factors such as factors VIIa, IXa, Xa, XIa and XIIa suggested high selectivity for 
thrombin. However, a few dimers were able to inhibit factor XIa also. The in vitro anticoagulant 
potency of these inhibitors was translated into higher system, such as human plasma. Based on 
competitive and mutagenesis studies, it was found that Arg173 residue played a crucial role in 
recognition of these inhibitors. A plausible binding mode was identified using molecular docking 
and scoring approaches. The proposed binding mode was able to explain majority of the SAR 
findings and GOLDScore correlated well with the experimental IC50 value. Thus, the proposed 
binding model offers an excellent opportunity to design new inhibitors with improved inhibition 
potency. 
In a quest to improve the thrombin inhibition potency, a small library of sulfated 
benzofuran trimers and tetramer was synthesized. It was found that extension of oligomeric chain 
to trimer improved the potency nearly 10-fold. However, increasing the chain length further to 
tetramer was detrimental for potency. This observation suggests that trimer is an optimal 
oligomeric chain length for potency. The allosteric mode of inhibition was also retained in higher 
oligomers. However, competitive studies suggest that sulfated trimers recognized a site different 
from sulfated dimers. The range of thrombin inhibition potency and efficacy discovered for 
sulfated benzofurans monomers and higher oligomers suggest that the designed sulfated 
benzofuran scaffold may be an excellent lead in developing anticoagulants radically different 
from those studied to-date. 
Finally, a pharmacophore query was designed based on the SAR results obtained from 
the library of sulfated dimers to virtually screen a larger chemical space. The combination of 
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both ligand-based and docking-based approach was used to identify new scaffolds as potential 
leads for allosteric inhibitors of thrombin. Three molecules were selected to purchase and 
sulfated to match the query. It was found that all three sulfated molecules were moderate 
inhibitors of thrombin with potency similar to that of the sulfated dimers. The anticoagulant 
potency of these new inhibitors translated well into human plasma. Thus, we identified three new 
scaffolds, which can serve as starting point to design the new inhibitors for thrombin. Overall, 
this work highlights the opportunity of exploring allosteric modulators of thrombin and other 
coagulation enzymes, e.g., factors Xa, IXa and XIa, through sulfated lignin scaffolds. 
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